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1. Inflammatory and degenerative rheumatic diseases 
Roughly, rheumatic diseases can be divided into two groups: inflammatory and degenerative 
diseases. The most prevalent inflammatory rheumatic diseases are Rheumatoid Arthritis (RA) and 
Spondyloarthritis (SpA) with a combined prevalence close to 2% [1, 2]. Both are chronic systemic 
inflammatory joint diseases, that may affect many tissues and organs, but pain and inflammation 
of joints is still the hallmark. Over time, persistent joint inflammation frequently leads to 
destruction of joints and periarticular structures. This structural damage is usually visible on 
conventional radiographs and, importantly, the amount of radiographic damage is directly 
associated with the level of functional disability and quality of life [3, 4]. 
Osteoarthritis (OA) is considered as a “wear and tear”degenerative joint disease, and is the most 
common rheumatological disease worldwide with an estimated prevalence of 15% [5, 6]. OA is 
characterized by a gradual degeneration of the cartilage eventually leading to failure of the synovial 
joints [7]. Erosive Osteoarthritis (EOA) is an important subtype of hand OA, involving the 
interphalangeal finger joints, and characterized by erosions and central cortical collapse on 
radiographs. Occasionally, EOA is characterized by an aggressive clinical course causing 
considerable pain and limitation of function [8, 9]. Because inflammatory episodes characterize the 
onset of EOA, it is sometimes called “inflammatory OA” [10].  
The main focus of this thesis lays on Spondyloarthritis. In the next paragraph, we briefly describe 
RA and EOA to move on with a more in depth overview of clinical manifestations, pathophysiology, 
imaging and treatment strategies in SpA.  
2. Rheumatoid Arthritis 
RA is a chronic, systemic, inflammatory disorder of unknown etiology that primarily involves 
synovial joints. The annual incidence of RA has been reported to be around 40 per 100,000. The 
disease prevalence is about 1 percent in Caucasians [11, 12]. Women are affected two to three 
times more often than men; the disease can occur in patients at any age with a peak onset between 
the ages of 50 and 75. Currently, the etiology of RA is unknown, but a combination of predisposing 
genetic factors, and person-related or environmental factors (age, gender, infectious agents, 
smoking, dietary factors) is suspected to play a role in this disease [13, 14]. The disease onset in RA 
is usually insidious, with the predominant symptoms being pain, stiffness (especially morning 
stiffness), and swelling of many joints [15]. Typically, symmetric involvement of the 
metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of the fingers, the 
interphalangeal joints of the thumbs, the wrists, and the metatarsophalangeal (MTP) joints of the 
toes, can be observed early in the disease. Larger synovial joints of the upper and lower limbs, such 
as the elbows, shoulders, ankles, and knees, can also be affected [16, 17]. The axial skeleton is not 
affected, with the exception of the cervical spine, where severe disease may cause serious 
neurologic compromise, generally in patients with longstanding disease. About 75 to 80 percent of 
patients with RA test positive for Rheumatoid Factor (RF), anti-citrullinated protein antibodies 
(ACPAs), or both; patients with RA and such antibodies are defined as having “seropositive RA” and 
the presence of the antibodies has diagnostic, therapeutic, and prognostic implications. Patients 
with poorly controlled disease typically experience progressive joint damage, which may result in 
significant joint deformities and functional impairment. Patients with RA develop joint space 
narrowing and bony erosions, which are best observed on plain radiographs of the hands and feet. 
These may already be present when first seen by a clinician but more usually become evident over 
time with ongoing synovitis beyond the first few months of disease. Erosions of cartilage and bone 
are among the cardinal features of RA. However, erosive structural damage can also occur in some 
other forms of inflammatory or gouty arthropathy, and are therefore not diagnostic of RA in and of 
themselves. Magnetic resonance imaging (MRI) studies and ultrasonography are more sensitive 
than radiography for the detection of changes resulting from synovitis, but additional research is 
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ongoing to determine the long-term prognostic importance of these observed abnormalities. 
Impairment of function and disability are the long-term consequences of the combined effect of 
inflammation and joint damage (fig 1)[18]. There is accumulating evidence that early diagnosis and 
treatment would improve long-term outcome.  
 
 
Fig 1: The interrelated triad of disease activity, joint damage and disability in RA [18]. 
 
Current treatment of RA is based upon a combination of symptomatic and disease-modifying 
treatments. The 2016 EULAR recommendations for the management of RA address conventional 
synthetic disease-modifying antirheumatic drugs (csDMARDs) (methotrexate (MTX), leflunomide, 
sulfasalazine); glucocorticoids (GC); biological DMARDs (tumor necrosis factor (TNF)-inhibitors 
(adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, 
tocilizumab, sarilumab and biosimilar (bs DMARDs) and targeted synthetic (tsDMARDs) (Janus 
kinase (Jak) inhibitors tofacitinib, baricitinib)[19]. MTX is recommended as first-line strategy (rapid 
escalation to 25 mg/week) plus short-term GC, aiming at >50% improvement within 3 and target 
attainment within 6 months. If this fails, stratification is recommended. Without unfavourable 
prognostic markers, switching to, or adding another csDMARDs (plus short-term GC) is suggested. 
In the presence of unfavorable prognostic markers (autoantibodies, high disease activity, early 
erosions, failure of 2 csDMARDs), any bDMARD (current practice) or Jak-inhibitor should be added 
to the csDMARD. If this fails, any other bDMARD or tsDMARD is recommended. If a patient is in 
sustained remission, bDMARDs can be tapered. 
3. Osteoarthritis and Erosive Osteoarthritis 
The primary symptoms of osteoarthritis (OA) are joint pain, stiffness, and limitation of motion. Joint 
deformity is a sign of advanced joint damage. Many of the characteristic clinical manifestations of 
OA are related to the involvement of particular joints. OA has a predilection for the knees, hips, 
interphalangeal joints, first carpometacarpal (CMC) joints, first MTP joints and apophyseal (facet) 
joints of the lower cervical and lower lumbar spine [20]. Lumbar facet joint OA leads to localized 
lumbar pain, which may radiate unilaterally or bilaterally to the buttocks, groin, and thighs, typically 
ending above the knees [21] and needs to be differentiated with low back pain appearing in axial 
Spondyloarthritis. Symptoms in lumbar facet joint OA or degenerative sacroiliitis are worse during 
periods of activity and are increased by stress, exercise, lumbar spine extension, rotary motions, 
and when standing or sitting [21]. Similarly, cervical facet joint OA may present with ipsilateral neck 
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pain, which does not radiate beyond the shoulder and is aggravated by neck rotation or lateral 
flexion [22]. Osteoarthritis of facet joints most commonly presents in patients over the age of 40. 
Erosive Osteoarthritis (EOA) is a particularly aggressive subset of hand osteoarthritis (HOA) and has 
a prevalence of 2.8% in the general population and 10.2% in individuals with symptomatic HOA 
[23]. It presents with a subacute or insidious onset of pain, stiffness, soft-tissue swelling, and 
sometimes paresthesia affecting multiple interphalangeal joints [9, 24]. Compared with hand OA, 
pain, tenderness, and inflammation (warmth, soft-tissue swelling, sometimes erythema) are more 
marked and prolonged [9, 25], and EOA is not associated with generalized OA. EOA targets just 
interphalangeal joints (the distal interphalangeal joints (DIP) more frequently than the proximal 
interphalangeal joints (PIP)) and usually spares the thumb bases and MCP joints [24, 25]. Lateral 
instability at the interphalangeal joints is an occasional but characteristic finding and spontaneous 
interphalangeal joint fusion may also occur. Heberden’s and/or Bouchard’s nodes may coexist [25]. 
The diagnosis is based upon conventional radiography (CR) that shows typical central erosions and 
collapse of the subchondral bone [8, 26, 27]. Several radiographic phases are being recognized in 
EOA. [26] Unfortunately, the radiographic appearance of erosions shows a delay with respect to 
the clinical presentation. Its more aggressive course compared to non-erosive OA is well known: 
patients with erosive joints experience a higher level of pain and more functional impairment. 
Moreover, radiographic damage seems to have the largest contribution to this functional 
impairment [28]. Whether EOA is a separate disease entity or reflects a severe phase in the course 
of hand OA is still under debate. Meaningful treatment for EOA should deal with the destructive 
events during the disease in order to prevent the progression of structural remodelling and 
accompanying loss of hand function. Currently, there are no treatments that can prevent structural 
damage in EOA; only symptomatic treatment is available.  
4. Spondyloarthritis 
4.1. Epidemiology and clinical signs and symptoms 
Spondyloarthritis (SpA) comprises a heterogeneous family of clinically and genetically closely 
related inflammatory rheumatic disorders, including ankylosing spondylitis (AS), psoriatic arthritis 
(PsA), reactive arthritis (ReA) and inflammatory bowel disease (IBD) related arthritis and/or 
spondylitis. The prevalence of SpA in Western European countries is estimated to be approximately 
0.5 - 1%, similar to  that of RA [29].  The disease is clinically characterized by a combination of 
sacroiliitis, spondylitis and peripheral joint involvement (arthritis, enthesitis, dactylitis), with a 
considerable amount of patients also exhibiting extra-articular manifestations.  There is a strong 
genetic link (HLA B27), partly explaining the increased occurrence of these diseases in family 
members of affected patients. Depending on the location of the predominant clinical manifestation, 
the SpA concept is nowadays split into axial and peripheral disease, the latter including PsA and 
non-psoriatic peripheral SpA (pSpA)[30]. Peripheral SpA is characterized by peripheral arthritis 
(predominantly of the lower limbs), enthesitis and dactylitis, as presenting symptom. Extra-articular 
manifestations related to axial and peripheral SpA include psoriasis, anterior uveitis and IBD. The 
estimated prevalence of AS, the most frequent subtype of SpA, ranges from 0.1 - 0.9% [29]. The 
incidence and prevalence rates of SpA are strongly dependent and directly correlated to the 
prevalence of human leucocyte antigen B-27 (HLA-B27) in a given population [29]. Other important 
contributors to variation in prevalence of axSpA include differences in selection of the target 
population, variation in the criteria used for case definition and study design [31]. Unlike most other 
forms of arthritis, the first symptoms of axSpA usually appear before the fourth decade of life [32]. 
Males are about three times more often affected with AS than females. However, in the whole 
group of axSpA, the male : female ratio approaches 1:1 [33]. 
 
4.1.1. Ankylosing spondylitis and non-radiographic axial Spondyloarthritis 
Ankylosing spondylitis (AS) is characterized by inflammation of the axial skeleton, that is, the 
sacroiliac joints (SIJ, usually the first to be involved) and the spine (spondylitis), with or without 
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peripheral arthritis or enthesitis. Typical for AS is that inflammation coincides with pathological new 
bone formation. This causes fusion of sacroiliac joints and vertebrae (ankylosis), which may lead to 
development of a so called ‘bamboo spine’ (fusion of consecutive vertebrae), with significant 
reduction of spinal mobility.  
Axial SpA is rather arbitrarily subdivided into AS and non-radiographic (nr)-axSpA, based on scoring 
of sacroiliitis on pelvic radiographs [34]. The availability of magnetic resonance imaging (MRI), 
which can detect active inflammation of the sacroiliac joints before structural lesions are seen on 
plain radiographs, has led to the identification of nr-axSpA. Patients with nr-axSpA may eventually 
progress to a radiographic stage, with an average progression rate of 10% after 2 years, and up to 
60% after 10 years [35-37]. In patients with axSpA the most important clinical feature is 
inflammatory back pain (IBP) caused by sacroiliitis and spondylitis [38]. IBP is typically characterized 
by awakening night pain, morning stiffness, improvement of pain with exercise, no improvement 
with rest and favorable response to non-steroidal anti-inflammatory drugs (NSAIDs) [39].  
 
4.1.2. Psoriatic Arthritis 
Psoriatic arthritis (PsA) is an arthritis associated with psoriasis, a chronic inflammatory skin disease 
[40]. PsA affects women and men equally, with an incidence of approximately 6 per 100,000 per 
year and a prevalence of about 1 to 2 per 1000 in the general population [40-45]. PsA may involve 
peripheral joints, axial joints, or both. Within PsA, different patterns of joint involvement can be 
observed. It most frequently presents as a polyarticular symmetrical arthritis of small joints, similar 
to rheumatoid arthritis, but with involvement of the DIP joints. Less often it presents as a more SpA-
like arthritis pattern: oligoarticular asymmetrical arthritis of the larger joints and/or sacroiliitis and 
spondylitis. Typical for PsA is the presence of dactylitis (‘sausage finger/toe’), but enthesitis and 
tenosynovitis may also occur. 
 
4.1.3. IBD related Arthritis 
Up to 30% of patients with IBD can develop SpA-like articular manifestations such as sacroiliitis and 
spondylitis (sometimes asymptomatic) and oligoarticular peripheral arthritis, although a 
symmetrical polyarthritis can also be seen. The oligoarticular form often involves large joints and 
parallels the activity of the underlying IBD, whereas the polyarticular form appears to be 
independent of IBD activity [46, 47]. No clear relationship has been found between axial 
involvement and IBD activity. 
 
4.1.4. Reactive Arthritis 
Reactive Arthritis (ReA) is an arthritis with a SpA-like pattern that develops usually within 6 weeks 
after an urogenital or gastrointestinal infection, although the pathogens cannot be cultured from 
the affected joints. Other infections (e.g. viral) can also trigger arthritis, but the term ReA is usually 
reserved for SpA-like arthritis following typical infections, that is Campylobacter, Yersinia, 
Salmonella, Shigella and Chlamydia trachomatis [48]. The risk of developing a chronic form of ReA 
is increased by carriage of HLA-B27. Also, the pattern of joint involvement is similar to that seen in 
other forms of SpA. Up to 20% of patients eventually develop AS within 10-20 years, especially if 
they are HLA-B27 positive [49]. 
 
4.1.5. Anterior Uveitis 
Anterior uveitis is a frequent complication of SpA, occurring in 25%-30% of patients. The initial 
attack of uveitis is usually acute and unilateral and may be the presenting problem, triggering a 
diagnostic work-out for SpA. Patients typically note redness, pain, and photophobia. Although 
ocular inflammation often responds well to topical therapy, and no residual lesions persist, 
recurrences are common and permanent impairment of vision is possible if treatment is 
unsuccessful [50, 51]. 
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4.1.6. Undifferentiated Spondyloarthritis  
Patients with suggestive axial or peripheral SpA disease manifestations, that could not be diagnosed 
as a specific disease entity (described above), were previously classified as having undifferentiated 
SpA (USpA). However, USpA is frequently mistakenly understood to be a mild, ill-defined or early 
stage of AS or PsA, whereas increasing evidence supports the concept that SpA is better seen, with 
respect to pathophysiology, clinical findings, and treatment, as a single disease (concept) with 
different phenotypes[52]. The term “undifferentiated SpA” will probably disappear with the wider 
acceptance of the ASAS classification criteria and their underlying assumptions, as most patients 
with conditions historically described as USpA can now be classified as having either peripheral SpA 
or non-radiographic axial SpA, depending upon the predominant features of their disease. 
 
4.2. Imaging in Spondyloarthritis  
4.2.1. Conventional radiography 
Conventional radiography is the most widely used imaging technique for assessing structural 
changes of the sacroiliac joints (SIJ) [53]. Radiographs of SIJ can demonstrate sclerosis, erosions and 
ankylosis [54]. The presence of sacroiliitis is graded from 0 (normal) to 4 (ankylosis) [55] (fig 2). The 
main disadvantage of conventional radiography in the clinical assessment of patients suspected of 
having axSpA is its low sensitivity, especially in early disease [38, 53]. In addition, only structural 
damage of the SIJs, which is probably the consequence of prior inflammation, can be detected. The 
diagnostic delay in AS patients is mainly a consequence of the relatively late appearance of definite 
sacroiliitis on X-ray according to the Modified New York classification criteria in most of the patients 
with axSpA [55]. Other major challenges when using conventional radiographs of the SIJs for 
detection of sacroiliitis are the low intra- and inter-observer agreement, projection artefacts and 
















The typical spinal changes in AS are squaring, erosions, sclerosis and syndesmophytes. The modified 
Stokes AS Spine Score (mSASSS) [58], evaluating lateral view X-rays of cervical and lumbar spine, is 
a validated scoring system, currently considered the best method for quantification of chronic 
spinal changes as detected by conventional radiographs [59] (fig 3). The Bath Ankylosing Spondylitis 
Radiology Index for the spine (BASRI-s) has also been found a reliable method for grading 
radiographic changes in patients with AS [60]. 
Fig 3: Chronic spinal changes in ankylosing spondylitis evaluated by the Modified Stoke Ankylosing 
Spondylitis Spinal Score (mSASSS). 
 
Plain radiographs of peripheral joints are often unremarkable and do not show the same type of 
erosions seen in RA. In patients with PsA, the coexistence of erosive changes and new bone 
formation may occur within the same joint or in different joints within the same digit. In the 
differential diagnosis of PsA (especially in older patients), EOA should be taken into account since 
both PsA and EOA may be characterized by involvement of the DIP joints, which may sometimes 
exhibit some inflammatory characteristics and can mimic PsA. PsA can generally be distinguished 
from osteoarthritis with Heberden’s nodes by the nodular bony change of osteoarthritis, the more 
diffuse swelling of the joint in PsA, and the presence of other findings of PsA, such as characteristic 
nail changes, inflammatory oligoarticular, polyarticular, and or axial disease, enthesitis, and 
dactylitis. Also other radiographic changes can differentiate both diseases (table 1).  Typical 
radiological changes in PsA include lysis of the terminal phalanges, fluffy periostitis, as well as new 
bone formation at the site of enthesitis, gross destruction of isolated joints, “pencil-in-cup” 







Table 1: Different clinical and radiographic features of RA, axial SpA, EOA and PsA. 
4.2.2. Computed Tomography 
Computed tomography (CT) scanning is not well validated for the diagnosis of sacroiliitis, 
demonstrates only structural changes, i.e. erosions, ankylosis and sclerosis, and is associated with 
relatively high radiation doses.  CT has certain advantages over radiography: with a complicated 
anatomical structure such as the SIJ, it permits multi-planar assessment for optimal analysis from 
the synovial joint space to the ligament compartment of the SIJ [62-69]. Low-dose CT has been 
shown to be accurate in examining the sacroiliac joints and is suggested as an effective alternative 
to plain radiography as the primary means to detect structural changes of the SIJ. In comparison 
with low-dose CT as the gold standard, conventional radiography missed more than half of the 
patients and two-thirds of the joints with structural changes indicating (radiographic) axSpA on low-
dose CT. Especially erosions—considered the most characteristic structural damage [70, 71], were 
not detected reliably on radiographs, confirming earlier studies demonstrating higher sensitivity of 
CT [62]. Recently, a study comparing conventional radiographs with low dose CT performed with a 
radiation exposure comparable with that of radiography showed that the sensitivity of T1-weighted 
MRI for the detection of structural lesions, especially erosions and joint space changes (including 
ankylosis), is similar to that of low dose CT and better than that of radiography [72]. 
 
4.2.3. Magnetic Resonance Imaging 
Nowadays, Magnetic Resonance Imaging (MRI) of the SIJs is considered an important imaging 
technique for establishing a diagnosis of sacroiliitis in an early stage. MRI can identify both 
inflammation and structural changes caused by inflammation, while radiographs show only 
structural changes [73]. Typical active (inflammatory) lesions in the SIJs are subchondral bone 
marrow edema (BME)/osteitis, and to a lesser extent synovitis, enthesitis and capsulitis [73]. Active 
lesions are best visualized on T2-weighted, fat saturated (FS) spin-echo (SE) sequence, T1-weighted, 
FS, gadolinium contrast-enhanced sequence or the short tau inversion recovery (STIR) sequence. 
Structural changes that can be detected by MRI are erosions, fat deposition (fatty lesions), sclerosis 
and ankylosis. These structural lesions are best visualized on the T1-weighted SE sequence. In 2009, 
the Assessment of SpondyloArthritis International Society (ASAS) published new criteria for axial 
(and peripheral) SpA based on characteristic disease manifestations, incorporating clinical, 
laboratory and imaging components, but with the addition of an MRI definition in order to enable 
the identification of patients without evidence of structural changes on radiography [38]. A ‘positive 
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MRI’ was defined as the presence of subchondral BME that is highly suggestive of axial SpA, and 
appears as two or more distinguishable lesions on one slice, or as one lesion on at least two 
consecutive slices. Recently the ASAS MRI working group conducted a consensus exercise to review 
the definition of a positive MRI for inclusion in the ASAS classification criteria of axial SpA [74]. The 
clear presence of BME on MRI in subchondral bone is still considered to be the defining observation 
that determines the presence of active sacroiliitis. Structural damage lesions seen on MRI may 
contribute to a decision by the observer that inflammatory lesions are genuinely due to SpA but are 
not required to meet the definition until more data are available regarding structural MRI features 
of the sacroiliac joint. The existing definition was clarified adding guidelines and images to assist in 
the application of the definition [74]. Several scoring methods for assessment and quantification of 
active lesions on MRI have been proposed [75-77].  
Several studies have shown that besides inflammation on MRI of the sacroiliac joints (MRI-SI), 
inflammatory lesions in the spine on MRI (MRI-spine) may also occur [78, 79]. A consensus 
definition for a positive MRI-spine was developed by the ASAS/Outcome Measures in 
Rheumatology (OMERACT) MRI working group [78]. A total of six different types of lesions were 
described for inflammation (anterior/posterior spondylitis, spondylodiscitis, arthritis of 
costovertebral joints, arthritis of zygoapophyseal joints and enthesitis of spinal ligaments) and 
another four for structural changes (fatty deposition, erosions, syndesmophytes and ankylosis).  In 
this consensus definition a positive MRI-spine is described as the presence of ≥3 inflammatory 
lesions in the vertebrae (anterior/posterior spondylitis), whereas each lesion needs to be present 
on ≥2 consecutive slices. In patients without sacroiliitis on MRI and conventional radiography of the 
SIJ, a positive MRI-spine was rare [80]. 
 
4.2.4. Bone scintigraphy 
Bone scintigraphy involves the intravenous injection of the bone-seeking radiopharmaceutical 
technetium-99m-labeled methylene diphosphonate. This method can demonstrate increased 
radionuclide uptake in the areas of accelerated bone turnover due to any cause, including 
inflammation. Early reports in the 1970s about the diagnostic role of scintigraphy to detect 
sacroiliitis were promising [81-84]; however, subsequent studies have suggested that clear 
separation of active AS from controls is difficult making its accuracy in the detection of sacroiliitis 
questionable [85-92]. In 2008, a review on the performance of scintigraphy in assessing sacroiliitis 
in patients with AS suggested that scintigraphy of the sacroiliac joints is at most of limited diagnostic 
value for this diagnosis [93]. Since then, only a few studies have aimed to investigate further the 
potential of radionuclide methods for the diagnosis of SIJ involvement. 
 
4.2.5. New imaging techniques: molecular imaging 
Anatomical imaging techniques have been in use for a long time, facilitating diagnosis and 
monitoring of arthritis, but providing little information on the underlying immunological changes in 
synovial tissue, cartilage, and bone. In contrast, the objectives of molecular imaging are the 
visualization, characterization and quantification of molecular and cellular processes non-
invasively. This can help evaluate physiological and pathophysiological processes, facilitate 
diagnosis and monitor effects of therapy. At the preclinical stage, novel molecular imaging 
techniques can also facilitate the development of new therapies and understanding of novel 
mechanisms of action of targeted biological agents. 
Positron emission tomography (PET) imaging is based on imaging emission from isotopes such as 
14F and 64Cu. These decay and emit positrons that on collision with electrons emit λ-rays at 180 
degrees to each other. These are detected when they reach a scintillator in the scanning device, 
creating a burst of light that is detected by photomultiplier tubes or silicon avalanche photodiodes. 
The fluorine-18 [18F] fluorodeoxyglucose (FDG) PET/CT technique has been examined previously as 
an additional tool for the diagnosis of enthesitis in SpA patients [94]. As a modality for the diagnosis 
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of sacroiliitis, [18F]FDG PET/CT has been shown to be of little value, with negative results in all 10 
patients with ankylosing spondylitis (AS) in one study [95], showing inconsistent results in another 
[96], and assessed as not useful for predicting response to TNF-alpha antagonist therapy in a third 
study [97]. However, [18F]fluoride, which is a bone tracer of osteoblastic activity, was found useful 
for demonstrating bone activity in AS patients [95]. Of importance, the lesions detected by 
[18F]fluoride PET/CT did not always correlate with bone marrow edema as seen on MRI, suggesting 
that this modality may reflect bone formation rather than inflammatory processes in AS patients 
[95, 98]. An additional study examined performance of [18F]fluoride PET/CT in 10 patients with nr-
axSpA and 5 patients with AS: PET/CT was reported as positive in all AS patients and negative in all 
nr-axSpA patients, further suggesting specificity of this imaging for bone formation, rather than for 
inflammation [99]. The sensitivity, specificity, and accuracy of [18F]fluoride PET/CT for detection of 
sacroiliitis was calculated as 80%, 77%, and 79%, respectively, in another study, involving 15 AS 
patients [100]. 
2Single photon emission computed tomography (SPECT) is a nuclear medicine tomographic imaging 
technique that utilizes the emission of gamma rays. SPECT imaging is performed by using a gamma 
camera to acquire two-dimensional images from multiple angles. This is reconstructed into a three-
dimensional dataset, similar to those obtained from other tomographic techniques such as MRI, CT, 
and PET. SPECT is similar to PET in its use of radioactive tracer material and detection of gamma 
rays. In contrast with PET, however, the tracer used in SPECT emits gamma radiation that is 
measured directly. SPECT scans are significantly less expensive than PET scans, in part because they 
are able to use longer-lived, more easily obtained radioisotopes than PET. The widespread use of 
PET is limited by a shortage of centres able to generate positron radioisotopes that also have short 
half-lives. SPECT uses isotopes that are already in widespread use, such as 111In and 99mTc. Rapid 
advances in SPECT, including the use of multiple pinhole collimators, allow high-resolution imaging 
to less than 1 mm. SPECT imaging increases sensitivity of bone scintigraphy, allowing slice-by-slice 
three-dimensional radionuclide uptake analysis. This possibility can be particularly useful in the 
study of the SIJ, where complex anatomy is probably the main cause of low accuracy of both plain 
radiography and bone scintigraphy. In the only recent report, SPECT of SIJ with calculated indices 
of uptake had sensitivity of 80% and specificity of 97% for sacroiliitis in 46 patients with chronic low 
back pain [101]. A combination of SPECT and CT has been used in various fields in medicine for 
functional and anatomical imaging; SPECT/CT has further increased specificity compared with 
SPECT in clinical practice by conjoining the anatomical information provided by CT and permitting 
better characterization of equivocal lesions. The SPECT/CT combination has been suggested 
previously as a useful diagnostic modality for the evaluation of sacroiliac dysfunction [102]. In a 
study involving 20 patients with early SpA, diagnosed by Amor criteria, SPECT/CT of SIJ 
demonstrated reliable reproducibility, sensitivity of 80%, and specificity of 84% for SIJ involvement 
[103]. 
 
4.3. Pathophysiology and genetics of SpA 
Since the 1970s, a series of hypotheses, each incorporating the available knowledge at the time, 
have been proposed to explain the pathogenesis of AS and other forms of SpA. Genetic 
predisposition is of particular importance in the pathogenesis of AS. The strongest genetic 
association with AS and other forms of SpA is with the major histocompatibility complex (MHC) 
region, particularly human leukocyte antigen (HLA)-B27 which plays a role in several of the 
processes that characterize the disease. HLA-B27 is present in about 80 to 95% of patients with AS 
in most ethnic groups. The disease prevalence also parallels the frequency of this allele in different 
populations. The HLA-B27 gene accounts for nearly 25% of the disease hereditability. There are 
several different hypotheses that could provide explanations for the mechanism by which HLA-B27 
may promote the development of SpA [104] (fig 4). None of them has been formally proven yet to 
operate in human SpA. The HLA-B27 misfolding hypothesis postulates that the HLA-B27 association 
with AS is based upon unusual structural features of HLA-B27. Hence, this protein is prone to 
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misfolding in the endoplasmatic reticulum (ER) [105, 106]. As a result, improperly folded HLA-B27 
proteins (ie, those not yet in the canonical mature class I conformation) accumulate in the ER which 
causes ER stress due to an unfolded protein response. This leads to activation of the IL-23/IL-17 
pathway (figure 1). However, there is no convincing evidence that HLA-B27-activated unfolded 
protein response exists in human AS patients. There is some evidence that misfolding of HLA-B27 
leads to another process termed autophagy, which could also be responsible for induction of IL-23 
and/or IL-17  [107]. 
 
Fig. 4: Three different HLA-B27 structures and hypotheses as to how they might induce disease 
processes in ankylosing spondylitis.  
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An alternate theory suggest that HLA-B27 heavy chains can form stable dimers without beta-2-
microglobulin. Such dimers can engage receptors on several types of cells in a way different from 
the classical structure, but this also needs independent confirmation [108-110]. The molecular 
mimicry/antigen presentation hypothesis postulates that there are certain microbial peptides that 
are very similar to self-peptides from the point of view of the TCRs of certain HLA-B27-specific CD8+ 
T lymphocytes (cytotoxic T lymphocytes). The reactivity of these T lymphocytes with these HLA-
B27-peptide complexes would then lead to autoreactivity and autoimmune disease [111, 112]. 
Interestingly, although HLA-B27 confers a survival advantage in the face of viral infections such as 
HIV, hepatitis C, and influenza, carriers of the gene are defective in the killing of intracellular 
bacterial species of genera including Yersinia, Salmonella, Shigella, and Chlamydia [113]. These 
bacteria have been well documented in the triggering of reactive arthritis[113].However, no 
convincing conserved peptide sequences allowing to support this hypothesis have been discovered. 
In addition, the fact that HLA-B27 transgenic rats can still develop arthritis in the absence of CD8+ 
T cells questions the validity of this arthritogenic peptide hypothesis [114].  
Additionally, many genes other than HLA-B27 have been identified as risk factors for the disease 
since the majority of HLA-B27 positive individuals do not develop SpA. Several large genome-wide 
association studies (GWAS) have been carried out [115-118] and have identified a total of at least 
48 GWAS risk loci. About 20 percent of the heritable risk is from MHC variants, of which HLA-B27 is 
the major contributor. About 7 percent of the heritable risk is from non-MHC variants [104, 119-
124]. Even though the total contribution of all these non-MHC genes to AS heritability is relatively 
small, these associations provide clues about the pathogenesis of AS. In addition, their significance 
can be amplified by gene-gene interaction [125]. These non-MHC AS-associated genes can be 
grouped into several functional categories:  
 IL-23/IL-17 pathway - One group of genes associated with AS provides evidence of a role of the 
IL-23/IL-17 pathway in the disease. GWAS have identified associations with genes for the IL-23 
receptor (IL-23R), as well as tyrosine kinase 2 (TYK2) and signal transducer and activator of 
transcription 3 (STAT3), which are involved in the IL-23R signaling pathway. 
 The endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 - The two endoplasmic 
reticulum aminopeptidases that encode genes related to AS are termed ERAP1 and ERAP2; 
each of the genes has variants that may increase the risk of AS and variants that are protective. 
These two enzymes are responsible in the endoplasmic reticulum for the generation as well as 
trimming and destruction of peptides to achieve the correct length for loading into HLA class I 
molecules, such as HLA-B27, for antigen presentation [126]. The biological activities of ERAP1 
in AS are closely associated with HLA-B27 function. The ERAP1 variants found in patients with 
AS are present mostly in patients who are HLA-B27-positive, rather than HLA-B27-negative 
[117]. In addition, the ERAP1 dysfunction appears to spare those HLA-B27 subtypes that do 
not cause AS [127]. ERAP1-related effects are complex, as the activity of ERAP1 is a combined 
effect of all of the substitutions in any particular variant and is also peptide-dependent. Both 
ERAP1 and ERAP2 polymorphisms might influence any of the different ways HLA-B27 cause AS 
[128]. 
 TNF receptor gene family – The presence of an additional group of genes, including those for 
the lymphotoxin beta receptor (LTBR) and TNFRSF1A (tumor necrosis factor receptor 
superfamily member 1A), provides additional support for the role of TNFα in disease activity 
[104].  
 T lymphocyte activation and differentiation – The association of AS with genes modulating 
activation and differentiation of either CD4+ or CD8+ T lymphocytes is consistent with 
potential involvement of these cells with disease pathways. 
 
The sharing of genes with Crohn disease, ulcerative colitis, and celiac disease may explain the 
overlap of AS with IBD and perhaps the presence of subclinical bowel disease in AS itself [119]. How 
these various genes are activated to express their respective proteins, and how their expression is 
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modulated in flares and relapses of AS, remains to be determined. AS, IBD, and psoriasis and PsA 
not only tend to occur in the same families, but also clearly share common genetic and immunologic 
mechanisms [129] (Table2). One example is the potentially defective intracellular processing of 
antigens (indicated by the association of the ERAP1 and HLA‑B27 gene–gene interaction in AS, and 
of ERAP1 and HLA‑Cw6 in psoriasis); another is defective autophagy (implicated by the NOD2, 
ATG16L1, and IRGM associations in Crohn’s disease). Shared associations with genes in the IL-17-
IL-23 axis (IL23R, IL12B, STAT3, JAK2, PTGER4, PUS10 and IL18RAP) and in the nuclear factor-κB 
(NFκB) pathway (REL, CARD9) suggest that alterations in these signalling cascades are also common 
to the pathogenesis of these related diseases. Associations with genes whose relevance to SpA is 
less clear (DEFB4, CDKAL1, KIF21B, ORMDL3, MST1 and PSMG) are also common to these disorders. 
 
Another important element in the pathogenesis of SpA appears to be the exposure of the immune 
system to microbes as a consequence of disruption of the human host’s barrier functions. As 
examples, in the genital tract, such exposure can result in Chlamydia-induced reactive arthritis; in 
the skin, psoriasis can be associated with psoriasis-related SpA; in the bowel, the exposure can lead 
to SpA related to Crohn disease or ulcerative colitis, and AS can occur with subclinical microscopic 
ileo-colonoscopic mucosal inflammation.  
Several observations demonstrate the potentially relevant role of interleukin (IL)-23 in the 
pathogenesis of AS, with the gut as a potential site where the process begins. IL-23 receptor (IL-
23R) is one of the genes associated with the development of AS and IL 23 is expressed in the 
microscopic mucosal lesions in the ileum of AS patients, especially by the Paneth cells and 
infiltrating monocyte-like cells of the gut epithelium. IL-23 is also elevated in the sera of AS patients 
and IL-23-producing cells are identified in the facet joints of AS patients. An antibody directed at 
the shared p40 subunit of IL-23 and IL-12 suppressed disease activity in patients with AS in an open-
label study, but phase III data are still pending.IL-23 is necessary for the maturation of Th17 cells 
and the ILC3 subset of innate lymphoid cells. These cells generate IL-17 and TNFα, both being major 
mediators of disease activity in AS. The importance of IL-17 is further supported by the clinical 
effectiveness of an anti-IL-17 antibody, secukinumab, for the treatment of AS.   
The loss of architectural and functional integrity in the intestinal epithelium in a substantial 
proportion of patients with SpA [130] are conduits for microbiota or their metabolites. The first line 
of defense is constituted by macrophages. While the macrophages in the gut of SpA are polarized 
     
Genetic factors by 
functional 
pathway and disease 
AS Psoriasis                                IBD  
   Crohn’s disease Ulcerative Colitis 
Intracellular antigen 
processing  
HLA‑B27, ERAP1 HLA‑Cw6, ERAP1 ERAP2 HLA‑DRA 
Autophagy - - IRGM IRGM 
TH17 pathway IL23R, IL12B STAT3,PTGER4 IL23R, IL12B IL23R, IL12B,STAT3, JAK2, 
PTGER4, PUS10, IL18RAP 
IL23R, IL12B, STAT3, 
JAK2, IL18RAP, PUS10 
NFκB pathway CARD9 REL REL, CARD9 REL, CARD9 REL 
Immune response  IL1R2, ORMDL3 DEFB4, IL2/IL21, 
PTPN22, TYK2 
DEFB4, IL2/IL21, NKX2‑3, 
ORMDL3, PTPN22, 
TNFRSF6B, TYK2 
IL2/IL21, IL1R2, NKX2‑3, 
ORMDL3, TNFRSF6B 
Genes of unclear immune 
relevance  
CDKAL1, KIF21B CDKAL1 CDKAL1, KIF21B, MST1, 
PSMG1 
MST1, PSMG1 
     
Abbreviations: AS, ankylosing spondylitis; IBD, iinflammatory bowel disease; TH17, type 17 T helper (cell). Adapted 
from: Reveille JD. Nat Rev Rheumatol. 2012 Apr 10;8(5):296-304 
Table 2: Genetic factors shared between susceptibility to AS, psoriasis and IBD 
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to accommodate the microbes, the IL-23 that is present activates several cells types which can 
mediate disease, Th17 cells and innate lymphoid cells (ILCs) and innate like T cells such as 
gammadelta T cells or invariant natural killer T cells.   
At the entheses, microtrauma from mechanical stress acts as a coactivator of inflammation [131]. 
IL23 responsive cells have also been described including innate like T cells (particularly gammadelta 
T cells) and ILCs.  
In reality, the most convincing test whether a particular pro-inflammatory mediator plays a role in 
ankylosing spondylitis is to determine if targeted therapies against the putative mediator are 
effective in controlling the disease. Three mediators have been demonstrated to play a role in AS 
based upon that criterion [132]. The first group of medications shown to control disease activity in 
some patients with AS was NSAIDs, suggesting that cyclooxygenase-2 dependent inflammation was 
important in maintaining disease activity [133]. Subsequently, therapeutic trials have focused upon 
those patients whose disease activity is resistant to NSAIDs; in many of these patients, a dramatic 
response is seen to targeted biologic agents that specifically inhibit TNFα [134]. Despite the likely 
importance of TNF-alpha, many of the cellular and molecular mechanisms in AS remain unknown 
[132]. Several clinical trial reports also support the view that IL-17  and IL-23 are important [135-
137]. The data of IL-23 in axial disease were only reported in open label trial and need confirmation. 
In psoriatic arthritis combined blockade of IL-12/IL-23 by anti-p40 is an effective and approved 
therapy. 
 
4.4. Therapy of SpA  
4.4.1. Nonpharmacological treatment: physical therapy and exercise 
Physical therapy and excercise remain the cornerstone of treatment in axial SpA. Home exercises 
are effective, but supervised exercise programs or formal physical therapy can be of greater benefit 
[138]. Optimally, an initial evaluation and training by a physical therapist should be part of the 
therapeutic regimen. Exercises include postural training, range of motion stretching, recreational 
activities, and perhaps hydrotherapy. Smoking cessation is recommended since smoking is a 
modifiable risk factor for poor functional outcome in axial SpA.  
 
4.4.2. Non-Steriodal Anti-Inflammatory Drugs (NSAIDs) 
In axSpA patients suffering from pain and stiffness NSAID should be the first-line drug treatment up 
to the maximum dose, taking risks and benefits into account [139]. Most patients will experience 
improvement as a consequence of the intake of NSAIDs to some extent [140]. Similar response rates 
to NSAIDs were observed in patients with AS and nr-axSpA [141]. For patients who respond well to 
NSAIDs continuous use is preferred if symptomatic otherwise. Whether continuous versus on-
demand treatment with NSAIDs has an inhibitory effect on new bone formation in the spine of 
patients with AS, is still not entirely clarified [142, 143]. Important consideration however needs to 
be given to the potential side effects of NSAIDs (gastrointestinal, cardiovascular and renal), 
especially when administered chronically. NSAIDs should therefore only be prescribed if patients 
are symptomatic.  While there is still discussion on the long-term safety of NSAIDs especially in 
relatively young patients, data from two studies have suggested that lack of exposure to NSAIDs is 
associated with an increase in mortality [144, 145]. This argues against a major or important safety 
problem associated with the use of NSAIDs.  
In patients with mild peripheral arthritis, treatment with NSAIDs can be initiated. Patients with a 
limited number of swollen joints may benefit from intra-articular glucocorticoid injections. In 
patients with arthritis of greater severity, a low to moderate dose of daily oral glucocorticoids can 






4.4.3. Disease Modifying Anti-Rheumatic Drugs (DMARDs) 
In axSpA there is no evidence that DMARDs (sulfasalazine, methotrexate and leflunomide) are 
efficacious for axial symptoms, although, there may be exceptional situations in which there is no 
other pharmacological treatment option left for a particular patient for reasons of toxicity, 
contraindications or costs [146-148].  
In peripheral SpA, sulfasalazine is the only disease-modifying anti-rheumatic drug (DMARD) that 
was proven to be moderately efficacious, however only in patients with peripheral arthritis [149]. 
Methotrexate is the most commonly used first-line DMARD in PsA with peripheral involvement, 
although only limited data are available supporting its efficacy in PsA. Despite the lack of 
randomized trial evidence of efficacy, observational studies and clinical experience indicate that 
methotrexate may be effective for some patients in clinical practice [150-152]. In PsA patients who 
have persistent joint inflammation despite three months of treatment with methotrexate (in 
maximal doses up to 25 mg weekly subcutaneously) and in patients who are unable to tolerate 
methotrexate due to adverse effects, leflunomide can be used [153-156]. 
 
4.4.4. Targeted biological therapies 
4.4.4.1. Response Criteria 
Assessment of treatment and monitoring is important in diseases as axSpA, pSpA and PsA that may 
have several signs and symptoms, and for which several treatments are available. 
In axSpA, the ASAS 20 improvement criteria are often used including four domains: patient global, 
pain, function (assessed by BASFI), and inflammation (mean of BASDAI questions 5 and 6). In order 
to meet an ASAS 20 response, three of the four domains should improve by at least 20 % and a 
minimum of one unit on a scale of 0 to 10. In the remaining domain, there should be no worsening 
of 20 % and a minimum of 1 unit, on a 0 to 10 scale. The ASAS 40 improvement criteria include four 
domains, identical to the ASAS 20 improvement criteria. In order to meet an ASAS 40 response, 
three of the four domains should improve by at least 40 % and a minimum of two units on a scale 
of 0 to 10. In the remaining domain, there should be no worsening of 20 % and a minimum of 1 
unit, on a 0 to 10 scale. 
Recently the Peripheral Spondyloarthritis Response Criteria (pSpARC) 40%, 50% and 70% for pSpA 
were developed and defined as ≥ 40%, 50% or 70% improvement from baseline (≥ 20mm or ≥ 30 
mm absolute improvement) respectively in the VAS scores for Patient Global Assessment of Disease 
Activity (PGA) and Patient Global Assessment of Pain on a 100mm Visual Analogue Scale (VAS), and 
≥40%,  ≥50% and ≥70% improvement in at least one of the following scores: (1) swollen 76-joint 
count (SJC) and tender 78-joint count (TJC); (2) total enthesitis count; or (3) dactylitis count. 
The most used primary endpoints in PsA trials are the ACR 20 , 50, or 70 response which are defined 
as at least 20%, 50%, or 70%, respectively, improvement in tender and swollen joint counts and 
three of five scores of individual elements (VAS scores of patient pain, physician and patient global 
assessment, a disability measure (HAQ) and an acute phase reactant (ESR or CRP)). 
 
4.4.4.2. TNFα inhibitors 
Over the past two decades, a revolution in the treatment of axSpA has been observed, as a 
consequence of the advent of targeted (anti)cytokine treatments, the most prominent ones being 
the compounds targeting TNFα. There are currently five original TNF inhibitors (TNFi) on the 
market, of which four are monoclonal antibodies directed against TNFα, with the fifth (etanercept) 
being a soluble receptor comprised of the TNF p75 receptor fused to human IgG1. TNFi have been 
successfully tested in numerous phase 3 studies in AS leading to clinically important responses such 
as the Assessment of SpondyloArthritis international Society (ASAS) 40% response rate, which was 
achieved in 38% up to 47% of patients (Fig 5). In axial SpA, anti-TNF agents have a comparable 
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efficacy in the early stages not fulfilling the modified New York criteria for AS now commonly called 
nr-axSpA (Fig 5)[140, 157-160]. 
The efficacy of the TNFi in patients with PsA has also been well-documented: in addition to 
improvement in clinical signs and symptoms, these agents also reduce radiographic progression of 






















Fig 5: Pivotal trials with the different TNFi and outcomes in AS, nr-axSpA and PsA. 
 
4.4.4.3. IL 17 inhibitors 
Currently, several agents blocking IL 17 are available (secukinumab) or still under investigation 
(ixekizumab and brodalumab). Given the importance of the Interleukin 17 (IL-17)/interleukin 23 (IL-
23) axis in SpA, this pathway became an obvious novel therapeutic target. Secukinumab is a 
monoclonal antibody directed against IL-17A, which demonstrated very rapid and high clinical 
response rates in moderate to severe plaque psoriasis [173]. Two phase III trials in PsA (FUTURE 1 
and 2) showed a significantly higher proportion of patients achieving an ACR 20 response with 
secukinumab versus placebo regardless of prior TNFi exposure. In the FUTURE 1 study, ACR 20 
responses were reported in 54% and 39% in TNFi naïve patients and TNF experienced patients 
respectively. Besides disease activity, also a positive effect of secukinumab was observed on 
structural damage [174, 175]. 
Two placebo controlled phase III trials in AS (MEASURE 1 and 2) were recently reported, showing 
positive responses, again regardless of prior anti-TNFα exposure. In the MEASURE 2 trial, 43.2% of 
subjects treated with secukinumab 150 mg achieved ASAS40 responses in the TNFi naive group and 
25% in the TNFi experienced group at week 16 [137, 176, 177]. Treatment with ixekizumab, another 
monoclonal antibody that inhibits interleukin-17A, resulted in improvements in disease activity and 
physical function, as well as in the inhibition of structural damage progression in patients with 
active PsA [178]. Evaluation of ixekizumab in patients with PsA with an inadequate response to TNFi 
revealed a signifcant higher proportion of patient achieving a ACR 20 response at week 24 
compared with placebo (53,3% vs 19,5%) [179]. Treatment with brodalumab, an IL-17R antagonist, 
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led to significant improvement in patients with PsA [180]. Although early data suggested a role for 
IL-17 in Crohn’s disease pathogenesis, phase 2 studies with both brodalumab and secukinumab 
failed to demonstrate efficacy in patients with active Crohn’s disease [181, 182]. 
 
4.4.4.4. IL12/23 inhibitors 
Ustekinumab is a humanized monoclonal antibody directed against the shared p40 subunit of IL 23 
and IL12. In a phase III placebo-controlled RCT in PsA (PSUMMIT2) ustekinumab led to significant 
and sustained clinical improvement in both skin and joint symptoms (including TNFi experienced 
patients)[183]. The efficacy and safety of ustekinumab was also evaluated in a prospective, open-
label, proof-of-concept study in AS patients, showing high ASAS40 response (in 65%) at week 24 
[135]. A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the 
efficacy and safety of ustekinumab in the treatment of subjects with active axial spondyloarthritis 
was stopped since neither dose of ustekinumab achieved the study’s primary or major secondary 
endpoints [184]. A phase III trial in patients with moderate to severe Crohn’s disease, refractory to 
TNF-blockers, showed efficacy of ustekinumab in inducing clinical response and remission without 
significant side-effects [185]. 
 
4.4.4.5. Other biologicals 
Biologic drugs targeting other cytokines or cytokine receptors such as IL-1 and IL-6, or controlling B 
and T lymphocytes have been tested in small uncontrolled or controlled trials in SpA. Trials on 
anakinra [186, 187], abatacept [188], rituximab [189, 190], and tocilizumab [191] have shown no 
consistent efficacy. In PsA, however, an ACR20 response of 48% was observed with abatacept, a 
solubilized CTLA-4 molecule fused to human IgG, which was significantly higher than in the placebo 
group [192]. Abatacept was also studied in 451 Crohn’s disease patients and 591 ulcerative colitis 
patients, but showed efficacy in neither condition [193]. 
 
4.4.5. Small molecules 
4.4.5.1. Apremilast  
Apremilast, an orally available, small molecule drug that specifically inhibits phosphodiesterase 4, 
an enzyme that modulates inflammatory cytokines, has been proven to be efficacious for the 
treatment of PsA in several pivotal phase 3 studies of similar design (PALACE 1 to 3). These trials, 
forming the basis for FDA and EMEA approval of apremilast (at a dose of 30 mg BID) for active PsA, 
showed achievement of an ACR20 response in patients receiving 30 mg twice daily after 16 weeks 
in about 40 percent of patients [194, 195]. Benefit was sustained in patients continuing apremilast 
for 52 weeks (ACR20 achieved in 63%), and responses were also maintained for secondary 
outcomes including skin psoriasis severity and physical function [196]. 
A small proof-of-concept placebo-controlled trial of 38 patients with symptomatic AS and active 
disease on MRI suggested some benefit in the change in BASDAI at week 12, although the 
differences between apremilast and placebo did not reach statistical significance [197]. Based on 
these preliminary observations, a larger phase 3 trial was performed in AS, comparing apremilast 
30 mg BID to placebo: however, no difference was observed [18]. 
 
4.4.5.2. JAK inhibitors  
The Janus activating kinase (JAK) family of receptors is associated with multiple cytokine receptors, 
including those for IL-2, IL-6 and IL-12 [198]. It interferes with the JAK–signal transducer and STAT 
signaling pathway, which transmits extracellular information into the cell nucleus, influencing DNA 
transcription. Oral JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib and filgotinib, have 
proven efficacy for the treatment of rheumatoid arthritis. The 2016 EULAR guidelines for the 
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management of RA, recommend JAK inhibitors as a second-line option (after DMARD) as either 
monotherapy or combination therapy [19].  
Tofacitinib demonstrated greater clinical efficacy versus placebo in reducing signs, symptoms and 
objective endpoints of active AS in a phase II trial after 12 week treatment [199]. In patients with 
moderate-to-severe chronic plaque psoriasis, all tofacitinib groups showed that PASI 75 response 
rates at week 12 were significantly higher [200]. Tofacitinib is also investigated for treatment of PsA 
patients: in TNFi-naive PsA patients, tofacitinib was superior to placebo in ACR20 response rates 
and HAQ-DI after 3 months treatment which was maintained to month 12 [201]; in the TNFi 
experienced group both tofacitinib doses showed ACR 20 response in 49.6% and 47% of patients 
treated with tofacitinib 5mg and 10mg respectively [202]. Recently, FDA recommended approval of 
tofacitinib for the treatment of adult patients with active PsA. In patients with active ulcerative 
colitis, tofacitinib was more effective as induction and maintenance therapy than placebo [203] 
although in moderate-to-severe Crohn’s disease primary efficacy endpoints were not met [204].  
 
Table 3: Effectiveness of different biological therapies in SpA and IBD. 
 
4.4.6. Predictors of response to treatment in axSpA 
It is relevant to identify predictors before start of treatment which are able to identify patients that 
will have a beneficial response to biological therapy in axSpA patients, especially considering the 
economic burden and potential side-effects of these agents. Although the majority of AS patients 
respond very well to TNF-blocking therapy, a significant proportion of patients have to withdraw 
from treatment because of inefficacy or adverse events. In clinical practice, the reported 1-year and 
2-year treatment survival rates are 70–85 and 60–75%, respectively [205-208].  
  
AS/axSpA PsA IBD   
TNFα inhibitor Infliximab Effective Effective Effective 
 Adalimumab Effective Effective Effective 
 Etanercept Effective Effective Ineffective 
 Certolizumab Effective Effective Effective 
 Golimumab Effective Effective Effective 
IL-17 inhibitors Secukinumab Effective Effective Ineffective 
 Brodalumab Study has been 
withdrawn prior to 
enrollment. 
Effective in phase III RCT in 
both TNFi naive patients and 
TNFi non-responders 
Ineffective 
 Ixekizumab Phase III trials 
ongoing 
Effective in phase III RCT 
inTNFi naive patients. Phase III 
in TNFi non-responders 
ongoing. 
Ineffective 
IL-12/IL-23 inhibitors Ustekinumab Ineffective Effective Effective 
T-cell costimulation 
blockade 
Abatacept Ineffective in small 
open label study 
Modest effect in phase II trial Ineffective 
B-cell depletion Rituximab Ineffective Modest effect in 2 small open-
label trials 
Ineffective in small RCT in 
UC. No other trials 
Phosphodiesterase 4 
inhibitors 
Apremilast Ineffective in RCT Effective 1 phase II trial ongoing in 
ulcerative colitis 
JAK-inhibitors Tofacitinib Effective in phase II 
trial 
Effective in phase III RCT in 
both TNFi naive patients and 
TNFi non-responders 
In CD: ineffective in two 
phase IIb studies. In UC: 
effective in phase III trials 
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The presence of inflammation at baseline was found to be an important independent predictor of 
achieving response to TNF blocking therapy in almost all studies in AS patients. Increased levels of 
CRP or ESR were predictive for BASDAI50, ASAS20, ASAS40, ASAS partial remission, and AS Disease 
Activity Score (ASDAS) major improvement [205, 206, 209-216], as well as for continuation of TNF-
a blocking therapy[205-207, 217]. The presence of peripheral arthritis was also identified as a 
predictor of both response (BASDAI50 and ASAS20) and treatment continuation [205, 208].  Higher 
Berlin MRI spine score (reflecting the extent of bone marrow edema) was shown to be predictive 
for BASDAI50 response [218]. In patients with nr-axSpA, a baseline SPARCC MRI score ≥2 for either 
the SI joint or the spine was associated with better response after 12 weeks of adalimumab [157].  
These results clearly indicate that axSpA patients with active inflammatory disease are more likely 
to benefit from TNFi therapy than patients with chronic, less inflammatory disease. The ASDAS, a 
composite score of patient-reported measures and acute phase reactants, was found to be an 
independent predictor of ASAS20 and ASAS40 response [205]. Furthermore, clinical responders had 
significantly higher ASDAS scores at baseline than non-responders [219]. Multiple studies have 
identified a better functional status as an independent baseline predictor of clinical response to 
TNFi treatment. Lower Bath AS Functional Index (BASFI) score (indicating better physical function) 
was found to be related to BASDAI50, ASAS20, ASAS40, and ASAS partial remission [206, 209, 211-
214]. In addition, lower Bath AS Metrology Index (BASMI) [214] and lower modified Schober test 
(reflecting less severe restriction of spinal mobility) were predictive for ASAS partial remission and 
BASDAI50 response, respectively [205]. Younger age was identified as a predictor of BASDAI50, 
ASAS20, ASAS40, and ASAS partial remission [205, 206, 213, 214], and shorter disease duration was 
related to BASDAI50 and ASAS40 response [209]. The fact that younger AS patients with shorter 
disease duration and better functional status respond better to TNFi may indicate that less 
structural damage has occurred and more acute inflammation is present in these patients [209]. 
Male sex was found to be predictive for both response (BASDAI50, ASAS20, and ASAS40) [205] and 
treatment continuation [205-208]. Two studies [213, 214] that included a very large number of 
patients in their analyses identified HLA-B27 positivity as a predictor of BASDAI50, ASAS40, and 
ASAS partial remission. It is unclear whether this predictive value can be explained by the fact that 
HLA-B27 positivity results in earlier diagnosis or that the disease biology differs between HLA-B27-
positive and HLA-B27-negative patients [213]. 
Until now, no biomarker nor a set of biomarkers have been found to predict clearly the response 
to TNFi. For evaluating TNFi, not only the response regarding disease activity is important, but also 
the effect on disease-related quality of life and radiographic outcome. A first step has been taken 
to create a prediction model that provides a potential basis for patient selection for TNF-a blocking 
therapy. Age, BASFI, enthesitis, CRP and HLA-B27 were associated with outcomes in AS. Their 
combined use enables adequate prediction of outcome resulting from anti-TNF and conventional 
therapy in various AS subpopulations [213]. The development of such a prediction model may lead 
to a more robust instrument to support physicians to make evidence-based decisions to start anti-
TNF-a treatment in daily clinical practice. 
 
4.4.7. Treatment strategies 
4.4.7.1. EULAR axSpA recommendations 
The individual treatment of patients with SpA is extremely challenging because of the 
heterogeneous character of the diseases that are part of this family of interrelated conditions. Not 
only is there a different therapeutic approach depending on whether the main presenting 
rheumatologic manifestation is back pain, arthritis, enthesitis, or dactylitis but also the presence 
and the extent of extra-articular manifestations such as anterior uveitis, psoriasis and IBD (in order 
of decreasing prevalence) significantly influences the therapeutic decisions in an individual patient. 
In line with a better delineation and acceptance of axSpA, in follow-up of the advent and approval 
of another class of bDMARDs (IL-17 inhibitors (IL-17i)), and after the publication of studies with 
patients covering the entire spectrum of axSpA, recent recommendations were published 
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integrating all different aspects of management into one set of updated recommendations 
applicable to the full spectrum of patients with axSpA [220]. A total of 5 overarching principles and 
13 recommendations were agreed on. The first three recommendations deal with personalized 
medicine including treatment target and monitoring. Recommendation 4 covers non-
pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-
inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6–8 define the 
rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic DMARDs 
for axSpA patents with predominant axial involvement. Recommendation 9 refers to bDMARDs 
including TNFi and IL-17i for patients with high disease activity despite the use (or 
intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an 
elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of 
sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is 
recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can 
be considered in patients in sustained remission (recommendation 11). The final two 
recommendations (12, 13) deal with surgery and spinal fractures [139]. With regard to axial and 
articular/entheseal disease manifestations, there is no evidence for a significant difference in 
efficacy of the various available TNFi. However, a specific recommendation is reserved for extra-
articular manifestations and comorbidities; these frequently observed conditions, such as anterior 
uveitis, psoriasis, and inflammatory bowel disease, should be managed in collaboration with the 
respective specialists. In these cases, a differential efficacy of the available conventional and 
biologic treatment modalities may play an important role. 
 
4.4.7.2. EULAR PsA recommendations 
In 2016, both the European League Against Rheumatism (EULAR) and the Group for Research and 
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) published recommendations on the 
management of PsA [221, 222], which update their earlier guidelines [223, 224]. Both 
recommendations recognize that PsA is a heterogeneous disease and that some patients have 
predominant manifestations that should guide treatment choices. The EULAR recommendations 
has a single flow chart that focuses on peripheral arthritis. This scheme also addresses other 
manifestations of PsA, particularly predominant axial disease, enthesitis, or dactylitis (requiring a 
different initial, but subsequently similar, treatment approach to peripheral arthritis) and 
predominant skin disease (requiring the patient to be referred to a dermatologist). 
The updated EULAR recommendations comprise 5 overarching principles and 10 recommendations, 
covering pharmacological therapies for PsA from NSAIDs, csDMARD and bDMARD, whatever their 
mode of action, taking articular and extra-articular manifestations of PsA into account, but focusing 
on musculoskeletal involvement. The overarching principles address the need for shared decision-
making and treatment objectives. The EULAR treatment algorithm is divided into phases with a 
chronological (or sequential) approach and, therefore, proposes the order in which drugs should 
be prescribed. The recommendations address csDMARDs as an initial therapy after failure of 
NSAIDs and local therapy for active disease, followed, if necessary, by a bDMARD or a targeted 
synthetic DMARD (tsDMARD). The first bDMARD would usually be a tumour necrosis factor (TNF) 
inhibitor. bDMARDs targeting IL-12/23 (ustekinumab) or IL-17 pathways (secukinumab) may be 
used in patients for whom TNF inhibitors are inappropriate and a tsDMARD, such as a 
phosphodiesterase 4-inhibitor (apremilast), could be used if bDMARDs are inappropriate. If the first 
bDMARD strategy fails, any other bDMARD or tsDMARD may be used. 
 
4.4.7.3. Concept of Treat to Target  
The 2017 updated EULAR recommendations for axSpA and PsA focus on a treat-to-target strategy 
[225]. They indicate that treat-to-target should be the standard and general approach to care of 
SpA.  The targets to be achieved within 3–6 months of starting therapy are defined as ‘remission’ 
or, alternatively, ‘low or minimal disease activity’. Patients should be assessed regularly and, if the 
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target is not attained, treatment should be escalated to the next phase of the algorithm. The 2017 
task force arrived at a single set of recommendations for axial and peripheral SpA, including PsA 
[225]. The question whether PsA should be assessed using unidimensional composite scores for its 
different domains or multidimensional scores that comprise multiple domains is not yet resolved 
and constitutes an important research agenda. The ASDAS for axial SpA and the Disease Activity 
index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA are recommended, 
although not supported by all task force members. Shared decision-making between the clinician 
and the patient is seen as pivotal to the process. The task force defined the treatment target for 
SpA as remission or low disease activity and developed a large research agenda to further advance 
the field. 
Minimal disease activity (MDA) in PsA has been defined as the presence of five out of seven criteria, 
comprising musculoskeletal and skin manifestations and patient-reported outcomes [226-229]. The 
results of the Tight Control in PsA (TICOPA) trial [230] provide new evidence for treating to target 
using the MDA criteria. In this trial, patients with active PsA were randomly allocated to either 
standard care or ‘tight control’ with treatment escalation (csDMARDs progressing to biologic 
agents) if the predefined target of MDA was not reached. Patients in the tight-control group had 
more favourable clinical and patient- reported outcomes after 48 weeks than those who received 
standard care. These results provided the first evidence for the validity of a treat-to-target approach 
in PsA, suggesting that MDA could be a useful treatment target in PsA. Treatment targets remain 
on the research agenda for PsA. In 2016, definitions of ‘remission’ and ‘low disease activity’ were 
developed using the DAPSA, which is a simple sum of five variables related to psoriatic joint disease 
[231]. DAPSA has proven face validity and construct validity [232], and remission status is associated 
with no or minimal residual ultrasound signals in the joints [233]. Modification of the MDA criteria 
to require all seven criteria to be met have recently been proposed as defining 'very low' disease 
activity although this state remains to be validated [234]. Other measures with validated definitions 
of remission include the Composite Psoriatic Disease Activity Index (CPDAI) and the GRAPPA 
developed PsA Disease Activity Score (PASDAS) and GRAPPA Composite Exercise (GRACE) Index. 
These indices are more time-consuming to use than DAPSA, but they encompass assessment of 
several PsA domains, including dactylitis and enthesitis, to give a total score. Certain drugs can 
improve some disease domains (for example, the skin) more than others, and how these differences 
are reflected in the multidimensional composite measures is not known. Future studies will 
determine the usefulness of these outcome measures as treatment targets.  
Although no treat to target-study has been performed in axial SpA, it is deemed that such an 
approach could also improve outcomes in axial SpA, given the correlation of damage progression 
with disease activity[4, 235]. Two trials on treatment to target in axSpA are currently ongoing 
(TICOSPA, NCT 03043846, and STRIKE, NCT 02897115), and the research agenda also calls for data 
in peripheral SpA aside from PsA. 
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Based on the overview discussed in the introduction section, it is clear that there are a number of 
unmet needs in diagnosing and treating patients with inflammatory arthritis in general and 
spondyloarthritis in particular.  In this thesis, we try to answer a number of these questions/issues. 
The work is divided into two parts.  
In the first part of this thesis we hypothesized that in vivo detection of TNF by immunoscintigraphy 
with Tc99m-labelled CZP as tracer, may allow better staging of the disease and evaluation of the 
disease activity state. Accurate information on TNFα expression in the joints by 
immunoscintigraphy with Tc99m-labelled CZP could lead to potential implications: pain symptoms 
could be objectified by the demonstration of a culprit cytokine and a positive scintigraphic result 
might indicate that joint tenderness in an individual patient is TNF-driven. A pre-therapy 
immunoscintigraphic approach may allow to help in the selection of the most efficient therapy and 
prediction of response to therapy. The findings of this technique could lead to early detection of 
inflamed joints that might be difficult to assess and may provide a possibility to perform ‘evidence-
based biological therapy’ of arthritis with a view to assessing whether an antibody will localize in 
an inflamed joint before using the same unlabeled antibody therapeutically. This might prove 
particularly important for the selection of patients to be treated since biological therapies can be 
associated with severe side-effects and are considerably expensive.  
The second part of this thesis focuses on treatment modalities in peripheral SpA. The therapeutic 
landscape has profoundly changed with the introduction of targeted (anti)cytokine treatments, 
particularly TNF-α. TNF inhibitors have been successfully tested in numerous phase 3 studies in AS 
and PsA, the two major diseases belonging to the SpA concept, leading to worldwide approval. In 
all management recommendations of axSpA, PsA and RA a treat-to-target approach is 
recommended to achieve a state of clinical remission or low disease activity as soon as possible. 
Several small studies suggest a good efficacy of anti-TNF-therapy in non-AS and non-PsA pSpA. In 
RA, there is accumulating evidence for a so-called ‘window of opportunity’ referring to the 
existence of a transient time frame in which the disease is more susceptible to treatment. In axSpA, 
it was shown that response to treatment was markedly higher in early forms of axial disease with 
high rates of clinical remission. To date, there are no data exploring this concept in pSpA. We 
hypothesized that there could also be a “window of opportunity” for drug-free remission in very 

























Overview of hypotheses and main research questions. 
 
 
PART I: New imaging modalities in SpA and RA 
Given the lack of specificity of current imaging modalities and the late appearance of definitive 
abnormalities, we hypothesized that in vivo demonstration of a culprit cytokine (e.g. TNF) could 
have the potential advantage of early detection of specific inflammatory pathways, thus providing 
a clue to more rational treatment decisions.  Therefore, our objective was to perform a proof-of-
concept study of in vivo detection of TNF by using an immunoscintigraphic procedure with Tc99m-
labelled CZP as tracer in active axial SpA and RA patients and to correlate this with clinical and 
imaging findings as well as therapeutic outcome. In chapter 3, we describe the work-up of this 
scintigraphic technique with focus on the TNF neutralizing activity of various concentrations 99mTc-
S-HYNIC CZP, the biodistribution and dosimetric profile and the effective dose calculation. In 
chapter 4 we report the results of a proof-of-concept study in patients with different forms of 
 Hypothesis Main research questions Chapter 
PART 1 In vivo detection of TNF 
by immunoscintigraphy 
with Tc99m-labelled 
CZP as tracer allows 
better staging of the 
disease and diagnosis of 
the state of activity. 
  
Is in vitro TNF-neutralizing effect of the 99mTc-S-
HYNIC CZP formulation comparable to blocking effect 
observed for unlabelled S-HYNIC CZP and non-
conjugated CZP? 
Chapter 3 
What is the biodistribution and dosimetric profile of 
this tracer in SpA and RA patients? 
Chapter 3 
Is there correlation between tracer-uptake and 
localization of active inflammation, detected clinically 
and by other imaging techniques such as MRI and 
US? 
Chapter 4 
Is the immunoscintigraphy predictive for response to 
treatment with CZP after 12 and 24 weeks? 
Chapter 4 
What are the clinical features of joints with most 
uptake by using this immunoscintigraphic technique 
in patients with EOA? 
Chapter 5 
PART 2 There is a window of 
opportunity for drug-
free remission in very 
early pSpA. 
  
How high is the clinical remission rate at w24 after 
induction therapy with GLM in patients with very early 
pSpA? 
Chapter 7 
What is the spontaneous remission rate in patients 
with very early pSpA? 
Chapter 7 
Is there a ‘window of opportunity’  for drug-free 
sustained clinical remission in very early pSpA?  
Chapter 8 
Which clinical parameters are predictive for sustained 
clinical remission or relapse after medication 




inflammatory arthritis.  In chapter 5, we explore this scintigraphic technique in erosive 
osteoarthritis, a less inflammatory control population, which may however be difficult to 
distinguish from PsA, disease that is also characterized by involvement of the DIP joints.  
 
PART II: New treatment strategies in peripheral SpA 
There is a growing interest in the field of SpA to move from rather restricted and longstanding 
diseases such as AS to a more comprehensive view, encompassing not only inflammatory low back 
pain, but also peripheral arthritis, enthesitis and dactylitis, as well as extra-articular manifestations. 
In chapter 6 we review the classification criteria, the prevalence of peripheral manifestations and 
their impact on biological treatment. The therapeutic options for pSpA are emerging and most of 
the data are coming from pivotal trials in PsA. Over the past two decades, a revolution in the 
treatment of these diseases has been observed, as a consequence of the advent of targeted 
(anti)cytokine treatments, the most prominent ones being the compounds targeting TNF-alpha. The 
efficacy of infliximab, etanercept, adalimumab, certolizumab pegol and golimumab has been 
demonstrated across the different established diseases of the SpA concept (AS,PsA)[1-10]. TNF-
blockade has also a proven beneficial effect on the peripheral manifestations of AS[11]. Several 
small studies suggest a good efficacy of anti-TNF-therapy in non-AS and non-PsA pSpA[12-17]. 
Recently two RCTs in longstanding peripheral SpA confirmed these findings[18, 19]. Moreover, in 
axial SpA, anti-TNF agents were also shown to be effective in treating the early stages of SpA. 
Studies in patients with “non-radiographic axial SpA” (nr-axSpA) have demonstrated at least similar, 
if not better, efficacy responses compared to treatment in a more advanced stage of the disease 
[5, 20-22]. In addition, trials in axial SpA (mainly AS) were set up to evaluate the efficacy of an anti-
TNF discontinuation strategy for maintaining low disease activity or remission after achieving this 
state with a standard dose of anti-TNF therapy. However, in most cases discontinuation of anti-TNF 
therapy led to the appearance of flare within a few months [23-28]. Nevertheless, in ongoing trials 
in axial SpA, a marked interest has been developed in the exploration of a therapy withdrawal 
strategy upon induction of clinical remission (ClinicalTrials.gov: NCT01808118 (adalimumab); 
NCT02509026 (etanercept); NCT02505542 (certolizumab pegol); NCT02407223 (ustekinumab). The 
advent of new medications and new treatment strategies in early stages of axial SpA made it 
possible to achieve remission in more patients than before. In addition to a decrease in the signs 
and symptoms, early and aggressive therapy may also improve the underlying immune disturbance, 
leading to biologic-free and even drug-free remission in a small subset of patients. Currently,  the 
sustainability of drug-free remission is not yet evaluated in early pSpA, although a fast relapse was 
observed in patients with longstanding pSpA after anti-TNF discontinuation [29]. In chapter 7 we 
explore the ‘window of opportunity’ hypothesis in very early peripheral SpA and evaluate if early 
treatment with a TNF-blocker can induce sustained clinical remission. In chapter 8 we investigate 
the possibility of drug-free remission after drug withdrawal and predictors for clinical relapse, as a 
second phase of this research project.  
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Objective: Biologicals directed against Tumor Necrosis Factor (TNF) have proven their efficacy in 
treatment of spondyloarthritis and rheumatoid arthritis. We present a radiolabelling method for 
certolizumab pegol (CZP), a commercially available humanized Fab’-fragment directed against TNF. 
A biodistribution and dosimetry study was conducted. 
 
Methods: 99mTc-S-HYNIC CZP was synthesized. The in vitro TNF neutralizing activity was tested by 
exposing L929s-cells to various concentrations 99mTc-S-HYNIC CZP and measuring TNF induced 
cytotoxicity. For biodistribution and dosimetry, WB images, blood and urine sampling were 
performed up to 24h pi. Cumulative activities were estimated using mono-exponential fitting and 
organ doses were estimated using OLINDA/EXM. The effective dose was calculated using the 
International Commission on Radiological Protection 103 recommendations. The uptake of the 
tracer in the peripheral joints was assessed visually and semi quantitatively. 
Results: In vitro tests showed blocking of TNF cytotoxicity by the 99mTc-S-HYNIC CZP formulation 
comparable to the effect obtained with the unlabelled CZP with or without the HYNIC linker. We 
analyzed 8 patients with rheumatoid arthritis or spondyloarthritis. The highest mean absorbed 
organ doses were recorded for kidneys, spleen and liver: 56 (SD 7), 34 (SD 6), 33 (SD 7) µGy/MBq. 
The effective dose was 6.1 (SD 0.9) mSv for a mean injected activity of 690 (SD 35) MBq. The urinary 
excretion was 15.1% (SD 8.1) of the IA at 22.5h. Blood analysis yielded a distribution half-life of 1.2h 
(SD 1.5) and an elimination half-life of 26.9h (SD 2.7). Visual analysis of the scans revealed marked 
tracer accumulation in the clinically affected peripheral joints. In addition, there was a statistically 
significant higher uptake of the tracer in the swollen joints (median uptake ratio compared to 
background of 3.3 in rheumatoid arthritis and 2.4 in peripheral spondyloarthritis) compared to 
clinically negative joints (respectively 1.3 and 1.6). 
Conclusion: We present a radiolabelling technique for CZP, a Fab’-fragment directed against TNF 
and currently used as a therapeutic agent in rheumatology. An effective dose of 6.1 mSv (SD 0.9) 
was estimated. We confirmed the uptake of this new radiopharmaceutical in clinically affected 
peripheral joints. 
 






Spondyloarthritis (SpA) and rheumatoid arthritis (RA) affect approximately 2% of the population [1, 
2]. A key insight in the pathogenesis was the discovery of the important role played by 
proinflammatory cytokines such as Tumour Necrosis Factor (TNF) [3, 4]. Fifteen years ago treatment 
options have been revolutionized by the introduction of ‘biological agents’, including monoclonal 
antibodies blocking TNF. However, some patients do not or only partially respond to TNF 
antagonism. This might be attributable to lower levels of TNF expression, the involvement of other 
proinflammatory cytokines and/or the development of neutralizing antibodies against the TNF 
blocking agent during treatment. Therefore, on an individual patient level, proof of TNF expression 
in the affected joints might be helpful to optimize biological treatment directed against TNF.  
Certolizumab pegol (CZP) is a Fab’ fragment derived from a humanized monoclonal antibody 
directed against membrane associated as well as soluble TNFα. It is commercially available as Cimzia 
(UCB Celltech, Slough, Berkshire, UK). In this manuscript we describe the procedure of 
radiolabelling CZP and report the in vitro activity. Secondly, we document the biodistribution and 
dosimetric profile of this new radiopharmaceutical. Finally, we correlated the uptake of 
radiolabelled CZP with the findings on clinical examination in patients with peripheral joint 
involvement. 
 
PATIENTS AND METHODS 
 
Synthesis of 99mTc-S-HYNIC CZP 
All preparations were carried out under aseptic conditions working in a LAF IIa cabinet. 
 
Derivatisation of CZP for injection with S-HYNIC 
A 200 mg lyophilized CZP vial was reconstituted with water for injection (B. Braun, Melsungen AG, 
Germany). Respectively 100 mg, 50 mg and 25 mg CZP was transferred to a Slide-A-Lyzer with cut-
off of 10 kDa (Pierce Protein Research Products, Thermo scientific, Rockford, USA) and dialyzed 
against 500 ml of a mixture of a Dulbecco’s Phosphate buffered saline (Lonza, Verviers, Belgium) 
and a self-prepared 0.9% m/v sodium chloride solution (Riedel-deHaën, Seelze, Germany) in 1:2 v/v 
ratio. Dialysis was maintained for 4h at 2-8°C, with the buffer refreshed after 1.5h. Subsequently, 
0.5 ml of a 8.4% sodium hydrogen carbonate (Merck, Darmstadt, Germany) solution was added to 
the solution followed by 10 5.0 µl portions of respectively a 1.7%, 0.86%, 0.43% m/v solution of S-
HYNIC (ABX GmbH, Radeberg, Germany) in dry DMSO (Merck, Darmstadt, Germany) at a pace of 1 
portion/min [5]. This yielded an average of 2.8 S-HYNIC groups per CZP. After 30 min incubation at 
room temperature in the dark, the reaction was quenched by adding 3.0 ml cooled 0.15 M acetate 
buffer pH 5.0 (Merck, Darmstadt, Germany). The unreacted S-HYNIC was removed by dialyzing the 
reaction mixture in a Slide-A-Lyzer (cut-off of 10 kDa) overnight at 2-8°C against 500 ml acetate 
buffer, which was refreshed after 1, 2 and 3h. The solution was diluted to 40.0 ml with 0.15 M 
acetate buffer pH 5.0 and membrane filtered (0.22 µm). Following dispensing into 1.0 ml portions, 
the glass vials were stored at -80°C or 2-8°C for 3 months. Three concentrations of CZP were 
obtained: respectively 2.5, 1.25 and 0.625 mg of S-HYNIC coupled CZP. Quality control was done by 
determination of the protein concentration (BCA protein reagent) and the p-NBA HYNIC assay to 
measure the number of S-HYNIC bifunctional chelator coupled to the protein.  
 
Preparation of the co-ligand kit 
A solution containing 4.66 mM tin(II) sulphate (Sigma Aldrich, Steinheim, Germany) and 55.81 mM 
tricine (Sigma Aldrich, Steinheim, Germany) dissolved in ultrapure sterile and pyrogen free water 






Radiolabelling with 99mTc 
50 µL co-ligand kit and 925 MBq (±10%) 99mTc pertechnetate were consecutively added to the S-
HYNIC CZP vial (2.5, 1.25 and 0.625 mg). After 15 min incubation, physiological saline was added in 
order to obtain a volume of 3 ml. Quality control was carried out by instant thin layer 
chromatography (iTLC) with SilG as stationary phase and 0.9% NaCl solution as mobile phase. For 
the clinical study, the 1.25 mg S-HYNIC CZP vials stored at -80°C were used and the radiochemical 
yield needed to exceed 90%. 
 
Stability study 
The impact of aggregation on the chemical stability and radiochemical yield during storage of the 
formulation at 3 different concentrations (2.5, 1.25 and 0.625 mg) was studied over a 3-month 
period. Aggregate formation was assessed by Size-exclusion HPLC (Agilent Zorbax Diol guard 
column), 4 x 12.5 mm, in series with a GF450, 9.4 x 250 mm and a GF250 Size exclusion analytical 
column, 9.4 x 250 mm (Agilent Technologies, Diegem, Belgium). The mobile phase was composed 
of a mixture of a 200 mM phosphate buffer pH 7.0 and ethanol 90:10 v/v (1 ml/min, 30 min). 
Influence on the radiochemical incorporation of 99mTc was studied by iTLC as described earlier. 
Analyses were performed after preparation, at 2 weeks, 1 month and 3 months post production. 
 
In vitro activity of 99mTc-S-HYNIC CZP against TNF-induced cytotoxicity 
Murine fibrosarcoma TNF-sensitive L929s cells were cultured for 24h by seeding 20,000 cells/well 
in 96 well plates, incubated at 37°C with 5% CO2. The culture medium consisted of DMEM (GIBCO-
BRL,41965-062) supplemented with 10% fetal calf serum, 400 µM sodium-pyruvate (Sigma) and 
non-essential amino acids (Lonza). The following day 55 µl human TNF (6,8x107U/ml), produced by 
the Protein Service facility of VIB (Ghent, Belgium) was added at various concentrations (10 
dilutions starting at 300 U/ml) to the test solutions at room temperature. The following solutions 
of antibodies directed against TNF were tested: CZP, S-HYNIC CZP, 99mTc-S-HYNIC CZP and infliximab 
(Remicade, Merck, Johnson & Johnson). Dilutions of 250, 50 and 10 ng/ml anti-TNF antibodies (55 
µl) were preincubated with the human TNF for 45 min, as well as control samples without TNF 
blocking agents. Actinomycin D (Sigma, 1mg/ml dissolved in absolute ethanol), at a final 
concentration of 1 µg/ml was also added. 24 hours following the exposure to the test solutions, 
TNF cytotoxicity was measured using the MTT-test by adding 20 µl filter sterilized 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma, 5mg/ml). After 4h, 80 µl 
stopping solution (10% SDS, 0.01M HCL) was added and the read out was performed by a 
multichannel plate reader at a wavelength of 595 nm with a reference at 655 nm. The percentage 
of cell survival was estimated according to the formula below: 




The study was conducted in accordance with the Helsinki declaration and was approved by the 
ethical committee of the Ghent University Hospital. All patients signed an informed consent. Patient 
selection was limited to subjects aged 18-70 years and meeting respectively the “American College 
of Rheumatology” (ACR) criteria for RA [6] or the “Assessment of SpondyloArthritis international 
Society” (ASAS) criteria for axial or peripheral SpA [7, 8]. Patients were not allowed if they had 
previously been treated with CZP or any other biological treatment. For more detailed information 
on the clinical eligibility criteria, we refer to the online detailed study protocol (EudraCT number: 
2009-017998-37, http://clinicaltrials.gov/show/NCT01590966). 
Scan procedure, blood and urine sampling  
All patients were scanned on the same double headed gamma-camera (BrightView, Philips 
Healthcare, Best, The Netherlands). First, an attenuation map was obtained from a whole body 
(WB) scan using a Cobalt-57 flood source. Subsequently, the patient was injected IV with 10.6 
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MBq/kg 99mTc-S-HYNIC CZP. The net IA was calculated following correction for rest activity in the 
syringe and exact time of administration (Veenstra ionization chamber VIK-202, Veenstra 
Instruments, The Netherlands). WB images (15 cm/min, 1024x512 matrix, pixel size 2.80 mm) were 
performed immediately following administration, at 1h, 4-6h and 24h post-injection (pi). A standard 
activity of approximately 5 MBq 99mTc in an unshielded syringe was always in the field of view for 
quantification purposes. Static images (5 minutes, 256x256 matrix, pixel size 2.33 mm) of hands 
and feet were acquired immediately following the first WB scan, at 4-6 and 24h. 
All visualized organs (heart, lungs, liver, spleen, kidneys), as well as regions of interest (ROIs) for the 
WB, background and standard activity were delineated manually on the 4 geometric mean images, 
generated from the WB scans (Nuclear Diagnostics, Stockholm, Sweden). For each organ, 
attenuation correction factors were calculated based on measured conversion factors on our 
camera from 57Co to 99mTc. These conversion factors were derived from sequential attenuation 
scans with a 99mTc flood source and a 57Co flood source in the first patient. The activity measured in 
the urine collections between the scans was used to correct the estimated activity in the WB 
compartment. Cumulated activities in the WB and various organs were estimated using mono-
exponential fitting and converted to time integrated activity coefficients to be processed by 
OLINDA/EXM 1.1 software (Stabin M. Vanderbilt University, Nashville) to estimate the absorbed 
organ doses. The adult male and female mathematical reference phantoms were applied. A bladder 
voiding interval of 4h was included in the model. In OLINDA/EXM 1.1, effective doses (ED60) were 
directly calculated using ICRP 60 tissue weighting factors [9]. In order to account for the recent ICRP 
103 recommendations, the effective dose was recalculated manually by combining the ICRP 103 
tissue weighting factors and the organ doses from the OLINDA/EXM 1.1 output (ED103) [10]. As 
some organs contributing to ED103 are not listed in the OLINDA/EXM 1.1, the sum of tissue-
weighting factors for the available target organs were calculated (0.913 for men and 0.922 for 
women). In the ED103 calculation these factors were accounted for by scaling [11].  
Urinary tracer excretion was measured in sequential urine collections at 1h, 4-6h and up to 24h pi. 
Total volumes were recorded. Blood sampling was performed immediately following IV tracer 
injection from a vein in the contralateral arm, and subsequently at 1h, 4-6h and at 24h pi. 99mTc 
activity was measured in 2ml blood and urine samples in triplicate  on a calibrated NaI(Tl) 3”x3” 
gamma well counter (Cobra II, Perkin Elmer, USA). The raw count data generated from the NaI(Tl) 
3x3” detector were converted to kBq by a calibration curve.  The standard samples -in the same 
geometry as the urine and blood samples- were prepared from a stock solution which was 
measured in the same calibrated dose calibrator (ionization chamber) used to measure the 99mTc-
HYNIC CZP syringes.  Results were decay corrected and expressed as kBq/ml and as %IA.  
To assess the tracer accumulation in the peripheral joints, we scored each joint visually and semi 
quantitatively. The latter was done by manually drawing ROIs around each joint (Hermes, Nuclear 
Diagnostics, Sweden). For each individual scan a background ROI was defined within the field of 
view, e.g left supraclavicular region on WB, right forearm on static images of the wrists and hands, 
right distal tibia for the static images depicting the ankles and feet. These results were compared 
with the findings on clinical examination for each assessable joint. The nuclear medicine physician 
reading the immunoscans and the clinician performing the clinical examination were blinded to 
each other’s observations. Groups were compared by Mann-Whitney U test using IBM SPSSv21 
software (NY, USA).  
 
RESULTS 
Preparation of S-HYNIC CZP  
After preparation, the 2.5, 1.25 and 0.625 mg vials contained respectively 105, 98.5 and 99.8% of 
the label claim for the total amount of protein indicating that no protein losses were observed 
during the different handling steps. The results of the p-NBA S-HYNIC incorporation test showed a 
respective ratio of S-HYNIC/CZP of 1.2, 1.5 and 2.0. No substantial losses were observed for the vials 
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stored at -80°C. In contrast, all formulations of the vials stored at 2-8°C suffered from a decrease of 
the S-HYNIC/CZP ratio <0.1 after 3 months of storage.  
The influence of storage temperature on aggregation and radiochemical yield 
At -80°C no change in the amount of aggregation was observed over time, nevertheless the amount 
of aggregation (mean for the 3 formulations: 1.7%) was somewhat higher compared to the CZP 
blank formulation (<0.5%). At 2-8°C however aggregation increased over time with the highest 
amount (20%) of aggregation observed for the 2.5 mg CZP formulation after 1 month of storage. All 
formulations stored at -80°C had radiochemical yields >95%. For the storage at 2-8°C all 
radiochemical yields were >95% except for the 2.5 mg formulation of which the yield decreased to 
55%. 
In vitro testing of the specific TNF neutralizing activity of the 99mTc-S-HYNIC CZP formulation 
In the samples exposed to 99mTc-S-HYNIC CZP, the cytotoxic activity of TNF was completely blocked 
at doses as low as 10 ng/ml (Fig. 1). The TNF neutralizing effect of the 99mTc-S-HYNIC CZP formulation 
was comparable to the effect obtained with the unlabelled CZP with or without the HYNIC linker. 
Infliximab, another TNF blocker that was used as a positive control, also showed good neutralizing 
activity, although it was less active at the doses used (Table 1). 
 
TABLE 1: Effect on survival of TNF sensitive L929s cells following exposure to 300 U/ml human TNF 
and various test solutions of TNF blocking agents in the presence of 1 µg/ml Actinomycin D.  
 
 Mean % cell survival (SD) 
Tested TNF blockers at 3 concentrations 99mTc-S-HYNIC CZP S-HYNIC CZP CZP Infliximab 
Control (no TNF blocker) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
250 ng/ml 109.1 (2.6) 111.9 (0.5) 81.8 (1.5) 81.1 (3.9) 
50 ng/ml 113.8 (4.2) 111.0 (2.2) 96.1 (23.2) 57.4 (1.4) 










Fig 1: Cell survival of TNF sensitive L929s cells following exposure to 0-300 U/mL of human TNF 
solutions and preincubated with 250 ng/ml, 50 ng/ml, 10 ng/ml 99mTc-S-HYNIC CZP. In the control 
experiment the cells are exposed to TNF but no inhibitor (99mTc-S-HYNIC CZP) is added.  
 
Patient study 
We analyzed 8 patients (4 males and 4 females): 1 RA patient, 2 peripheral SpA patients and 5 axial 
SpA patients. The median age was 44 years (range 26-68). A mean (standard deviation, SD) activity 
of 690 (SD 35, range 665-728) MBq 99mTc-S-HYNIC CZP (1.07 mg, SD 0.04, range 1.01-1.10) was 
injected. There were no adverse or clinically detectable pharmacologic effects in any of the 
subjects. 
On the WB images we observed high tracer uptake in the bloodpool and liver, and less pronounced 
uptake in the spleen and kidneys. WB scintigraphy and static images of the hands of a woman 
suffering axial SpA are depicted in Fig. 2 and illustrate the ‘normal peripheral distribution’ of 99mTc-
S-HYNIC CZP. Patients with peripheral joint involvement showed typical patterns on 
immunoscintigraphy with a poly-articular pattern in RA and involvement of the distal interphangeal 
joints, dactylitis and tenosynovitis in psoriatic arthritis (Fig. 3 and 4). The tracer uptake in the 
affected joints persisted over time. In the patient with RA, 16 joints showed marked tracer 
accumulation, and 4 of these joints were clinically swollen. Out of the 50 negative joints on 
scintigraphy, all but one were also negative on clinical examination for swelling. Semi quantitative 
analysis yielded a median uptake ratio in swollen joints of 3.3 (range 0.6-7.5) vs 1.3 (range 0.8-5.0) 
in joints negative for swelling on clinical examination (p<0.001 Mann-Whitney U test). In the 2 
patients with peripheral SpA, 29 joints were visually scored positive on the immunoscan of which 
20 joints were swollen on clinical assessment. Amongst the 147 joints negative on scintigraphy, 144 
were also clinically classified as not swollen. Semi quantification yielded a median uptake ratio of 
swollen joints of 2.4 (range 1.0-6.3) versus 1.6 (range 0.3-3.3) in non-swollen joints (p<0.001 Mann-




Fig 2: A: WB images immediately (left), 5h (middle) and 24h (right) pi of 706 MBq 99mTc -S-HYNIC 
CZP. B: Static images (at 5h pi) of the hands in a female suffering axial SpA. This patient presented 
with only radiographic axial involvement and had no signs of peripheral articular involvement. No 
enhanced tracer uptake in peripheral joints or the axial skeleton was noted.  
 
Fig 3: Static images approximately 15 min (left) and 5h (right) pi of 99mTc -S-HYNIC CZP in a patient 
suffering RA. A typical poly-articular pattern in the hand joints without distal interphalangeal 
involvement is observed. 
 
Fig 4: Left: Static images in a man suffering psoriatic arthritis, acquired approximately 5h pi of 99mTc-
S-HYNIC CZP. Uptake in the metacarpophalangeal, proximal and distal interphalangeal joint of the 
right 2nd digit is observed, compatible with dactylitis. Right: Tracer uptake 5h pi in both the joints 
and the accompanying flexor tendon in a female suffering psoriatic arthritis with clinically dactylitis 




According to our dosimetry study, the highest organ doses were attributed to the kidneys, spleen 
and liver with estimates of respectively 38.7 (SD 5.1) mGy, 23.4 (SD 4.3) mGy and 22.6 (SD 4.8) mGy 
or 56 (SD 7), 34 (SD 6), 33 (SD 7) µGy/MBq. Table 2 summarizes our findings for the various organs 
included in the analysis. The estimated mean ED60 and ED103 were 8.93 (SD 1.14) µSv/MBq and 
8.89 (SD 1.31) µSv/MBq respectively. Taking into account the administered activity of 690 (SD 35) 
MBq, a mean ED60 and ED103 of 6.2 (SD 0.9) mSv and 6.1 (SD 1.0) mSv is obtained.  Fig. 5 shows 
the average time-activity curves as a percentage of the IA for the different organs. It can be 
observed from this figure that the mono-exponential fit adequately models the data. The urinary 
excretion was 15.1% (SD 8.1) of the IA at 22.5h. The cumulative urinary excretion is tabulated in 
Table 3. The blood clearance shows a biphasic bi-exponential shape.  Blood samples were fitted to 
a 2-compartment model by the least square method. As illustrated in Fig. 6, a distribution half-life 
of 1.2h (SD 1.5) and an elimination half-life of 26.9h (SD 2.7) were estimated. 
 
Fig 5: Average time-activity curves for the organs with the highest tracer uptake, as a percentage of 










Fig 6: Clearance of radioactivity (kBq/mL) from the blood for all individual patients. The mean curve 
represents the calculated mean clearance from the blood according to a 2-compartment model. 
Activities are decay corrected to the time of injection. A distribution half-life of 1.2h (SD 1.5) and 
an elimination half-life of 26.9h (SD 2.7) were estimated. 
 
TABLE 2: Summary of the organ doses, expressed per injected MBq of 99mTc labelled S-HYNIC CZP 
as well as for the total mean administered activity of 690 MBq. 
organs organ dose  
µGy/MBq 
mean and SD 
total organ dose 
mGy 
mean and SD 
Brain 1.3 0.5 0.9 0.3 
Skin 1.8 0.3 1.2 0.2 
Thyroid 2.1 0.4 1.4 0.3 
Uterus 4.6 0.5 3.3 0.4 
Ovaries 3.9 0.5 2.7 0.4 
Testes 1.7 0.5 1.1 0.4 
Breasts 3.7 0.5 2.5 0.4 
Red Marrow 3.8 0.4 2.6 0.3 
Muscle 3.5 0.5 2.4 0.3 
Small Intestine 4.3 0.6 3.0 0.4 
ULI Wall 4.9 0.7 3.4 0.5 
LLI Wall 3.1 0.7 2.2 0.5 
Stomach Wall 6.3 1.0 4.3 0.7 
Thymus 6.9 0.8 4.7 0.5 
Osteogenic Cells 7.4 1.4 5.1 1.0 
Pancreas 10.8 1.6 7.4 1.1 
Adrenals 11.2 1.7 7.7 1.2 
Gallbladder Wall 11.9 1.8 8.2 1.2 
Lungs 18.6 2.7 12.8 1.9 
Urinary Bladder Wall 19.9 8.3 13.7 5.8 
Heart Wall 30.6 5.1 21.1 3.5 
Liver 32.7 6.9 22.5 4.7 
Spleen 34.0 6.2 23.4 4.3 








Based on large randomized controlled trials there is evidence for a therapeutic benefit of TNF 
blocking agents in RA, axial SpA and psoriatic arthritis [12-14]. Several TNF-blockers have also 
proven their clinical value in psoriasis and inflammatory bowel disease [15, 16]. Imaging studies 
utilizing these biological agents could offer an individually tailored approach to pick the treatment 
which targets the disease best. This is in the interest of the patient who will not be exposed to 
unnecessary therapies. It also represents a cost saving for society, since these biologicals often 
involve substantial financial costs. But besides these practical potential benefits, the imaging 
studies open a window on various pathophysiological and pharmacokinetic aspects. 
CZP differs from other TNF-blockers because of its link with polyethylene glycol [17-20]. This 
PEGylation has been shown in animal studies to drive preferential distribution to inflamed tissue 
over normal tissue, to a greater extent than observed with adalimumab and infliximab [20].  
In the past only few attempts were made to visualize TNF antagonists in patients (21). So far no 
radiolabelling was reported for CZP.  
In a first step, we confirmed that the in vitro TNF neutralizing effect of the 99mTc-S-HYNIC  CZP 
formulation was comparable to the blocking effect observed for the unlabelled S-HYNIC CZP and 
the non-conjugated CZP. Considering the low ratio of radiolabelled S-HYNIC CZP to cold S-HYNIC 
CZP in the samples exposed to 99mTc-S-HYNIC CZP, this experiment cannot serve as a direct proof of 
specific binding of 99mTc-S-HYNIC CZP to TNF. However, the satisfying blocking effects obtained with 
cold S-HYNIC CZP are a strong indirect indication since it is rather the conjugation with S-HYNIC that 
is expected to affect the TNF affinity rather that the addition of 99mTc.  
In a second step, the conditions for derivatisation with S-HYNIC, storage temperature and 
radiolabelling of CZP were optimized. Optimal yields were obtained in storage conditions at -80°C. 
Under these conditions no cleavage of S-HYNIC from CZP was observed as indicated by the molar 
ratio of incorporated S-HYNIC/CZP which remained stable at 1.5 for the 1.25 mg CZP formulation. 
The influence of mass was demonstrated with approximately 20% of aggregates for the 2.5 mg 
formulation. For these reasons the 1.25 mg CZP formulation stored at -80°C was selected for the 
clinical part of the study.  
The presented clinical trial reports on the first in vivo use of 99mTc-S-HYNIC CZP. WB images were 
acquired and blood and urine samples were collected up to 24h pi in 8 patients suffering from RA 
or SpA. The highest organ doses were recorded for kidneys, spleen and liver. The effective dose was 
6.1 mSv for a mean IA of 690 MBq. The obtained estimate for ED60 (8.9 µSv/MBq) should be viewed 
in the light of other tracers, such as 99mTc labelled bisphosphonates (5.7 µSv/MBq) and HIG (Human 
ImmunoglobulinesG) (7.0 µSv/MBq), which are – despite their limited clinical value in this specific 
context – often used in this patient population [21].  
We observed marked tracer accumulation in the clinically affected peripheral joints, which 
persisted at 24h. Barrera and coworkers published encouraging findings with radiolabelled 
adalimumab in 10 patients with active RA [22]. They radiolabelled this human anti-TNF monocIonal 
IgG1 with 99mTc via S-HYNIC. They report uptake in most of the affected joints, starting within 
minutes after injection and persisting at 24h. The accumulation of tracer in clinically involved joints 
Interval p.i 
Mean (SD) 
cumulative urinary excretion  
mean (SD) %IA 
1.5h (0.3) 4.3% (2.1) 
4.5h (0.4) 8.5% (3.2) 
22.5h (1.4) 15.1 % (8.1) 
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was often a factor 2 higher compared to the clinically unaffected joints, which is concordant with 
our observations. However, in a clinical context of increased vascularization and capillary 
permeability, it is doubtful to attribute the 99mTc-S-HYNIC CZP uptake predominantly to specific in 
vivo binding despite the encouraging in vitro assay described above.  
The presented study, mainly dealing with biodistribution and dosimetry data from 8 patients, was 
conducted in the framework of a larger clinical trial (24). In this trial 20 patients underwent 
immunoscintigraphy with 99mTc-S-HYNIC CZP and were subsequently treated with CZP for 24 weeks. 
The expected joint involvement patterns in both peripheral and axial disease were detected by 
immunoscintigraphy with radiolabeled CZP: poly-articular pattern in RA, distal interphangeal 
involvement and dactylitis in psoriatic arthritis, and enthesitis and sacroiliitis in SpA. The probability 
of a joint remaining tender despite 24 weeks of CZP treatment was significantly smaller in joints 
with clear tracer uptake as compared to those without on baseline immunoscintigraphy.  
No adverse events were recorded following injection of 99mTc-S-HYNIC CZP. No clinical effect on 
disease activity was observed within a timeframe of 2 weeks after the scintigraphic procedure. This 




We present a radiolabeling technique for CZP, a biological agent, directed against TNF and currently 
indicated for treatment of moderate to severe RA, axial SpA and psoriatic arthritis. Following 
injection of 690 MBq 99mTc-S-HYNIC CZP in 8 patients, an ED103 of 6.1 (SD 0.9) mSv or 8.9 (SD 1) 
µSv/MBq was estimated. Urinary excretion was 15.1% of the IA at 22.5h pi. The distribution and 
elimination half-life in blood was estimated to be respectively 1.2 (SD 1.5) and 26.9h (SD 2.7). We 
obtained good accumulation of the tracer in the clinically affected peripheral joints of patients 
suffering from active RA or peripheral SpA.  
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Background: Biologicals are the cornerstone of many treatment algoritms in inflammatory arthritis. 
While TNF inhibitors may achieve important responses in approximately 50% of rheumatoid 
arthritis (RA) and spondyloarthritis (SpA) patients, a significant fraction of patients are partial or 
non-responders. We hypothesized that in vivo assessment of TNF by scintigraphy with 99mTc-
radiolabeled Certolizumab pegol (CZP) might lead to a more ‘evidence-based biological therapy’.  
Objectives: Our goal was to perform a proof of concept study of in vivo detection of TNF by 
immunoscintigraphy of a radiolabeled TNF inhibitor in RA and SpA and correlate with clinical, 
imaging findings and therapeutic outcome. 
Methods: CZP was conjugated with succinimidyl-6-hydrazino-nicotinamide (S-HYNIC) and 
subsequently radiolabeled with Tc99m. Whole body and static images of hands, feet and sacroiliac 
joints of 20 patients (5 RA; 15 SpA) were acquired at 3 time points. Immunoscintigraphic findings 
were scored semiquantitatively. Subsequently, all patients were treated with CZP. 
Results: In peripheral joints, clinical affected joints  or abnormal ultrasound findings were observed 
more frequently (P<0.001) in the scintigraphic positive group. In axial SpA patients, bone marrow 
edema (BME) on MRI was detected more frequently (P<0.001) in quadrants with tracer uptake. On 
patient level, the odds of a joint remaining tender despite 24 weeks of CZP treatment, was 
significantly smaller in joints with clear tracer uptake as compared to those with no uptake 
(OR=0.42, P=0.04).  
Conclusions:  Immunoscintigraphy with radiolabeled CZP  demonstrated both axial and peripheral 
inflammation and displayed good correlation with clinical features, conventional imaging and 
therapy response. 
 
Key messages:  
 Typical joint involvement patterns in both peripheral and axial disease were detected by 
using a immunoscintigraphic procedure with radiolabeled CZP: poly-articular pattern in RA, 
DIP involvement and dactylitis in psoriatic arthritis, and enthesitis and sacroiliitis in SpA.  
 A strong relation with clinical involvement and immunoscintigraphic uptake was observed: 
tender or swollen joints or abnormal ultrasound findings, were significantly more prevalent 
when scintigraphy was positive.  
 In axial SpA patients, bone marrow edema on magnetic resonance imaging was observed 
more frequently  in quadrants that also showed uptake of the radiolabeled CZP.  
 A marked relation with therapy response was observed: the odds of a joint remaining 
tender despite 24 weeks of CZP treatment, was significantly smaller in joints with clear 














INTRODUCTION:   
Rheumatoid arthritis (RA) and Spondyloarthritis (SpA) are both chronic inflammatory joint diseases 
with a combined prevalence close to 2%. If untreated, persistent inflammation may lead to 
functional disability, progressive structural damage and potentially also a number of extra-articular 
manifestations or comorbidities [1, 2].  Currently, the etiology is unknown, but a combination of 
predisposing genetic factors, and person-related or environmental factors (age, gender, infectious 
agents, smoking and dietary factors) is suspected to play a role in disease pathogenesis [3, 4].  
Treatment strategies for SpA and RA have changed dramatically over the last decade, mainly as a 
consequence of our growing knowledge of the pathogenetic role of proinflammatory cytokines, 
such as tumor necrosis factor alpha (TNFα) [5, 6].  
Immunohistological studies demonstrated the presence of TNFα and its receptors in inflamed 
tissues of peripheral and/or sacroiliac joints [7]. The introduction of ‘biological agents’ targeting 
TNFα, with either monoclonal antibodies (incl. Fab fragments) or receptor-fusion proteins, has 
revolutionized our therapeutic armamentarium. Treatments neutralizing TNFα have the longest 
track record in RA and SpA: currently 4 monoclonal antibodies (adalimumab, certolizumab, 
golimumab, infliximab) and 1 receptor-fusion protein (etanercept) are available[8]. Certolizumab 
pegol (CZP) (UCB Celltech, Slough, Berkshire, UK) is an engineered humanized monoclonal antibody 
Fc-free Fab′ fragment with specificity for human TNF-α, manufactured in E. coli. The antibody 
fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol 
(PEG) (40kDa). CZP is approved worldwide for adult patients with moderate to severe active RA, AS 
and psoriatic arthritis [9-11]; moreover, the drug also received marketing authorization in Europe 
for the indication of non-radiographic axial SpA [12]. In addition to RA, CZP has demonstrated a 
positive benefit risk in Crohn’s disease and psoriasis [13, 14]. 
In clinical trials, both for RA and SpA, approximately 50% of patients achieve a clinically important 
response such as an American College of Rheumatology (ACR) 50% response rate or the 
ASsessments in Ankylosing Spondylitis (ASAS) 40% response rate [9, 11, 15-22]. Despite an overall 
impressive improvement in clinical signs and symptoms when a TNF-blocking agent is administered, 
there is still a significant proportion of patients that do not reach a relevant response (primary non-
responder), have insufficient improvement, or that loose an initial good response over time 
(secondary non-responder). This may be due to lower levels of TNFα expression at the site of 
inflammation as it is known that there may be a large inter and intra-individual variability in these 
levels [23], or to the fact that the disease is in fact predominantly driven by other proinflammatory 
cytokines. In an era of evidence-based medicine, it is disappointing to realize that treatment 
decisions or strategies, even for expensive biological agents, are driven by patient reported 
outcomes, difficult to standardize clinical examinations (joint counts), rather aspecific laboratory 
parameters (elevated CRP), or questionable imaging cut-offs (erosions, sacroiliitis grade 2 by 
modified New York criteria for AS). An accurate way of predicting a relevant clinical response to a 
certain targeted treatment would allow  better patient selection. Molecular imaging studies aiming 
at selectively visualizing TNFα (or another suspected culprit cytokine) in vivo at the site of clinical 
inflammation, could be an attractive alternative to other less specific and/or invasive techniques 
such as bone scintigrapy with 99mTc labeled diphosphonates or synovial biopsies taken by 
arthroscopic procedures. Such a more rational approach of determining the most appropriate 
biological treatment for an individual patient, may also have relevant consequences for the cost-
efficacy of our currently available biological drugs, and even have an impact on the design of future 
clinical trials with targeted therapies. Therefore, we performed a proof-of-concept study to explore 
the possibility of visualizing TNF-driven disease in patients with active RA and SpA using scintigraphy 
with Tc99m-labeled certolizumab pegol (CZP) as tracer and to correlate the anti-TNF bound tracer 






PATIENTS AND METHODS 
Patients 
The study was approved by the Medical Ethics Committee of the Ghent University Hospital and 
each patient gave written informed consent. The study was conducted in compliance with 
International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration 
of Helsinki. (EudraCT number: 2009-017998-37). 
We included 20 adult (18-70 years) patients with RA (n=5), peripheral SpA (pSpA) (n=6) or axial SpA 
(axSpA) (n=9). Patients were recruited from the Rheumatology Outpatient Clinic of the University 
of Ghent, Belgium from November 2012 till November 2013. 
All patients with RA fulfilled both the ACR revised criteria for the diagnosis of RA [24] and the 2010 
American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 
classification criteria [25] and all patients with SpA fulfilled the current ASAS classification criteria 
for axial or peripheral SpA [26, 27]. Patients with RA fulfilled Belgian reimbursement criteria for the 
initiation of anti-TNF agents (including failure of at least 2 disease modifying anti-rheumatic drugs 
(DMARDs), one of these being methotrexate) and had active disease (DAS 28 ≥3.7) with at least 5 
swollen joints at screening. Patient with pSpA had active arthritis, dactylitis or enthesitis at 
screening despite treatment with an adequate stable dose of Sulfasalazine or Methotrexate for at 
least 3 months, or a stable, full dose of NSAIDs for at least 4 weeks.  Patients with axSpA patients 
were required to still have active disease (despite a stable, full dose of NSAIDs for at least 4 weeks), 
defined as a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4 (0-10) and active 
inflammatory lesions on magnetic resonance imaging (MRI) of the sacroiliac joints (according to the 
definition of a positive MRI proposed by the Assessment of SpondyloArthritis international Society 
(ASAS) consortium) or radiographic sacroiliitis according to the Modified New York criteria [26]. 
Prior treatment with any biological treatment was an exclusion criterion. All patients were screened 
for latent tuberculosis by means of a tuberculin skin test and chest x-ray.   
 
Clinical and Laboratory Assessments 
Patients were evaluated at screening, baseline (prior to the CZP scintigraphy), prior to initiation of 
CZP, and at weeks 12 and 24 after start of CZP. Evaluations were performed by the same 
rheumatologist (PC) and consisted of a full rheumatological examination, including a 66/68 joint 
count, enthesitis and dactylitis assessments as well as an evaluation of axial metrology. At all visits, 
a number of patient reported outcomes was assessed, including patient global assessment (PGA) 
of disease activity, PGA of pain and SF-36 for all patients, BASDAI and BASFI for patients with axSpA 
and the Health Assessment Questionnaire (HAQ) for patients with RA. During the screening, 12 and 
24 weeks after treatment routine blood samples were taken to assess potential toxicity of CZP 
treatment and determine erythrocyte sedimentation rate (ESR; normal level <20 mm/h) and C-
reactive protein (CRP; normal level <5 mg/L). This allowed for the calculation of validated composite 
disease activity scores, such as the Disease Acitivity Score in 28 joints (DAS28) for RA, and the 




Ultrasound (US) evaluation was performed at baseline and after 12 weeks treatment with CZP in 
RA and pSpA patients. Systematic multiplanar grey-scale (GS) and power Doppler (PD) examinations 
were carried out with an ESAOTE MyLab60 using multifrequency linear transducers (6–18 MHz). PD 
imaging was performed by selecting a region of interest that included the bony margins, articular 
space, and a variable view of surrounding tissues (depending on the joint size). PD variables were 
adjusted to the lowest permissible pulse repetition frequency (PRF) to maximize sensitivity. This 
setting resulted in a PRF between 500 and 1000Hz depending on the joint scanned. Low wall filters 
were used. Colour gain was set just below the level at which colour noise appeared underlying bone 
(no flow should be visualized at the bony surface).  We evaluated both wrists, ankles and subtalar 
joints, as well as all metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints. Synovitis 
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and tenosynovitis were assessed according to the EULAR criteria [28] and the OMERACT definition 
[29]. Synovitis and synovial and tenosynovial vascularity were scored semiquantitatively (grade 0–
3) by PDUS according to Szkudlarek et al [30]. Synovitis (effusion and synovial hypertrophy 
combined) in GSUS was analyzed semiquantitatively as described by Scheel et al [31]. Tenosynovitis 
in GSUS was registered as being absent (0) or present (1). 
 
Magnetic Resonance Imaging MRI  
All axial SpA patients and 1 peripheral SpA patient underwent MRI of the sacroiliac joints (SIJ). 
Images were obtained on a 1.5 T MRI unit (Avanto/Symphony, Siemens Medical, Erlangen, 
Germany). The SIJ were imaged in a body flexed array coil (Siemens Medical, Erlangen, Germany). 
The sequence protocol included semicoronal (along long axis of the sacral bone) T1-weighted turbo 
spin echo (TSE) (slice thickness (ST) 3 mm; repetition time/echo time (TR/TE) 595/20 ms), 
semicoronal STIR (ST 3 mm; TR/TE/inversion time (TI) 5030/67/150 ms) and axial STIR (ST 5 mm; 
TR/TE/TI 7540/67/150 ms). Sacroiliitis on MRI was scored positive or negative according to the 
definition proposed by the Assessment of SpondyloArthritis international Society (ASAS) 
consortium [26]. Each SIJ was divided in 4 quadrants and evaluated on 8 coronal 3 mm MRI slices. 
Bone marrow edema was scored per quadrant as either absent or present (on two consecutive 
slices), thus providing a total score between 0 and 8. BME of the SIJ was also scored using the 
Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system by certified readers for 
the SPARCC scoring system[32]. The presence of an intense signal (comparable to blood vessels) or 
depth ≥ 1 cm anywhere within each SI joint of the 6 slices is given an additional score (0=absent / 
1=present). As in our center 3 mm slices are used, 8 slices were evaluated and converted to a 
maximum score of 72. MRI of the SIJ was performed within the week before the 
immunoscintigraphy was obtained. 
 
Scintigraphic Assessments 
Radiolabelling procedure of Certoluzimab pegol 
Lyophylised CZP was reconstituted with water for injection, filtered and dialysed and subsequently 
incubated with succinimidyl-6-hydrazino-nicotinamide (S-HYNIC, ABX GmbH, Radeberg, Germany). 
After removal of the unreacted S-HYNIC, a bifunctional crosslinker, the solution was diluted with 
acetate buffer to a pH of 5 and filtered through a 0.22 µm membrane filter. 1.25 mg S-HYNIC 
certolizumab pegol solutions were dispensed in 1.0 ml glass vials stored at -80°C. 
For the radiolabelling procedure, a co-ligand kit consisting of a tin(II) sulphate (4.66 mM, Sigma 
Aldrich, Steinheim, Germany) and tricine (55.81 mM, Sigma Aldrich, Steinheim, Germany) diluted 
solution (50 µL) was added to the S-HYNIC certolizumab pegol vial. Subsequently, 925 MBq (±10%) 
freshly eluated Tc99m pertechnetate was added to this vial. This was incubated for 15 minutes at 
room temperature. Finally, physiological saline was added to dilute the radiopharmaceutical 
formulation in a total volume of 3 mL. All handling was performed under aseptic conditions. Quality 
control was carried out by instant thin layer chromatography (iTLC) with SilG as stationary phase 




Patients were injected intravenously with approximately 740 MBq Tc99m labelled certolizumab 
pegol (10.6 MBq/kg). All patients were scanned on the same double headed gamma-camera 
(BrightView, Philips Healthcare, Best, The Netherlands). Whole Body (WB) images (15 cm/min scan 
speed, matrix size 1024x512, pixel size 2.80 mm) were performed immediately following 
administration, at 1h, 4-6h and 24 hours postinjection. A standard activity of approximately 5 MBq 
Tc99m in an unshielded syringe was always in the field of view for quantification purposes. Static 
images (5 minutes, matrix size 256x256, pixel size 2.33 mm) of hands and feet were acquired 
immediately following the first WB scan which was started within a couple of minutes post-
injection, at 4-6h and 24h post injection. A single photon emission tomography (SPECT) was 
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acquired from the axial skeleton. In selected cases a SPECT/CT was performed to depict in detail 
the involved joints. 
To assess the tracer accumulation in the peripheral joints, each joint was scored semi quantitatively, 
using the following scoring system: score 0=no tracer uptake, score 1=faint uptake of the tracer and 
score 2=clear uptake of the tracer. The same score was applied to every quadrant of the SIJ in axial 
SpA patients. The scintigraphic result was defined as positive if there was faint or clear tracer-
uptake 4 to 6 hours post injection. As the scintigraphic images do not provide anatomic details, 
fusion of the MRI with the nuclear image was performed to allow scoring of the tracer uptake per 
quadrant. For each individual scan a background ROI was defined within the field of view, e.g left 
supraclavicular region on WB, right forearm on static images of the wrists and hands, right distal 
tibia for the static images depicting the ankles and feet. These results were compared with the 
findings from clinical examination for each assessable joint. The nuclear medicine physician reading 




Data were analysed using SAS Version 9.3 (SAS Institute Inc., Cary, NC, USA). Both a joint-based and 
patient-based analysis were done. In the joint-based analysis, each individual joint contributes an 
observation, but clustering of the joints within the patient was taken into account in the statistical 
analysis. For this analysis a scintigraphic score corresponding to either faint or clear tracer uptake 
4 - 6 hours postinjection was considered as positive. To determine the relationship between the 
scintigraphic variable and the (clinical or ultrasound) status of the joint at baseline, a mixed logistic 
regression model with patient as random effect was used. For the predictive value of the 
scintigraphic variable on the status of the joint 12 and 24 weeks after treatment, the data set is 
reduced to only those joints that were tender and/or swollen at baseline according to the variable 
assessed in the analysis. A mixed logistic regression model with patient as random effect is used on 
this reduced data set. The results of the logistic regression model are summarized in terms of the 
odds ratio and percentage of tender and/or swollen joints in the positive and negative scintigraphic 
group. In the patient-based analysis summary statistics at the patient level was used. In this analysis 
the sum of the semiquantitative scintigraphic scores was used: for patients with rheumatoid 
arthritis, the scores of wrists, MCP and PIP joints were used whereas in pSpA, the scores of the hand 
DIP joints were added; in patients with axSpA, the sum scores of the quadrants of the SI joints was 
used. To assess the predictive value of the scintigraphic variable at baseline on the clinical 
improvement at 12 and 24 weeks after treatment (measured by ASDAS for axSpA and pSpA 
patients, measured by DAS28 for RA patients), a linear regression model is used with the 
scintigraphic scores included as a continuous variable. The results are summarized in terms of the 
slope. The slope describes the change in the respective clinical score with a unit increase in the 
scintigraphic variable. For all analyses p < 0.05 was considered statistically significant. 
RESULTS 
Patients baseline and disease characteristics and clinical response after 12 and 24 weeks 
treatment with CZP  
Table 1 depicts the baseline characteristics and the clinical response after 12 and 24 weeks of 
treatment with CZP. The mean age of RA, pSpA and axSpA patients at baseline was 56.2, 41.0 and 
37,1 years with a mean symptom duration of 13.1, 12.6 and 9 years respectively. The mean CRP 
level at baseline for patients with RA, pSpA and axSpA was 10.9, 15.4 and 4.7 mg/l respectively. In 
general, there was a clear improvement of signs and symptoms in all patients treated with CZP. 
Three of the five RA patients had a good EULAR DAS28 response and two a moderate EULAR DAS28 
response after 12 weeks treatment. At 24 weeks loss of response was observed in one RA patient. 
Three of the six pSpA patients showed a major ASDAS improvement after 12 weeks treatment and 
two a clinically important ASDAS improvement. One patient with pSpA was a (primary) non-
responder and one pSpA patient lost response after 24 weeks treatment.  In the axSpA patients 
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group, 2 out of 9 had a major ASDAS response and 6 patients a clinically important ASDAS response. 
Again, one patient with axSpA was a primary non-responder and one patient with axSpA lost 
response at 24 weeks treatment. The scintigraphic procedure was well tolerated. No procedure-
related adverse events were observed. 
Table 1: The baseline characteristics of all patients and their clinical response after 12 and 24 weeks 
treatment with Certolizumab pegol.  
axSpA, axial Spondylarthritis; RA, rheumatoid arthritis; pSpA, peripheral Spondyloarthritis; MTX, Methotrexate; SSZ, 
Sulphasalazine; LEF, leflunomide; M/F, male/Female; sDMARDS, synthetic Disease Modifying Anti-Rheumatic Drug;  CZP, 





 Baseline characteristics After 12 weeks CZP After 24 weeks CZP 
 Demographics Disease characteristics   
 Age Gender Symptom 
duration 








F 38.7 MTX 10mg  YES NO 32 23 6.77 - 1.5 4 1.93 - 0.8 4 1.76 - 
F 3.1 MTX 10mg  YES NO 8.6 11 6.33 - 13.
3 
13 4.79 - 9.1 16 3.29 - 
M 1.5 MTX 15mg  YES NO 9.5 24 5.8 - 0.6 4 4.31 - 0.7 6 4.86 - 
F 11.6 MTX 
12.5mg 
 NO NO 3.9 15 4.62 - 2 12 2.16 - 3.7 11 2.24 - 









M 17.3 MTX 15mg  NO YES 51.9 67 - 4.78 2.8 6 - 1.56 0.6 2 - 0.99 
F 0.9 NO  NO YES 3.4 5 - 4.16 1.6 4 - 3.87 1.6 4 - 3.87 
F 39.9 NO  NO YES 0.1 6 - 2.18 0.6 3 - 1.02 0.6 7 - 2.98 
M 4.2 LEF  NO YES 28.2 57 - 3.89 0.6 5 - 0.46 0.7 5 - 0.93 
M 1.2 SSZ  NO YES 3.5 6 - 3.64 0.6 1 - 1.38 0.6 2 - 0.88 








F 4.4 NO  NO YES 9 8 - 3.05 2.7 3 - 1.65 0.7 2 - 1.61 
M 5.2 NO  NO YES 2.5 5 - 2.94 0.7 2 - 2.22 0.6 1 - 2.91 
M 19 NO  NO YES 4 11 - 2.67 0.6 3 - 0.73 0.6 3 - 0.68 
M 3.5 NO  NO YES 6.3 4 - 3.38 3.9 5 - 1.58 4.2 7 - 3.25 




29.2 M 4.6 NO  NO YES 8 15 - 4.27 4.1 8 - 1.66 1.3 1 - 1.14 
27.2 M 12.3 NO  NO YES 1.1 1 - 3.28 4.2 2 - 1.32 0.6 2 - 0.63 
26.3 M 1.6 NO  NO YES 3 4 - 2.31 0.6 2 - 0.63 0.6 2 - 0.44 
56.4 M 11.4 NO  NO YES 4.6 6 - 3.4 1.3 2 - 1.2 2.1 5 - 1.52 
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Description of distinct scintigraphic patterns observed in RA and SpA patients 
In most of the clinically involved joints of hands and feet in RA and peripheral SpA patients a tracer 
uptake was already visualized within minutes following injection, probably due to vascular 
hyperaemia. At 4-6 hours postinjection, more joints were showing an enhanced uptake, with a 
more favorable joint-to-background ratio, allowing a good anatomical discrimination of the various 
joints. In most joints the tracer accumulation persisted over time on the 24-hour post-injection 
images. A typical poly-articular pattern of hand and feet joints without DIP involvement was seen 
in RA (fig 1a). In contrast there was clear DIP involvement seen in the hands of a poly-articular 
psoriatic arthritis patient (fig 1b). As a proof-of-concept, selected patients with pathognomonic 
clinical features were also scanned: in peripheral SpA patients with dactylitis a specific scintigraphic 
pattern was observed with tracer uptake in both the joints and the accompanying flexor tendon of 
the clinically involved digit of the hand or foot (fig 1c). Clear tracer uptake was also noticed at the 
enthesis of Achilles tendon and plantar fascia in SpA patients with clinical and ultrasound-confirmed 
enthesitis (fig 1d). Tracer uptake could also be detected in the region of the SIJ in axial SpA patients 
with active inflammatory lesions on MRI (fig 1e). 
 
Figure 1: Distribution of Tc99m-radiolabelled certolizumab pegol in hands, feet and SIJs 4–5 hours 
postinjection. Fig 1a: A typical polyarticular pattern of hand and feet joints without distal 
interphalangeal joint (DIP) involvement was seen in a patient with active rheumatoid arthritis. Fig 
1b: Distal interphalangeal joint uptake of the left second digit in a patient with polyarticular 
psoriatic arthritis. Fig 1c: Tracer uptake in both the joints and the accompanying flexor tendon in a 
patient with clinically dactylitis of the fourth digit at the right side. Fig 1d: SPECT-CT of the right foot 
in a patient with spondyloarthritis with enthesitis of the Achilles tendon. Fig 1e: Fusion of MRI and 





Relationship between scintigraphic results and status of peripheral and sacroiliac joints at 
baseline 
Results of the joint based analysis are presented in tables 2-4. First, using the clinical evaluation of 
all peripheral joints in all patients as a reference, we compared the percentage of tender and/or 
swollen joints to the scintigraphic result at baseline. The percentage clinically involved joints was 
significantly higher (P<0.0001) in the scintigraphy positive as compared to the scintigraphy negative 
joints. In patients with RA and pSpA, the baseline US GS and PD results were additionally compared 
to the scintigraphic result. Also, the percentage GS-positive and PD-positive joints was significantly 
higher (P<0.001) in the scintigraphy-positive as compared to the scintigraphy-negative joints. 
Higher ORs were observed for the swollen joint count and PD- positive joints as compared with the 
tender joint count and GS positive joints. Finally, in patients with axial SpA, the percentage of SIJ 
quadrants showing BME on MRI was significantly higher (P=0.001) in the scintigraphic positive as 
compared to the scintigraphic negative joints (table 4). Maksymowych et al graded a lesion as deep 
on MRI if there is a homogeneous and unequivocal increase in signal extending over a depth of at 
least 1 cm from the articular surface[32]: this type of lesion was observed in seven of the nine 
patients with axSpA: in five out of these seven patients with axSpA (71%), clear scintigraphic tracer 
uptake was observed in the same quadrant of the SI joints, where the extended lesion (>1 cm from 
joint space)  was also located. Interestingly, in one AS patient with complete fusion of the SI joints 
(bilateral grade 4 sacroiliitis on X-ray), who was suffering from peripheral arthritis (and hence was 
included in the pSpA part of the study), there was an absence of BME of the SIJs on MRI.  In this 
patient we could also not detect tracer uptake on scintigraphy.  Although this is only a solitary case, 
it might suggest that in vivo detection of TNF correlates with active inflammatory lesions on MRI 
and not with structural damage. 
Table 2: The number and percentages of tender joints at baseline, and after 12 and 24 weeks of 
treatment as a function of the scintigraphic status at baseline. 
 Scintigraphic negative Scintigraphic positive OR P-value 
All patients                     No tenderness Tenderness No tenderness Tenderness 
    
Tender joints at 





w12 or w24 
Remains 
tender at 




w12 or w24 
Remains 
tender at 
w12 or w24 
  
Tender joints at w12 
  
69 (72.6%) 26 (27.4%) 
  
58 (79.5%) 15 (20.5%) 0.69 0.309 
Tender joints at w24 
  
65 (68.4%) 30 (31.6%) 
  
64 (87.7%) 9 (12.3%) 0.30 0.004 
 
Table 3: The number and percentages of swollen joints at baseline, and after 12 and 24 weeks of 
treatment as a function of the scintigraphic status at baseline. 
The odds ratio refers  to the odds of a joint being tender and/or swollen in the scintigraphic positive as compared to the 
scintigraphic negative group. For all tests, p values <0.05 are considered to indicate statistical significance.  ⃰ Odds Ratios 
for swollen joint count could not be estimated due to the fact that one cell, i.e. scintigraphic negative-symptom has 
frequency zero. w12, week 12; w24, week 24. 
  Scintigraphic negative Scintigraphic positive OR P-value 
All patients No swelling Swelling No swelling Swelling 
    





w12 or w24 
Remains 
swollen at 




w12 or w24 
Remains 
swollen at 
w12 or w24   




56 (88.9%) 7 (11.1%) * 0.339 




58 (92.1%) 5 (7.9%) * 0.581 
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Tabel 4: The number and percentages of US –Grey Scale and US-Power Doppler and MRI positive 
joints at baseline as a function of the scintigraphic status at baseline. 
The odds ratio refers  to the odds of a joint being US-Grey Scale and and US-Power Doppler positive or MRI positive in 
the scintigraphic positive as compared to the scintigraphic negative group. For all tests, p values <0.05 are considered to 
indicate statistical significance. AxSpa, axial Spondylarthritis; MRI, Magnetic Resonance Imaging; OR, Odds Ratio; pSpA, 
peripheral Spondylarthritis; RA, rheumatoid arthritis; SIJ, sacroiliac joints; US, Ultrasound. 
Relation scintigraphic results and status of the patient at baseline 
On a patient level, a linear regression model was fitted regressing the sum of the semiquantitative 
scintigraphic scores on patient reported outcomes (SF36, PGA of disease activity, PGA of pain) and 
relevant disease activity scores (DAS28 for RA, ASDAS for SpA). No significant linear relationship 
was found between the scintigraphic sum score and patient reported outcomes or disease activity 
scores at baseline. Nevertheless we found a significant relationship between the scintigraphic sum 
score of the SIJ and the SPARCC score (P=0.010). Each unit increase in the SPARCC score corresponds 
to an increase of 0.4139 (SE=0.119) in the scintigraphic sum score (Fig 2).   
Fig 2: Relationships between the baseline disease activity scores and scintigraphic sum scores for 
the patients with RA, pSpA and axSpA. ASDAS, Ankylosing Spondylitis Disease Activity Score; axSpA, 
axial spondyloarthritis; DAS28, Disease Activity Score in 28 joints; pSpA, peripheral 
spondyloarthritis; RA, rheumatoid arthritis; SPARCC, the Spondyloarthritis Research Consortium of 
Canada scoring system.  
 
 
 Scintigraphic negative Scintigraphic positive OR P-value 
RA and pSpA patients 
      
US assessment Normal US findings Abnormal US findings Normal US findings Abnormal US findings   
US-Grey Scale 192 (90.6%)  20 (9.4%) 28 (37.8%)  46 (62.2%) 15.77 <0.001 
US-Power Doppler  207 (97.6%)  5 (2.4%) 33 (44.6%)  41 (55.4%) 51.44 <0.001 
 
AxSpA patients    
                                              
MRI assessments SIJ No BME  BME No BME  BME   
BME per quadrant 34 (70.8%)  14 (29.2%) 7 (21.9%)  25 (78.1%) 8.67 <0.001 
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Prediction of therapy response by scintigraphic result on joint and patient level at week 12 and 
24.   
Finally the scintigraphic result was analyzed as a potential predictor of therapy response on joint 
level and patient level . On the joint level, we observed a significant result for the number of tender 
joints at week 24 (table 2): of all tender joints that were positive on scintigraphy at baseline, only 
11,9% remained painful at week 24, compared to 26,5% in the scintigraphy-negative joints 
(OR=0.38;P=0.030).  Results for swollen joints and ultrasound findings are summarized in table 3: 
no significant correlation was found.  
At the patient level, a linear regression model was fitted regressing the sum of the semiquantitative 
scintigraphic scores on the change in patient-reported outcomes (SF36, PGA of disease activity, PGA 
of pain), physician global assessment and relevant disease activity scores inserting group as 
adjusting factor in the model. For patients with RA, the difference in DAS28 score between baseline 
and week 12 and 24 was used and regressed on the scintigraphic sum score. For patients with SpA, 
the difference in ASDAS between baseline and week 12 and 24 was used and regressed on the 
scintigraphic sum score. No significant relationships were found.  
DISCUSSION 
We performed a proof-of-concept study on patients with RA and SpA to detect in vivo TNF-α-driven 
inflammation by scintigraphy using radiolabeled CZP. We visualized in most of the clinically involved 
joints a marked tracer uptake within minutes following injection, suggesting fast uptake into the 
inflamed tissue. The best results were seen at 4-6 hours postinjection, but tracer uptake was still 
observed on the 24h postinjection scan, suggesting that uptake is not solely caused by a 
vascularization effect. We were able to visualize specific tracer uptake patterns pathognomonic for 
the studied diseases. Although similar results have been reported with radiolabeled adalimumab in 
patients with RA[33, 34], this is – to the best of our knowledge – the first study to evaluate 
immunoscintigraphic patterns in patients with different subtypes of SpA, visualizing enthesitis, 
dactylitis and sacroiliitis.  
Secondly, in patients with peripheral joint involvement, we could establish a good correlation 
between the clinical evaluation and conventional imaging of the individual joints, and the tracer 
uptake on scintigraphy. Interestingly, this correlation was strongest for more objective signs of 
inflammation: higher ORs were observed for the swollen joint count and PD-positive joints as 
compared to the tender joint count and GS-positive joints. At the patient level, no significant 
correlation was found between the scintigraphic sum score and global disease activity scores or 
relevant patient reported outcomes. In patients with axial SpA, the scintigraphic findings correlated 
well with BME on MRI of the SIJs, which is the item that is required in the ASAS-definition of a 
positive MRI [35] and is one of the anchors of the ASAS classification criteria for axial SpA. 
Nevertheless, the interpretation of a ‘positive MRI’ in the context of SpA remains difficult, certainly 
when the presence of BME is subtle or when there may be other causes for the observed BME, such 
as mechanical stress. As a consequence, there is still an unmet need to determine wether observed 
BME is caused by underlying cytokine-driven inflammation in patients with axial SpA. At present, 
there is no agreement on a precise definition of the minimum size (area) of BME which is necessary 
to be defined as ‘positive’. There is an impression that the presence of so-called “deep” BME lesions 
on MRI of the SIJs, defined as a homogeneous and unequivocal increase in signal extending over at 
least 1 cm from the articular surface on STIR images, would be more suggestive of axial SpA. In our 
study, taking only these extended lesion on MRI of the SIJs into account, better correlations 
between scintigraphy and MRI were found. Finally, at the patient level, there was a significant 
relation between the scintigraphic sum score of the SIJs and the SPARCC scoring system.  
Third, we looked whether the baseline scintigraphic detection of TNF could predict a therapeutic 
response to CZP therapy after 12 to 24 weeks. We need to emphasise that this study was not 
designed or powered to predict therapy response by baseline scintigraphic results. Nevertheless, 
we could demonstrate a significant predictive value of the immunoscintigraphy at the joint level 
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with regard to the tender joint count: tender joints with uptake at baseline had a significantly higher 
probability of not being painful after 24 weeks of treatment.  The lack of predictive value for the 
other joint assessments as well as for the global disease activity scores at the patient level, could 
probably be explained by the fact that the study included only small numbers of patients with 
heterogeneous inflammatory diseases. These preliminary findings are, however, interesting 
because a positive scintigraphic result might indicate that joint tenderness at baseline is TNF driven, 
and this result could serve as a more objective measurement tool for tender joints.  Surprisingly, 
only two prospective cohort studies in RA have assessed the use of imaging techniques to predict 
response to anti-TNF therapy. Ellegaard and colleagues measured US Doppler activity and clinical 
parameters at baseline to predict which patients would benefit from treatment, assessed by 
treatment persistence at 1 year. They identified US Doppler activity to be the only baseline 
parameter able to predict treatment persistence (p=0.024); baseline clinical measures including 
tender and swollen joint counts, CRP, DAS28 and HAQ showed no significant association[36]. Elzinga 
and colleagues used changes in PET uptake 2 weeks after treatment to predict future treatment 
response, according to DAS28. A significant correlation was seen between the changes in PET 
activity at 2 weeks and DAS28 at 14 and 22 weeks after treatment (r 0.62,p<0.05; r 0.65, p<0.01 
respectively)[37]. 
In the past only few attempts in molecular imaging using radiolabeled monoclonal antibodies in 
rheumatic diseases were made, and the earliest experiences and clinical context are excellently 
summarized by Malviya et al[38]. Our study is the first using a radiolabeling procedure with 
certolizumab pegol, a PEGylated Fab fragment directed against TNFα. One of the reasons for 
choosing CZP as a tracer was the observation made in an animal model for arthritis using 
biofluorescence imaging: a greater ratio of penetration and more prolonged duration of exposure 
in inflamed versus normal tissue was described for CZP compared to adalimumab and infliximab. 
One possible explanation could be the link with PEG in CZP[39].  
We acknowledge that our study has several limitations, both regarding the scintigraphic technique, 
as well as concerning the type of patients that was studied. Barrera et al[33] published encouraging 
findings with radiolabelled adalimumab in 10 patients with active RA. A subset of patients 
underwent repeat imaging following administration of a therapeutic dose of cold antibody. Based 
on this competition study, the authors suggested a partial specific targeting of TNF-α by Tc99m 
labelled adalimumab. These findings were in agreement with Roimicher et al[34]. We decided not 
to include a competition study and prioritised to first have an estimation of the radiation burden 
before exposing volunteering patients twice[40]. We also did not perform a second 
immunoscintigrapy after 12 or 24 weeks of treatment in order to evaluate the change in tracer 
uptake over time. We first wanted to establish a proof of concept with this new 
radiopharmaceutical before endorsing more complex follow-up scintigraphic procedures. 
Nevertheless it was Conti et al[41] who showed a positive predictive role of 99mTc-infliximab 
scintigraphy in therapy decision-making in patients with refractory monoarthritis who were given 
intra-articular infliximab treatment by comparing the pretherapy and post-therapy target-to-
background ratio from affected joints. 
With regard to patient selection, this was obviously a proof-of-concept study, which included only 
limited numbers of patients with different inflammatory rheumatic diseases. We did not include a 
non-inflammatory control group: as a consequence, we cannot exclude that the observed tracer 
uptake could be an aspecific phenomenon, although the good correlation with the clinical 
evaluation and conventional imaging results would argue against this. The low number of patients 
in each disease subgroup evidently does not allow to make conclusions regarding prediction of 
clinical response in case of a positive scintigraphy: nevertheless, the finding that individual painful 
joints that were scintigraphy-positive had a higher odds of becoming not tender after treatment 
with certolizumab could be a promising find. Indeed, since treat-to-target principles have found 
their way in the daily management of patients with RA[42], a high number of tender joints might 
be one of the triggers to change the therapeutic strategy: information as to whether the observed 
pain pattern is related to in vivo expression of a culprit cytokine could potentially avoid 
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overtreatment with biologicals in individual cases where pain is driven by other pathophysiological 
mechanisms. 
CONCLUSION 
In conclusion, we demonstrated that it is safe and feasible to perform scintigraphy with 
radiolabelled certolizumab pegol in patients with different types of inflammatory arthritis, whereby 
specific joint involvement patterns could be recognised. Future research should confirm these 
preliminary results, specifically with regard to the potential to predict clinical response to a 
biological treatment targeting TNF. If confirmed, the technique could be a step towards 
personalized medicine, where each patient receives the right drug and the right intensity of 
treatment for as long as needed; it could allow the selection of patients for a specific therapy in a 
much more rational way than the current “trial and error” approach. In particular, future studies 
should address if a pretherapy scintigraphic approach with a radiopharmaceutical targeting TNF 
identifies the presence of the target cytokine in the inflammatory lesion and if positive, whether 
these patients with clear uptake of the anti-TNF tracer would respond better to anti-TNF therapy 
as compared with strategies targeting other inflammatory pathways.  This might be a crucial step 
in enhancing the safe and cost-effective use of expensive biological treatment by avoiding exposure 
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Erosive hand osteoarthritis (OA) of the interphalangeal (IP) joints is characterised by a more 
pronounced inflammatory burden of disease [1]. Whether it is a subset of hand OA or just a 
radiographic phase remains a matter of debate. The pathogenesis of erosive OA is not yet 
understood, but articular cartilage degeneration and subchondral bone resorption are some of the 
major characteristics. In general, several cytokine-driven pathways such as receptor activator of 
nuclear factor κB, interleukin-1 and tumour necrosis factor (TNF) alpha are involved at the level of 
the subchondral bone-inducing dynamic morphological changes [2-4]. In post hoc analyses in two 
recent placebo-controlled pilot studies in erosive OA, it was shown that adalimumab and 
etanercept were able to diminish structural progression after 1 year of treatment in a subgroup of 
patients who showed soft tissue swelling at baseline[5, 6]. We hypothesised that radiolabelled 
antibodies could help in demonstrating their in vivo abundance in joints and help to identify joints 
at particular risk for progression amenable for targeted therapies. The aim of the study was to 
assess the biodistribution of TNF in erosive OA and to identify the clinical features of the joints with 
most uptake.  
 
PATIENTS AND METHODS 
Study design 
Five patients were selected from the outpatient clinics of Rheumatology from the Ghent University 
Hospital to undergo an immunoscintigraphy with 99m Tc radiolabeled certolizumab pegol. Approval 
from the local Ethics Committee and oral and written informed consent were obtained before any 
procedure. The diagnosis of erosive OA was based on the presence of at least two erosive joints on 
recent standardized anterior/posterior radiographs of both hands, according to the anatomical 
scoring system[10]. Presence of at least two joints with clinical soft tissue swelling was obligatory. 
Exclusion criteria were presence of any other underlying inflammatory rheumatic disorder or 
familial or personal cutaneous psoriasis.  
 
Scintigraphy and image analysis 
Patients were injected intravenously with approximately 740 MBq 99m Tc certolizumab pegol (10.6 
MBq/kg). All patients were scanned on the same double headed gamma-camera (Millenium VG, GE 
Healthcare, UK) at the baseline visit. Static images of both hands were performed immediately and 
approximately 4-6 hours following administration (referred to as early and late uptake 
respectively). To assess the tracer accumulation in the hands, all carpometacarpal joints (CMC),  
metacarpophalangeal (MCP), proximal IP (PIP) and distal IP (DIP) joints were scored in a semi-
quantitative way (0 = no tracer uptake, 1 = weak uptake,  2 = clear uptake) by the same observer 
(BL), blinded to any clinical, radiographic or sonographic findings.  
 
Clinical and sonographic assessments 
A focused clinical examination and ultrasonography of the hand joints were performed at baseline. 
Tenderness and presence of soft tissue swelling of CMC, MCP, PIP and DIP joints of both hands were 
assessed. The sonographic presence of effusion, synovial hypertrophy and Power Doppler (PD)  
signal was assessed by another observer on a semi-quantitative scale (0 – 3). A linear high frequency 
transducer (12-18 Mhz) was used and settings were adapted to provide the best quality images 
(MyLab60, Esaote, Genova, Italy). A sonographic active joint was defined as any presence of 
effusion or synovial hypertrophy or PD signal. All patients completed a pain visual analogue scale 






Descriptive statistics for baseline patient characteristics  and prevalence frequencies of 
scintigraphic, sonographic, radiographic and clinical features were calculated and differences in 




Five patients (4 females) with median age of 55.6 years (range: 53.4 - 60.7) and median disease 
duration of 8.4 years (range: 5.1- 13.3) were studied. On patient level (n = 5), the median number 
[range] of joints with active early and late uptake was resp. 1 [0 – 4] and 5 [0 – 9] (out of 18). 
On IP joint level (n = 90), uptake was seen in only seven joints in early phase (7.8%) (all weak) and 
in 24 joints in late phase (26.7%) (19 weak, 5 strong). Prevalence of both early and late uptake were 
higher in PIP joints (7/50 and 20/50) as compared to DIP joints (0/40 and 4/40) (resp. p = 0.014 and 
0.001). Example images are shown in figure 1. Table 1 shows the absolute number and prevalence 
of early and late uptake in joints and RR (95% CI) for late uptake according to several clinical, 























Table 1: Prevalence and associations between early and late uptake in joints according to presence 
of clinical, sonographic and radiographic characteristics (n = 90). MCP joints were excluded from 
the analysis. Associations between uptake and specific features by crude risk ratios (RR) (95% CI) 




Early uptake Late uptake 
Present (%) Absent (%) Present (%) Absent (%) RR a (95% CI) 
Clinical features 
Tenderness 
   Present 33 5 (15.2) 28 (84.8) 12 (36.4) 21 (63.6) 2.2 (0.8 – 5.6) 
   Absent 57 2 (3.5) 55 (96.5) 12 (21.1) 45 (78.9) - 
Soft tissue swelling 
   Present 23 5 (21.7) 18 (78.3) 14 (61.0) 9 (39.0) 8.9 (3.3 – 26.0) 
   Absent 67 2 (3.0) 65 (97.0) 10 (14.9) 57 (85.1) - 
Sonography    
Sonographic active joint b 
   Present 62 6 (9.7) 56 (90.3) 18 (29.1) 44 (70.9) 1.5 (0.5 – 4.3) 
   Absent 28 1 (3.6) 27 (96.4) 6 (21.4) 22 (78.6) - 
Radiography       
   N 36 2 (5.6) 34 (94.4) 10 (27.8) 26 (72.2) - 
   S 24 1 (4.2) 23 (95.8) 4 (16.7) 20 (83.3) 0.5 (0.1 – 1.9) 
   J 4 0 (0.0) 4 (100.0) 1 (25.0) 3 (75.0) 0.9 (0.1 – 9.3) 
   E 14 1 (7.1) 13 (92.9) 4 (28.6) 10 (71.4) 1.1 (0.3 – 4.1) 
   R 12 3 (25.0) 9 (75.0) 5 (41.7) 7 (58.3) 1.9 (0.5 – 7.2) 
a Only associations by RR between late uptake and other features were calculated since the low number of joints with 
early uptake; b: defined as presence of any synovial hypertrophy or PD signal or effusion. No.: number; RR: Risk Ratio; CI: 
confidence interval; radiographic anatomical phases: N: normal; S: stationary; J: loss of joint space; E: erosive; R: 
remodelling. 
Considerably more uptake was present in joints with soft tissue swelling compared to non-swollen 
joints both in early and late phase: in resp. 5 (21.7%) and 14 (61.0%) of 23 swollen joints and in 2 
(3.0%) and 10 (14.9%) of 67 non-swollen joints. Presence of soft tissue swelling is found to be 
significantly associated with uptake with RR = 8.9 (95% CI = 3.0 – 26.0). A trend towards more 
uptake in tender joints was seen compared to non-tender joints (RR = 2.1 (95% CI = 0.8  - 5.6). 
Similarly, a trend towards more uptake in sonographic active joints was seen (RR = 1.5 (95% CI = 0.5 







This is the first study in erosive hand OA where the presence of TNF in PIP and DIP joints is 
demonstrated by scintigraphic detection with radiolabeled certolizumab. Uptake was present in 
almost 27% of IP joints, predominantly being PIPs. The strongest correlation with uptake was seen 
in joints with soft tissue swelling. Surprisingly, no significant correlation was seen with any 
radiographic phase or sonographic feature.  
In previous placebo-controlled clinical trial in erosive OA with TNF-blocking agents, it was 
demonstrated that presence of soft tissue swelling was the best predictor for preventing further 
erosive progression compared to placebo [5, 6]. The current observations reinforce the hypothesis 
that TNF is an important contributor to the inflammatory burden of disease in erosive OA. 
Our study could not detect any association between ultrasound detected features of inflammation 
and certolizumab uptake in the joints while several previous studies showed that these features are 
frequently seen [7, 8] and predict future erosive progression [9, 10]. A composite variable was 
created to define a sonographic active inflammatory joint but also analysis of individual features 
did not show any significant association with uptake.  
Questions rise about the specificity of the uptake of radiolabeled TNF-blocking agents. In early 
phase, some uptake might just correspond to the vascular phase or uptake in any inflamed tissue. 
Planar scintigraphies of the hands immediately following tracer injection showed no increased 
uptake, whereas progressive accumulation of the tracer in the positive joints was observed over 
the following hours. A previous study showed that the uptake remained up to 24 hours after the 
administration and therefore, no later scans were made in this study [11]. The present study has 
some limitations: first, the low number of patients studied. Second, all assessments were 
performed by single observers, hence no reliability analyses are done. Third, a reference construct, 
such as MRI is missing to study the true nature of inflammation on subchondral level. 
The observations of this pilot study implicate a role for inflammation in the pathogenesis of erosive 
OA, and might lead to new treatment options that can reduce the radiographic progression. Further 
studies are warranted with more patients and preferably with other imaging constructs to 
investigate whether these results are reproducible. 
 
Figure 1: Early (A) and late (B) scintigraphic images showing uptake of 99mTc certolizumab. (A) 
Uptake in PIP3 joint of the right hand, becoming more clear in (B). (B) Also uptake in PIP3, IP1 and 
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Purpose of review 
The field of spondyloarthritis (SpA) has evolved enormously over the last few years, starting with 
the advent of biological therapies at the end of the previous millenium. A lot of work has been done 
to construct valid outcome measures and treatment guidelines based upon the results of pivotal 
studies with Tumor necrosis factor (TNF)-blocking agents. Most of these trials were performed in 




Over recent years a reappraisal has been done with regard to considering again the full spectrum 
of diseases belonging to the SpA concept, especially in early disease stages. This effort culminated 
in the construction of new classification criteria for axial and peripheral SpA. Around the same time, 
a number of patient registries were set up, allowing the follow-up of patients in order to study the 
natural evolution of patients classified early. The first data from these cohorts provide interesting 
information on peripheral joint manifestations such as arthritis, enthesitis or dactylitis. Recognition 
and monitoring of these manifestations are essential for clinicians in order to provide 
comprehensive patient care. 
 
Summary 
There is a growing interest in the field of SpA to move from rather restricted and longstanding 
diseases such as AS to a more comprehensive view, encompassing not only inflammatory back pain, 
but also peripheral arthritis and enthesitis, as well as extra-articular manifestations. The new 
classification criteria and guidelines for follow-up are applied now in a number of prospective 
patient registries, and provide us with valuable information on the early disease stages of SpA. 
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The spondyloarthritides (SpA) are a family of heterogeneous diseases which, however, share 
common clinical, radiological, genetic and even therapeutic characteristics. Originally, a disease 
such as ankylosing spondylitis (AS) was considered to be an axial variant of rheumatoid arthritis, 
and it wasn’t until  the 1960s that (especially European) rheumatologists started to realize that this 
disease was a distinct separate entity. In the 1970s Moll and Wright [1,2] published seminal work 
formulating the unified concept of ‘seronegative spondarthritis’; ‘seronegative’ referred to the 
absence of rheumatoid factors (considered to be typical for rheumatoid arthritis), whereas the 
prefix ‘spond-’ was used to emphasize the close relationship between the different diseases and 
AS. In the original description, diseases such as AS, psoriatic arthritis (PsA), reactive arthritis, and 
arthritis/spondylitis associated with inflammatory bowel diseases (Crohn’s disease, ulcerative 
colitis) were included. The concept was clinically characterized by peripheral arthritis and enthesitis, 
radiological sacroiliitis (with or without spondylitis), evidence of clinical overlap (including skin, gut 
and eye disease) and a tendency for familial aggregation. Shortly after the initial description of the 
SpA concept, the discovery of a strong association of these diseases with the genetic marker Human 
Leucocyte Antigen (HLA) B27 was simultaneously reported by two independent research groups, 




Given the heterogeneous character of the diseases belonging to the SpA concept, classification is a 
major issue, with the purpose of defining homogeneous subgroups of patients that can be followed 
prospectively (e.g. to obtain data on the natural evolution of the disease) or in whom a specific new 
treatment can be tested. When discussing classification criteria, it is important to stress the 
difference with diagnostic criteria and to remember that classification should only be applied to 
patients who already have an established diagnosis. Typically, however, physicians will use the 
different components of classification criteria and take them into account when making a diagnosis 
in daily life.  
The first classification criteria within the field of SpA were the Rome and later New York criteria for 
AS [3]; they allowed identification of a homogeneous group of patients with axial complaints and 
definite structural damage defined as radiographic sacroiliitis (bilateral grade 2 or unilateral grade 
3–4). The latter is also the major drawback of these criteria because radiographic sacroiliitis is 
usually developing slowly (typically over years), thus allowing only patients with rather longstanding 
disease to be classified. Furthermore, these criteria also do not take the peripheral joint 
manifestations into account. In the 1990s, two sets of new criteria were published encompassing 
the full spectrum of SpA, namely the Amor criteria [4] and the European Spondylarthropathy Study 
Group (ESSG) criteria [5]. The different items in these criteria take into account not only axial 
disease, but also peripheral joint involvement, extra-articular manifestations and response to 
therapy. Whereas the Amor criteria are based on a list of 12 criteria, none of which is mandatory, 
the ESSG criteria introduced the concept of an ‘entry criterion’: in order to classify a patient as SpA, 
either inflammatory back pain or synovitis (asymmetric or predominantly of the lower limbs) needs 
to be present, in addition to one extra typical SpA feature. Both classification sets also have, 
however, limitations, especially in early disease, with Amor’s criteria being quite specific but with a 
lower sensitivity, whereas ESSG criteria have higher sensitivity, but low specificity [6,7].  
The arrival of new, expensive treatment options such as Tumor necrosis factor (TNF)-blockade 
provoked a therapeutic revolution unknown in the field of SpA. One consistent finding in all trials 
with biologicals targeting TNF-a is the fact that response to treatment seems to be higher in patients 
with shorter disease (symptom) duration. With regard to the existing classification criteria, two 
problems became evident; on one hand it was clear that the modified New York criteria for AS did 
not allow classification in an early disease stage, thus excluding treatment at an early (possible) 
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‘window of opportunity’; on the other hand, there was a legitimate fear that using the less-specific 
ESSG criteria would result in an unnecessary high number of patients being considered candidates 
for treatment. In order to provide a solution to this problem, the Assessment in SpondyloArthritis 
international Society (ASAS) started a study with the construction of new classification criteria for 
axial and peripheral SpA as a final goal. In this study, consecutive patients presenting with either 
back pain or peripheral joint involvement reminiscent of SpA, which usually began before 45 years 
of age, were evaluated in depth.  
The criteria for classification of axial SpA [8] lie beyond the scope of this review. In 2011, the 
classification criteria for peripheral SpA were published [9&&]. In this study, 266 patients with 
current peripheral arthritis, enthesitis and/or dactylitis, of less than 1-year’s duration, were 
included in 24 centers in 15 countries in Asia, Europe and South America. A diagnosis of peripheral 
SpA was made in 176 patients (66.2%). A total of 15% of patients were older than 45 years at disease 
onset but were not excluded. Peripheral SpA patients were younger and more often men, 
compared with patients in whom a diagnosis of SpA could not be established. Peripheral arthritis 
was the most frequent single manifestation, observed in 46.6% of patients, followed by enthesitis 
(9.8%) and dactylitis (1.9%). A combination of symptoms (mostly arthritis and enthesitis) was seen 
in 41% of patients. None of the patients had back pain at presentation. Nevertheless, radiographic 
evaluation of the sacroiliac joints (performed in 85.3%) revealed definite radiographic sacroiliitis in 
19.5% of patients diagnosed as having SpA; likewise, of the 22.5% of patients in whom MRI was 
performed, 44% of SpA patients had active inflammatory lesions. Out of a number of prespecified 
criteria sets, the best tradeoff, with a sensitivity of 77.8% and a specificity of 82.2%, was obtained 
when combining the presence of arthritis, enthesitis, or dactylitis, with either at least one ‘specific’ 
SpA-feature (psoriasis, inflammatory bowel disease, preceding infection, HLA-B27, uveitis, 
sacroiliitis on imaging) or at least two of the remaining SpA-features (arthritis, enthesitis, dactylitis, 
inflammatory back pain in the past, positive family history for SpA). 
 
PREVALENCE OF PERIPHERAL AND EXTRA-ARTICULAR MANIFESTATIONS 
 
Recently, a number of national SpA registries have described the clinical characteristics of the 
included patients.  
The results of the German Spondyloarthritis Inception Cohort were published by Rudwaleit et al. 
[10]. They described the early disease stage in axial SpA by comparing in a cross-sectional analysis 
226 patients with non-radiographic axial SpA (nr-axSpA; symptom duration ≤ 5 years) and 236 
patients with AS (symptom duration ≤10 years). The two groups did not differ in the frequency of 
HLA B27 positivity and inflammatory back pain, but also with regard to peripheral manifestations 
such as arthritis, enthesitis and dactylitis, there was no significant difference. Current peripheral 
arthritis was observed in 14.4% of AS patients compared to 18.2% in nr-axSpA; likewise, enthesitis 
was detected in 20.8 and 24.8%, and dactylitis in 2.1 and 3.1%, respectively. Looking at the 
percentage of patients that had ever experienced arthritis or enthesitis, the numbers rose to 
approximately 40% in both groups.  
In the Spanish Registro de Espondiloartritis de la sociedad espanola de reumatologia-cohort, a total 
of 150 SpA patients were selected because of a disease course of 2 years or less from the onset of 
symptoms; the majority of these patients suffered from AS (n=46), PsA (n=51) or undifferentiated 
SpA (USpA) (n=43) [11]. On inclusion, peripheral arthritis was observed in 20% of AS, 51% of PsA 
and 21% of USpA patients, whereas enthesitis was observed in 24, 14 and 26%, respectively.  
An interesting cohort is the French Devenir des Spondyloarthropathies Indifferenciées Récentes 
cohort [12]. In this nation-wide, prospective follow-up study, patients presenting with early 
inflammatory back pain are followed in order to set up a database to facilitate investigations on 
diagnosis, prognosis and epidemiology in the field of SpA. Dougados et al. [12] published the 
baseline results of the 708 recruited patients. Peripheral arthralgia (past history or current 
symptoms) was observed in 56.9% of all patients; synovitis was observed in 21.3%. Comparable 
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percentages were observed regardless of the classification criteria used. Likewise enthesiopathy 
was observed in 49% of patients (any site) and in 41.5% of patients at the heel. Extra-articular 
manifestations were also reported; acute anterior uveitis occurred in 8.5% of patients, 
inflammatory bowel disease in 4.2% and psoriasis in 15.8%.  
Finally, a large series of Brazilian patients with SpA was published by de Carvalho et al. [13]. The 
authors describe 1505 patients fulfilling the ESSG classification criteria. Clinical and demographic 
variables were recorded; AS was the most frequent disease (65.4%), followed by PsA (18.4%) and 
USpA (6.7%). The influence of sex on the disease pattern was studied; the 415 female patients were 
significantly older and reported shorter disease duration compared with male patients; the female 
sex was associated to peripheral arthritis and dactylitis, a higher number of painful and swollen 
joints and a higher MASES score (Maastricht Ankylosing Spondylitis Enthesitis Score), whereas pure 
axial involvement was more frequently observed in men. A similar increased frequency of 
peripheral arthritis in female AS patients was found in the Icelandic population [14].  
In our own prospective cohort of consecutive, newly diagnosed SpA patients (unpublished data), 
we have included over the past year 85 patients with predominantly axial SpA (41 AS, 44 nr-axSpA). 
The data on peripheral manifestations are consistent with the international cohorts presented 
above. The percentage of peripheral arthritis is 17.1% in AS and 25.6% in nr-axSpA; percentages for 
enthesitis are 22 and 25%, respectively. The importance of peripheral arthritis cannot be 
underestimated. In one retrospective analysis of 271 AS patients (according to modified New York 
criteria), 84 had peripheral arthritis. In these patients a significantly higher prevalence of childhood 
onset (36 vs. 25%, P¼0.04), hip joint involvement (55 vs. 44%, P=0.04), dactylitis (10 vs. 
1%,P=0.0006), enthesitis (28 vs. 7%, P=0.0006) and uveitis (36 vs. 20%, P¼0.005) was observed [15]. 
 
MONITORING OF PERIPHERAL MANIFESTATIONS 
 
Very recently, the ASAS-group also produced recommendations regarding variables to be collected 
in clinical trials or epidemiological studies of SpA [16]. According to these guidelines, the follow-up 
of peripheral joint involvement, dactylitis and enthesitis is an important issue (beside the 
recognition of extra-articular manifestations such as uveitis, psoriasis and inflammatory bowel 
disease), even when the primary interest of a therapeutic trial would be to focus on axial symptoms. 
The underlying idea is clearly that recognition and monitoring of these manifestations are very 
important. It could be argued that a systematic minimal follow-up of these specific SpA features 
should not take too much additional time in daily clinical practice, and would provide useful 
information and assure more comprehensive care for the patients. From a diagnostic point of view 
it seems even more important to at least inquire about ‘extra-axial’ manifestations in SpA. In our 
own cohort mentioned above, there is a statistically significant difference concerning time between 
symptom onset and diagnosis, which is only 0.5 years for peripheral vs. 1.83 years for axial SpA 
(median values). 
 
PERIPHERAL MANIFESTATIONS AND RESPONSE TO (BIOLOGIC) THERAPY 
 
In a large Belgian epidemiological study [17], a random sample of 847 AS patients (according to 
modified New York criteria) were in-depth evaluated in both academic and nonacademic outpatient 
settings. In the follow-up of these patients, the commencement of anti-TNF therapy was evaluated; 
in 263 patients anti-TNF was started. Besides having a higher bath ankylosing spondylitis diseases 
activity index (BASDAI) and elevated C reactive protein (CRP) (which are two required 
reimbursement criteria for treatment of AS patients with biologicals in Belgium), the prevalence of 
peripheral arthritis and, more specifically, hip joint involvement was significantly higher in the 
treated group (arthritis: 29 vs.22%, P=0.029, hip joint involvement: 36 vs. 22%, P<0.001). This 
underscores the importance of peripheral joint manifestations with regard to decisions about the 
initiation of more effective therapies.  
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Few studies have evaluated clinical characteristics as possible predictors of long-term treatment 
continuation of anti-TNF agents in AS patients. Several studies have studied predictors of treatment 
response, finding shorter disease duration, lower age, HLA-B27 positivity, lower bath ankylosing 
spondylitis functional index (BASFI) and indicators of active inflammation, such as higher CRP or 
erythrocyte sedimentation rate level, higher BASDAI and presence of spinal inflammation on MRI 
at baseline to predict a more favorable outcome. Data on clinical characteristics predicting drug 
continuation, however, remain scarce.  
In the Danish nationwide registry of biological therapies [18], predictors of short-term clinical 
response such as raised CRP, lower BASFI and younger age at baseline were confirmed. Raised CRP 
above 14 mg/l was also one of the characteristics associated with  longer drug survival, besides 
male sex and a low visual analogue scale for fatigue. Age, type of TNF-inhibitor and methotrexate 
use were insignificant with regard to drug continuation.  
In another Scandinavian registry, the South Swedish Arthritis Treatment Group Register, Kristensen 
et al. [19] found that the presence of peripheral arthritis and male sex predicted better anti-TNF 
therapy continuation in patients with active AS, mainly due to a lower risk of ceasing treatment 
because of insufficient therapeutic response. Because anti-TNF agents are similarly effective with 
regard to axial and peripheral rheumatological manifestations, the authors speculate that a possible 
explanation might be that the identification of patients with active inflammation (which are those 





Peripheral joint manifestations, such as arthritis, enthesitis and dactylitis, are inherently part of the 
different diseases belonging to the SpA concept. They should be recognized as such and could act 
as a red flag in young patients with a suspicion of SpA, with the presence of arthritis potentially a 
more stringent reason for referral compared with chronic back pain as the main rheumatological 
manifestation.  
The recent publication of the ASAS classification criteria for peripheral SpA provide a framework for 
clinicians to recognize this frequent problem. Especially with regard to therapeutic studies, they 
allow definition of, at a certain point in time, groups of patients with similar signs and symptoms 
within the full SpA concept; although sub classification in specific diseases such as AS and PsA might 
still be useful when one is studying specific pathogenic disease mechanisms, the classification 
according to the predominant symptom seems to be closer to the daily practice of clinicians, 
evaluating patients, especially in an early stage of the disease.  
The overall prevalence of peripheral manifestations seems to be very similar across different 
studies and registries, and these manifestations are present both in early and longstanding disease. 
Although SpA was historically considered a ‘male’ disease, newer datasets all point towards more 
women being affected; there are preliminary data to suggest that pure axial disease is more 
frequently observed in men, whereas peripheral joint manifestations might be more problematic 
in women.  
Recognition and monitoring of these manifestations should be part of a concise standard evaluation 
of SpA patients, especially because they seem to be playing a role in the decision on initiation or 










KEY POINTS  
 
 The new Assessment in SpondyloArthritis international Society criteria for axial and peripheral 
spondyloarthritis (SpA) allow classification of homogeneous groups of SpA patients according 
to their predominant clinical manifestation.  
 Peripheral arthritis, enthesitis and dactylitis occur in a relevant number of SpA patients with a 
consistent prevalence across different registries. 
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Objective. To evaluate the efficacy and safety of golimumab to induce clinical remission in patients 
with very early, active peripheral Spondyloarthritis (pSpA). 
Methods. CRESPA (Clinical REmission in peripheral SPondyloArthritis) is a monocentric study of 
golimumab treatment in pSpA patients. All patients fulfilled the Assessment of SpondyloArthritis 
international Society (ASAS) classification criteria for pSpA, with a symptom duration ≤ 12 weeks. 
Patients were randomized 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 
24 weeks. The primary endpoint was the percentage of patients achieving clinical remission at week 
24, defined as absence of arthritis, enthesitis and dactylitis. Secondary endpoints included joint and 
enthesis counts, patient reported outcomes, ESR and CRP. From week 12, non-responders were 
allowed to receive rescue medication with golimumab. Adverse events were recorded. 
Results. 60 patients were randomized with similar baseline characteristics. At week 24, a 
significantly higher percentage of patients receiving golimumab achieved clinical remission 
compared to placebo (75% (30/40) versus 20%  (4/20); P<0.001). At week 12 similar results were 
observed (70% (28/40) versus 15% (3/20) ; P<0.001 ). All secondary endpoints were met at week 
24. Rescue medication was necessary in 50% in the placebo group opposed to only 10% in the 
golimumab arm. Rates of adverse events were low and similar in both groups.  
Conclusion. Markedly high remission induction rates were noted with golimumab  in very early 
pSpA. Of interest, in placebo treated patients, very low spontaneous remission rates were 
observed. 
 
















The spondyloarthritis (SpA) concept is split depending on the predominant clinical manifestation 
into axial and peripheral disease, the latter including Psoriatic Arthritis (PsA) and non-psoriatic 
peripheral SpA (pSpA). The natural evolution of pSpA is poorly understood, especially in early forms. 
However, there are some reports suggesting a benign course with a high rate of spontaneous 
remission [1, 2]. At present, it is unclear if early pSpA demands intensive therapy similar to early 
Rheumatoid Arthritis (RA) and axial SpA.  
The therapeutic landscape has profoundly changed with the introduction of targeted (anti)cytokine 
treatments, particularly anti-tumour necrosis factor (TNF-α)[3]. TNF inhibitors have been 
successfully tested in numerous phase 3 studies in ankylosing spondylitis (AS) and PsA, the two 
major diseases belonging to the SpA concept, leading to worldwide approval[4-11]. TNF-blockade 
also has a proven beneficial effect on the peripheral manifestations of AS[12]. Several small studies 
suggest a good efficacy of anti-TNF-therapy in non-AS and non-PsA pSpA[13-18]. Recently two RCTs 
in longstanding peripheral SpA confirmed these findings[19, 20].  
In RA, there is accumulating evidence for a so-called ‘window of opportunity’ referring to the 
existence of a transient time frame in which the disease is more susceptible to treatment[21]. In 
axial SpA, anti-TNF agents are effective across the full spectrum from non- radiographic axial SpA 
(nr-axSpA)[22-25] to AS. It was shown that response to treatment was markedly higher in early 
forms of axial disease with high rates of clinical remission [26]. This suggests there could also be a 
“window of opportunity” for drug-free remission in axial SpA. This is currently explored in ongoing 
clinical trials in axSpA. To date, there are no data exploring this concept in pSpA. We tested this in 
a proof of concept placebo-controlled study, exploring the efficacy and safety of an induction 
therapy with the TNF-blocking agent golimumab in very early pSpA. The placebo controlled design 
permitted to estimate the spontaneous remission rate in this population. Our data highlight a 
markedly high clinical remission rate in anti-TNF treated patients as opposed to only low 
spontaneous remission in the placebo group.  
METHODS 
Study design 
Overall, 60 patients with pSpA were randomized in a single center, double-blind clinical trial to 
receive golimumab 50 mg or placebo subcutaneously every 4 weeks through week 24. Patients 
were randomized in a 2:1 ratio (2 golimumab:1 placebo). There was an option to start  rescue 
medication with golimumab 50 mg sc starting at week 12 if all 3 of the following criteria were met: 
(1) no improvement of patient reported outcomes (PROs) of disease activity compared to baseline 
(Bath AS Disease Activity Inde (BASDAI), Patient Global Assessment (PGA) of Disease Activity (0–100 
mm VAS), Patient Global Pain Assessment(0–100 mm VAS) (2) severe disability defined as Bath AS 
Functional Index (BASFI) >6 on a 10-scale numerical rating scale (NRS) and (3) no improvement of 
peripheral arthritis, enthesitis and/or dactylitis compared to baseline. The study drug was provided 
in prefilled syringes containing golimumab 50 mg or matching placebo (Janssen Pharmaceutica NV). 
The study was approved by the Medical Ethics Committee of the Ghent University Hospital and 
written informed consent was obtained from each patient before study related procedures were 
performed. The study was conducted in compliance with International Conference on 
Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. 
 
Patients 
Adult patients, newly diagnosed with active peripheral SpA and fulfilling the Assessment of 
SpondyloArthritis International Society (ASAS) criteria for peripheral SpA, were included. This was 
defined as presence of arthritis, enthesitis or dactylitis at screening visit with at least one of the 
following SpA features: anterior uveitis, Crohn’s disease, evidence of a preceding infection (acute 
diarrhea or non-gonococcal urethritis or cervicitis 1 month before arthritis), psoriasis, HLA B27 
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positivity or sacroillitis by imaging defined as bilateral grade 2–4 or unilateral grade 3–4 sacroiliitis 
on plain radiographs, according to the modified New York criteria or active sacroiliitis on MRI 
according to the ASAS consensus definition. All subjects had to have onset of peripheral SpA 
symptoms (arthritis, enthesitis, dactylitis) ≤ 12 weeks prior to the screening visit. Active disease was 
defined as the persistent presence of arthritis, enthesitis and/or dactylitis and by Patient Global 
Assessment of Disease Activity VAS ≥ 40mm and Patient Global Assessment of Pain VAS ≥ 40mm at 
both screening and baseline visits. In patients  with concurrent axial SpA symptoms, the peripheral 
SpA symptoms had to be the predominant symptoms at study entry based on the Investigator’s 
clinical judgment. In all patients a MRI of the sacroiliacal joints was performed at screening. 
Sacroiliitis on imaging was defined as active sacroiliitis on MRI according to the ASAS consensus 
definition. Women of childbearing potential or men capable of fathering children had to be using 
adequate birth control measures during the study and for 6 months after receiving the last 
administration of study agent. Female patients of childbearing potential had to test negative for 
pregnancy. Exclusion criteria included serious infections in the previous 4 weeks, history of 
malignancy in the past 10 years, significant history of other severe diseases or uncontrolled 
concomitant disease. All patients were screened for latent tuberculosis with a purified protein 
derivative test and chest radiography. If screening was positive, adequate chemoprofylaxis 
according to local guidelines was started. Patients with positive rheumatoid factor or anticyclic 
citrullinated peptide antibody at screening and subjects with diagnosis and current symptoms of 
fibromyalgia were excluded.   
 
Concurrent and prior medication 
Patients were allowed to be treated with non-steroidal anti-inflammatory drugs (NSAIDs) provided 
that the dose at baseline was stable for 2 weeks. During the trial, tapering of NSAIDs guided by 
clinical signs and symptoms was allowed and reported. No concomitant disease-modifying 
antirheumatic drug (DMARD) therapy or corticosteroid therapy was allowed with the exception of 
patients already treated for established psoriasis or inflammatory bowel disease and provided that 
the dose was stable 4 weeks before baseline that developed spondyloarthritis signs and symptoms 
for the first time. Local corticosteroid treatments of skin psoriasis and local treatments for uveitis 
were allowed. Treatment with intra-articular corticosteroid injection(s) for pSpA symptoms in the 
preceding 12 weeks were not allowed. 
 
Efficacy assessments 
Primary efficacy endpoint  
The primary endpoint for this study was the proportion of patients achieving a status of clinical 
remission at week 24, defined as complete absence of peripheral arthritis, enthesitis and dactylitis 
on clinical examination.  
Secondary efficacy endpoints  
Several secondary efficacy variables were analyzed. As PROs, we evaluated at baseline and every 4 
weeks the PGA of Disease Activity (0–100 mm VAS), the BASDAI (0–10), the BASFI (0-10) and the 
36-item Short-Form Health Survey with the Physical Component Summary and the Mental 
Component Summary scales. Clinically, we evaluated at baseline and every 4 weeks the 76/78 
tender and swollen joint count (TJC,SJC),  dactylitis count (0-20) and enthesitis count included the 
Maastricht Ankylosing Spondylitis Enthesitis Score (0–13) with the addition of the plantar fascia 
insertion to the calcaneus, quadriceps tendon insertion into the superior pool of the patella and 
patellar ligament insertion into the inferior pool of the patella which accounts for a total of 19 
entheseal locations. Also the Bath Ankylosing Spondylitis Metrology Index and scores for psoriasis 
including the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) were evaluated 
every 4 weeks. The following response criteria were evaluated at week 12 and 24: clinical remission 
status at week 12, peripheral Spondyloarthritis Response Criteria (pSpARC) 40%, 50% and 70% 
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response at week 12 and 24 defined as ≥ 40%, 50% or 70% improvement from baseline (≥ 20mm or 
≥ 30 mm absolute improvement) respectively in the VAS scores for Patient Global Assessment of 
Disease Activity (PGA) and Patient Global Assessment of Pain on a 100mm Visual Analogue Scale 
(VAS), and ≥40%,  ≥50% and ≥70% improvement in at least one of the following scores: (1) swollen 
76-joint count (SJC) and tender 78-joint count (TJC); (2) total enthesitis count; or (3) dactylitis count 
[19]. The ASAS 20 and 40 response, the BASDAI 50% response and the ASDAS improvement criteria 
were evaluated at week 12 and 24. Also the  Physician’s Global Assessment (PhGA) was recorded 
every 4 weeks. At baseline, week 12 and 24 laboratory tests were performed including C reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR). At baseline the NSAID intake was 
calculated using the ASAS NSAID index based on the last 2 weeks of NSAID intake; during the study 
time frame of every 4 weeks the NSAID index was calculated based on the last 4 weeks of NSAID 
intake[27].   
Safety assessments 
The safety was assessed by recording adverse events (AEs) and serious AEs (SAE) that began or 
worsened after the first dose of study medication during study time. Routine laboratory 
investigations were performed on the screening visit and on week 12 and 24 for safety evaluations 
to explore AEs.  
 
Statistical analysis 
The intent-to-treat population analyzed for efficacy and safety included all randomized patients 
who received at least one dose of blinded study medication. A sample size of 60 patients (20 
placebo and 40 golimumab) was calculated based on previous anti-TNF trials which included pSpA 
to provide 80% statistical power and α level of 0.05[28, 29]. For categorical  improvement and 
response variables, patients with missing data at week 24 were considered to be non-responders 
using non-responder imputation. For all other variables, last observation carried forward was 
applied to impute missing values at week 24. At each time-point, differences between placebo and 
golimumab were tested using a Fisher’s exact test for the categorical outcome variables and a 
Mann-Whitney U test for the continuous outcome variables. All statistical tests were two-sided and 




Sixty patients were enrolled in the study and subsequently randomized to treatment with 
golimumab (n=40) or placebo (n=20) from March 2012 to July 2015. All patients completed the 24-
week double-blind placebo controlled period (supplementary file). The demographic features and 
disease characteristics of the patients were comparable across both treatment arms and 
summarised in table 1. The mean symptom duration was 4.4 and 5.2 weeks in the placebo and 
golimumab arm, respectively.  Presence of peripheral arthritis, enthesitis and dactylitis was 
observed in 59, 25 and 24 patients out of the 60, respectively. There was only 1 patient with 
dactylitis as the unique peripheral manifestation.  In all other patients with dactylitis and/or 
enthesitis there was also concomitant arthritis. There was no difference in concomitant NSAID use 
at baseline between the two treatment groups. None of the included patients were on DMARD 
therapy except for one patient who was on a stable dose of Sulfasalazine for an established 
inflammatory bowel disease. No patients received glucocorticoids at screening. The most frequent 
extra-articular manifestation was skin and/or nail psoriasis in 23 out of the 60 patients with an 
overall median disease duration of 4.3 years. Only 7 out of 60 patients reported having experienced 
inflammatory back pain in their past medical history; nevertheless 35% of patients (21/60) exhibited 
BME of the SI joints on MRI and fulfilled the ASAS definition of a positive MRI. The median tender 
and swollen joint count and proportion of patients with dactylitis and enthesitis at baseline were 
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comparable in both groups. Most patients were on NSAIDs at baseline with a comparable median 
NSAID index.  
 
Table 1. Demographic features and baseline disease characteristics of the study patients by 
treatment group. 
 
† Acute diarrhea or nongonococcal urethritis or cervicitis 1 month before arthritis. Sacroiliitis on 
imaging is defined as active sacroiliitis on MRI according to the ASAS consensus definition. ASAS, 
Assessment of SpondyloArthritis international Society; CRP C-reactive protein; IBD, Inflammatory 






  Golimumab  
(n=40) 
Placebo 
 (n=20)  
Demographics      
Male, n (%) 26 (65) 13 (65) 
Age, mean ± SD years 38.3 ± 13.2 42.3 ± 13.7 
HLA B27 positive, n (%) 20 (50) 13 (65) 
Disease characteristics  
 
Symptom duration, mean ± SD weeks 5.2 ± 2.8 4.4 ± 2 
Concomitant NSAIDs use at baseline, n (%) 32 (80%) 18 (90%) 
NSAID index, median (p25,- p75) 89.3 (35 - 100) 100 (65.1 – 100) 
SpA features  
 
Anterior uveitis, past or present, n (%) 1 (2.5) 0 (0) 
IBD, past or present, n (%) 0 (0) 1 (5) 
Preceding infection†, n (%) 6 (15) 2 (10) 
Skin and/or nail psoriasis, n (%) 15 (37.5) 8 (40.0) 
Percentage of patients with elevated CRP (≥5mg/L) 24 (60%) 15 (75%) 
Sacroiliitis on MRI, n (%) 12 (30) 9 (45) 
Family history of SpA, n (%) 13 (32.5) 8 (40) 
Inflammatory back pain (history/presence), n (%) 5 (12.5) 2 (10) 
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Table 2. Disease activity and response criteria at baseline, week 12 and week 24.  
Descriptive statistics: median (p25, p75) for continuous variables, percentages for categorical variables. *P-value is 
calculated compared to baseline findings. Except where indicated otherwise, values are the number (%) of patients. 
pSpARC 40%,50%,70% peripheral SpondyloArthritis 40%, 50% and 70% remission criteria. CRP, C-reactive protein; ESR, 
erythrocyte sedimentation rate; NA, not available;  NS, not significant; PGA, Patient Global Assessment; pSpA, peripheral 
spondyloarthritis; pSpARC, peripheral spondyloarthritis remission criteria; SJC, swollen joint count; TJC, tender joint 
count; VAS, visual analog scale. 
 
Clinical Efficacy at week 12 and 24  
The primary endpoint of the study was met. At week 24, 75% (30/40) of golimumab treated patients 
reached a status of complete absence of arthritis, enthesitis and dactylitis compared to only 20 %  
(4/20) in the placebo group (P<0.001)(Figure 1). The status was already  achieved as early as week 
12 (70% (28/40) versus 15% (3/20; P<0.001). At week 12, a pSpARC 40%, 50% and 70% response 
was observed in respectively 57.5%, 55% and 50 % of patients treated with golimumab versus 20%, 
20% and 15% in the placebo group. In table 2 the individual components of the pSpARC response 
criteria, as well as ESR and CRP, are described at baseline, week 12 and 24. All assessments 
demonstrated a statistical significant improvement at week 12 and 24 with golimumab treatment 
compared to placebo. The evolution over time of the mean tender and swollen joint count, 
enthesitis (0 -19) and dactylitis count, and PGA and Physician’s Global Assessment of disease activity 
















Clinical Remission Status, n (%) NA NA NA 28 (70%) 3 (15%) <0.001 30 (75%) 4 (20%) <0.001 
Peripheral Spondyloarthritis 
Response criteria 
         
pSpARC 40%, n (%) NA NA NA 23 (57.5%) 4 (20%) 0.007 20 (50%) 3 (15%) 0.011 
pSpARC 50%, n (%) NA NA NA 22 (55%) 4 (20%) 0.013 22 (55%) 3 (15%) 0.005 
pSpARC 70%, n (%) NA NA NA 20 (50%) 3 (15%) 0.011 16 (40%) 3 (15%) 0.077 
Individual components of 
pSpARC  
         
TJC, median (p25,p75) 5 (3 , 8) 4 (2 , 9)   NS 0 (0, 2)  4 (1, 11) 0.001 0 (0 , 2) 5 (1 , 7) <0.001 
SJC, median (p25,p75) 4 (2 , 5) 3 (2 , 5) NS 0 (0, 0) 2 (0, 7) <0.001 0 (0 , 1)  1 (0 , 6) <0.001 
Percentage of patients with 
enthesitis n (%) 
16 (40%) 9 (45%) NS 6 (15%) 5 (25%) 0.48 7 (17.5%) 16 (80%) <0.001 
Percentage of patients with 
dactylitis, n (%) 
15 (37.5%) 9 (45%) NS 3 (7.5%) 8 (40%) 0.004 7 (17.5%) 12 (60%) 0.003 
Patient Global Pain (0-10 NRS 
scale) 
5 (4 , 7) 6 (4 , 8) NS 1 (1, 4) 6 (3, 7) <0.001 2 (0 , 4) 6 (3 , 7) <0.001 
Patient Global Disease Activity 
(0-10 NRS scale ) 
7 (5 , 8) 8 (4 , 9) NS 2 (1 , 5) 6 (4, 7) 0.002 1 (0 , 3) 6 (4 , 8) <0.001 
ESR, mm/h 21 (8 , 41) 28 (11 , 60) NS 3 (2 , 6) 
17 (4 , 
31) 
0.002 3 (2 , 8) 8 (4 , 21) 0.024 




(PhGA) is visualized in figure 2. A statistically significant improvement in TJC, SJC,PGA and PhGA was 
already achieved after 4 weeks of treatment and was sustained up to week 24. Of note, the intake 
of NSAIDs also decreased significantly in the golimumab treated patients, compared to a stable 
NSAID index over time in the placebo group.  
We additionally evaluated more conventional axial SpA response criteria. At week 24, golimumab 
patient reached ASAS 20 and 40 response and BASDAI 50% response in respectively  67.5%, 65% 
and 72,5% as opposed to only 30%, 15% and 20% in the placebo group (p<0.05 for all parameters). 
Comparable efficacy was observed using the ASDAS improvement criteria: at week 24, in 
golimumab treated patients a clinically important or major improvement of ASDAS  was observed 
in respectively 77,5% and 45% of patients versus in 20% and 20% in the placebo group. (p<0.05). 
Similar results were observed at week 12 (data not shown).  
As expected, physical function and health-related quality of life also improved significantly in the 
active treatment group compared to placebo (p<0.05 for all parameters).  
 
Figure 1: Primary outcome: percentage of patients in clinical remission after 12 and 24 weeks in the 







Figure 2: Changes in the clinical disease activity parameters during treatment with golimumab and 
placebo from week 0 till week 24. The panels represent the tender and swollen joint count, 
dactylitis and enthesitis count, non-steroidal anti-inflammatory drug (NSAID) index and Patient 
Global Assessment of disease activity on a 100 mm visual analogue scale. Data are presented as 







Dropouts and safety analysis 
All patients completed the 24-week placebo-controlled phase. The safety analysis is summarized in 
table 3.  Overall, there were no unexpected safety signals.  The overall incidence of any AE in the 
golimumab group was similar to that in the placebo group. The most common events (MedDRA 
preferred terms) were nasopharyngitis and upper respiratory tract infection in both groups.  There 
were no SAE observed in the placebo group, compared with four events in golimumab treated 
patients (p=0.29), all of which were considered to be not related to study drug by the investigator: 
elective prostatectomy because of known benign prostatic hypertrophy, acute calculous 
cholecystitis, food poisoning and worsening of arthritis. No local injection reactions were observed. 
No deaths or malignancies were noted during the study period. No tuberculosis reactivation was 
observed.  
Table 3: Incidence and types of adverse events during the 24-week double-blind period. 
  
AE, adverse events. 
Need for rescue and efficacy in subgroups 
From week 12 onwards, there was an option to start rescue medication with open label golimumab 
if patients were not responding. In the placebo group 10 out of 20 patients (50%) entered the rescue 
arm, compared to only 4 out of 40 (10%) patients in the golimumab arm. We analyzed whether 
treatment effect was different in patients with or without elevated CRP at baseline: no interaction 
could be demonstrated with regard to the major outcome parameters. We also assessed whether 
response to  treatment was comparable in patients with PsA (n=25) versus non-psoriatic 
(undifferentiated peripheral) SpA (n=35). The overall median disease duration of skin and/or nail 
psoriasis was 4.3 years: again there were no statistically significant differences for all primary and 
secondary end points between these two groups. 
 
DISCUSSION 
The results from this study provide several novel and clinically relevant findings with important 
implications for management of patients with pSpA. First, very early recognition of disease and 
initiation of biologic treatment leads to a substantially higher response compared with published 
reports in patients with more established disease [19, 20]. Second and of equal importance, the 
results from the placebo arm do not support the hypothesis that a substantial proportion of early 
peripheral SpA patients goes into spontaneous clinical remission.  
  Placebo (n=20) Golimumab (n=40) 
Any AE 25 AEs in 11 patients 52 AEs in 26 patients 
Serious AE 0 4 
AE leading to discontinuation of study 
drug 
0 0 
Infectious AE 17 33 
Hepatic-related AE 0 0 
Hematologic AE 0 0 
Death 0 0 
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Our study was the first to explore the therapeutic potential of an anti-TNF agent, golimumab, in 
patients with very early (<12 weeks symptom duration) pSpA, classified according to the ASAS-
criteria. Our main results show improvement in all clinical and laboratory assessments and PROs, 
as well as validated measures of quality of life. We especially observed high remission rates, defined 
in a very stringent way as the complete absence of arthritis, enthesitis and dactylitis. Given the 
paucity of large clinical trials conducted in patients with pSpA at this moment, no efficacy end point 
has been specifically developed and validated for a patient population with predominant pauci-
articular joint and enthesis involvement. It seems logical that classic response criteria based on the 
decrease in the number of active joints/entheses are probably not the best evaluation method to 
assess efficacy. Therefore, we chose as our primary endpoint an outcome based on the actual 
disease activity status and not on a percentage of improvement. 
Contrary to most phase III clinical trials in PsA, our patient population consisted of mainly oligo-
articular and very early, DMARD-naïve disease. Recently two other RCTs in established pSpA were 
performed [19, 20]. In both trials, the mean symptom duration was around 7 years compared with 
only 5 weeks in our study. Paramarta et al [20] evaluated the efficacy of adalimumab in 40 patients 
with active pSpA fulfilling the European Spondyloarthropathy Study Group or Amor criteria but not 
the criteria for AS or PsA  As primary endpoint they used the patient’s global assessment at week 
12 and found a strong improvement at week 12 compared with baseline in the adalimumab group 
(-31.0 ±SD23.3mm) while the placebo group showed almost no improvement (-5.9 ±SD 21.4mm). 
In our study population we found a numerically even larger decrease regarding the patient’s global 
assessment at week 12 in the golimumab treated patients  (-37.8 ±SD 33.2mm). In the ABILITY-2 
study the efficacy and safety of adalimumab was evaluated in 165 patients with active non-psoriatic 
pSpA fulfilling the peripheral ASAS classification criteria[19]. In this trial, efficacy was evaluated with 
newly designed peripheral SpA Remission Criteria (pSpARC), with as primary endpoint a 40% 
improvement.  At week 12, a greater proportion of patients receiving adalimumab achieved this 
pSpARC40 response compared to patients receiving placebo (39% vs 20%; P =0.006).  In our study 
the pSpARC40 response was achieved in 57,5% of patients treated with golimumab vs 20% in the 
placebo group (P=0,0069). Despite the fact that the included study populations in both trials were 
not exactly identical compared with ours, we observed at least a trend that efficacy was better in 
patients with short symptom duration, compared with more longstanding disease. This concept is 
already established in axial SpA, but our data are the first to also demonstrate this in pSpA.  
Interestingly, more conventional axial SpA response criteria, such as ASAS 20 and 40 response, 
BASDAI 50% response and ASAS improvement criteria, also showed good discriminatory capacity in 
our patients, with our results indicating again a higher response rate compared with patients with 
longer symptom duration.  
An obvious strength of our study is the inclusion of a placebo-group.  In pSpA, one might consider 
that there is a danger of overtreatment in a very early phase of the disease, because a fraction of 
these patients might go spontaneously into remission, a phenomenon regularly observed in 
reactive arthritis. The rationale for including a placebo-group in this 24-week study design, was 
indeed to estimate the spontaneous remission rate. We observed that only 20% of the patients in 
the placebo group reached our definition of clinical remission. This number should however be 
interpreted with caution, because these patients had a higher intake of NSAIDs which makes it 
impossible to exclude remission induced by continuous NSAID use.  Starting at week 12, there was 
an option to start rescue medication with open label golimumab. In the placebo group 10 out of 20 
patients (50%) entered the rescue arm, compared to only 4 out of 40 (10%) patients in the 
golimumab arm. This finding, together with the difference in NSAID intake over time in both groups 
and the clinical evolution (persistence of increased TJC and SJC, enthesitis and dactylitis in up to 
80% of the placebo patients at week 12 and 24), indicates that our patient population with pSpA do 
not have self-limiting disease.  
We also examined whether distinct different treatment effects were present in patients with 
psoriasis or elevated CRP at baseline, but could not demonstrate any significant interaction.  Of 
note, in our study 65% of patients had an elevated CRP at baseline, compared with only 38 % in the 
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trial by Paramarta et al and 44 % in the Ability-2 trial. This suggests that the overall inflammatory 
burden in this group of very early pSpA is higher than in more longstanding disease.  
The data of our proof-of-concept study will need to be confirmed in larger multicentre studies. In 
any case, the data reiterate the importance of early recognition and referral strategies from primary 
care to rheumatologists, in order to install adequate treatment and consequently achieve better 
outcomes. Future strategy trials should also include other relevant treatment arms, such as 
sulfasalazine since this is the current standard of treatment for peripheral symptoms according to 
the ASAS/EULAR recommendations [3]. Our CRESPA-cohort provides unique opportunities to study 
potential biomarkers of remission, as well as the possibility to achieve drug-free remission. 
CONCLUSION 
Our findings indicate that a large majority of patients with early pSpA does not go into spontaneous 
remission, and benefits from intensive treatment. In this study, initiation of TNF blockade in pSpA 
with short symptom duration, leads to high rates of clinical remission and significant improvement 
in all secondary efficacy outcomes. 
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Background: New treatment algorithms using TNF blockers in early stages of spondyloarthritis 
(SpA) induce high rates of clinical remission or low disease activity. It could be anticipated that such 
early intervention strategies in peripheral SpA (pSpA) could induce drug-free remission. Such a 
window of opportunity for drug-free remission would point to a transient time frame in which the 
disease is more susceptible to treatment resulting in better outcomes.  
Objective: To evaluate drug-free clinical remission after induction therapy with golimumab (GLM) 
in patients with active pSpA in a very early stage of the disease. To identify patient characteristics 
predicting sustained drug-free remission. 
Methods: CRESPA (Clinical REmission in peripheral SPondyloArthritis) is an ongoing monocentric 
study of golimumab treatment in pSpA patients, including both psoriatic arthritis and non-psoriatic 
pSpA. Eligible patients were ≥18 years and fulfilled the Assessment of SpondyloArthritis 
international Society (ASAS) classification criteria for pSpA. All patients had symptom duration <12 
weeks. Sustained clinical remission was defined as the absence of arthritis, enthesitis and dactylitis 
at two consecutive major visits (at week 12, 24, 36 and 48), after which treatment was withdrawn. 
Patients were prospectively followed to assess the rate of sustained drug-free clinical remission and 
clinical relapse. 
Results: Eighty-two percent (49/60) of patients fulfilled sustained clinical remission criteria. Thirty 
patients already reached this status at week 24, with an additional 11 and 8 at weeks 36 and 48 
respectively. All patients had at least a follow-up of 18 months after drug withdrawal. 53% (26/49) 
of patients are still in drug-free remission. Predictors for maintaining sustained clinical remission 
after therapy withdrawal included presence of HLA B27. Conversely, negative predictors were the 
presence of psoriasis and poly-articular disease (SJC≥5) .  
Conclusion: Anti-TNF treatment in very early pSpA results in a remarkably high rate of sustained 
clinical remission. More than 50% remain in remission after therapy withdrawal highlighting a 
















Peripheral Spondyloarthritis (pSpA) represent a common form of spondyloarthritis including 
Psoriatic Arthritis (PsA) and non-psoriatic peripheral SpA (pSpA)[1] with limited therapeutic options. 
Most pSpA-patients with symptoms of peripheral arthritis, dactylitis and/or enthesitis will 
experience some level of improvement by the intake of non-steroidal anti-inflammatory drugs 
(NSAIDs) but addditional treatment is necessary. Sulfasalazine is the only disease-modifying anti-
rheumatic drug (DMARD) that has proven some level of efficacy in pSpA [2].  
The use of biologic therapies have drastically improved clinical responses in pSpA with approved 
indications in PsA for TNF, Il-17a and IL12/IL-23 inhibitors. In particular, the efficacy of the TNF 
inhibitors infliximab, etanercept, adalimumab, certolizumab pegol and golimumab has been 
demonstrated across the different established diseases of the SpA concept (AS,PsA)[3-12]. 
Over the past decade several studies have shown improved therapeutic responses  in early versus 
longstanding forms  of various rheumatic diseases. In axial SpA, TNF inhibitors (TNFi) were also 
shown to be effective in treating the early stages of SpA. Studies in patients with non-radiographic 
axial SpA (nr-axSpA) have demonstrated at least similar, if not better, efficacy responses compared 
to treatment in a more advanced stage of the disease[7, 13-15]. In addition, trials in axial SpA 
(mainly AS) have been set up to evaluate the efficacy of a TNFi discontinuation strategy. However, 
in most cases discontinuation of TNFi after achieving a status of sustained low disease activity or 
remission led to the appearance of flare within a few months[16-21]. Nevertheless, in ongoing trials 
in axSpA, a marked interest has been developed in the exploration of therapy withdrawal strategy 
upon induction of clinical remission to achieve biologic-free remission or even the ultimate goal of 
therapy, drug-free remission, resembling recovery[22](ClinicalTrials.gov: NCT01808118 
(adalimumab); [23]NCT02509026 (etanercept); [24]NCT02505542 (certolizumab pegol); 
[25]NCT02407223 (ustekinumab).  
There are currently no data on ability to induce drug-free remission in early pSpA, although a fast 
relapse was observed in patients with longstanding pSpA after TNFi discontinuation[26]. Here we 
explore the window of opportunity hypothesis in very early pSpA  to evaluate drug-free sustained 
clinical remission and clinical relapse after an induction therapy with golimumab. In addition, we 
identify patient and disease characteristics predicting a status of drug-free sustained clinical 
remission or occurrence of relapse after reaching remission. 
METHODS 
PATIENTS 
All included patients were adults, newly diagnosed with active peripheral SpA and fulfilling the 
Assessment of SpondyloArthritis International Society (ASAS) criteria for peripheral SpA[27]. Active 
disease was defined as the persistent presence of arthritis, enthesitis and/or dactylitis and by 
Patient Global Assessment of Disease Activity VAS ≥ 40mm and Patient Global Assessment of Pain 
VAS ≥ 40mm at both screening and baseline visits. All subjects had onset of peripheral SpA 
symptoms (arthritis, enthesitis, dactylitis) ≤ 12 weeks prior to the screening visit. In patients with 
concurrent axial SpA symptoms, the peripheral SpA symptoms were the predominant symptoms at 
study entry based on the Investigator’s clinical judgment. Exclusion criteria included serious 
infections in the previous 4 weeks, history of malignancy in the past 10 years, and a history of 
significant other severe or uncontrolled disease. The study was approved by the Medical Ethics 
Committee of the Ghent University Hospital and written informed consent was obtained from each 
patient before study-related procedures were performed. The study was conducted in compliance 
with the International Conference on Harmonisation Good Clinical Practice guidelines and the 




PROCEDURES DURING EVERY VISIT 
Clinically, the 76/78 tender and swollen joint count (TJC, SJC), dactylitis count (0–20) and enthesitis 
count including the Maastricht AS Enthesitis Score (0–13) with the addition of the plantar fascia 
insertion to the calcaneus, quadriceps tendon insertion into the superior pool of the patella, and 
patellar ligament insertion into the inferior pool of the patella accounting for a total of 19 entheseal 
locations were examined. Body surface area (BSA) for psoriasis were evaluated. 
The clinical remission status and the peripheral spondyloarthritis remission criteria (pSpARC) 40%, 
defined as ≥40% improvement from baseline (≥20 or ≥30 mm absolute improvement), respectively 
in the VAS scores for PGA of disease activity and PGA of pain on a 100 mm VAS, and ≥40%, 
improvement in at least one of the following scores: (1) 76 SJC and 78 TJC; (2) total enthesitis count 
or (3) dactylitis count [28] were determined as response criteria. Laboratory tests including CRP and 
ESR were performed at each visit.  
The proportion of patients reaching a status of clinical remission at weeks 12, 24, 36 and 48, drug-
free sustained clinical remission, clinical relapse after reaching remission, major clinical response at 
week 48 and non-responding after an induction therapy with golimumab was calculated. Patients 
and disease characteristics were identified predicting a status of drug-free sustained clinical 
remission or occurrence of relapse after reaching remission. Data regarding duration of drug-free 
interval until recurrence of symptoms were documented. 
STUDY DESIGN 
CRESPA 
In the CRESPA trial, a placebo-controlled part of the study followed by an open-label phase starting 
at week 24 till week 48, sixty patients fulfilling the ASAS criteria for peripheral spondylarthritis were 
enrolled. Patients were randomized in a 2:1 ratio (2 golimumab:1 placebo) and golimumab 50mg 
or placebo was administrated subcutaneously every 4 weeks (q4wk) through week 20. Multiple 
scenarios could occur during this study (Fig 1). Patients with still active disease at the end of the 
placebo-controlled phase (week 24), golimumab 50 mg q4wk will be administered till week 48. 
Active disease was defined as still presence of clinical arthritis, enthesitis or dactylitis. In the open-
label CRESPA extension part of the study, patients had to fulfil the scenario of clinical relapse after 
reaching remission or major clinical response at week 48 and treatment with golimumab 50 mg 
q4wk was continued for a total of 104 weeks. Clinical evaluations, standard laboratory evaluations 
including ESR and CRP and patient reported outcomes were evaluated every 3 months according to 
daily practice guidelines for the treatment of AS and/or PsA with biological agents. 






Sustained clinical remission 
If patients were in sustained clinical remission, defined by the absence of clinical arthritis, enthesitis 
and dactylitis at two major consecutive visits planned at weeks 12, 24, 36 and 48, all treatment was 
stopped. Subsequently, these patients were prospectively followed to assess the possibility of 
maintaining drug-free remission. All patients were instructed to call the treating physician’s office 
in case of increasing symptoms in between planned visits and a rheumatological evaluation was 
carried out within 3 days. In case of clinical relapse after drug withdrawal, therapy was restarted 
with golimumab 50 mg q4wk for a total of 104 weeks in the CRESPA extension part of the study. 
Clinical relapse was defined as the presence of at least one swollen joint, as well as the presence of 
enthesitis or dactylitis, in the context of SpA.  
 
Major clinical response at week 48 
If patients did not reach sustained clinical remission at week 48, but were major responders defined 
as meeting the Peripheral Spondyloarthritis 40% Response Criteria (PSpARC 40), then they went 
directly to the CRESPA extension part of the study in order to receive uninterrupted treatment with 
golimumab 50 mg q4wk for a total of 104 weeks. PSpARC 40 response was defined as ≥ 40% 
improvement from baseline (≥ 20mm or ≥ 30 mm absolute improvement) respectively in the VAS 
scores for Patient Global Assessment of Disease Activity (PGA) and Patient Global Assessment of 
Pain on a 100mm Visual Analogue Scale (VAS), and ≥40% improvement in at least one of the 
following scores: (1) swollen 76-joint count (SJC) and tender 78-joint count (TJC); (2) total enthesitis 
count; or (3) dactylitis count. 
Non-response 
Patients that did not reach sustained clinical remission nor met the PSpARC 40 criteria at week 48 
were considered as non-responder. In these patients, study treatment was discontinued and 
conventional treatment options available in daily practice were initiated. 
STATISTICAL ANALYSIS 
Data were analysed using SAS v 9.4.  A sample size of 60 patients (20 placebo and 40 golimumab) 
was calculated based on previous anti-TNF trials which included peripheral SpA to provide 80% 
statistical power and α level of 0.05 [29, 30]. Descriptive statistics were provided as the proportion 
of patients achieving the following outcomes: a state of clinical remission at weeks 12, 24, 36 and 
48, drug-free sustained clinical remission, clinical relapse after reaching remission, major clinical 
response at week 48 and non-responding after an induction therapy with golimumab. Logistic 
regression models were applied to estimate the effects from different patients and disease 
characteristics on the likelihood that patients achieved these outcomes. The following predictors 
were analyzed at baseline: duration between onset first symptoms and start golimumab treatment, 
age, CRP, ASDAS, BASFI, presence of psoriasis, and SJC>5 vs SJC≤5. A rapid response to treatment 
defined as clinical absence of arthritis, enthesitis and dactylitis at week 4, 8 or 12 was analyzed as 
predictor for the different outcomes and compared to patients who achieved this status only after 
12 weeks. Estimated Odds Ratios (OR) are presented with their corresponding 95% confidence 
intervals.  The time to relapse was correlated with the duration of golimumab treatment by using 
the Spearman correlation test. Kaplan-Meier curves were created to describe the drug free 
remission time. Log-rank tests were used to determine if there were differences in the survival 
distribution for different subpopulations: presence/absence for psoriasis, SJC>5 and HLA B-27 







Baseline demographics and characteristics 
Sixty patients were enrolled in the study and subsequently randomized to treatment with 
golimumab (n=40) or placebo (n=20) from March 2012 to July 2015. The demographic features and 
disease characteristics of the patients were comparable across both treatment arms and 
summarized in table 1. The mean symptom duration was 4.4 and 5.2 weeks in the placebo and 
golimumab arm respectively.  Presence of peripheral arthritis, enthesitis and dactylitis was 
observed in 59, 25 and 24 patients out of the 60 respectively. There was only 1 patient with 
dactylitis as the unique peripheral manifestation. In all other patients with dactylitis and/or 
enthesitis there was also concomitant arthritis. The overall median tender and swollen joint count 
was 4. The overall number of patients with a SJC>5 at baseline was 14 (23%). 
Almost all patients were on NSAID at baseline and had a high NSAID index with no differences 
between the two treatment groups. None of the included patients were on DMARD therapy except 
for one patient who was on a stable dose of Sulfasalazine for an established inflammatory bowel 
disease. No patients received glucocorticoids at screening. The most frequent extra-articular 
manifestation was skin and/or nail psoriasis in 23 out of the 60 patients with an overall median 
disease duration of 4 years. Psoriasis involvement was mild since all 23 patients had a BSA < 5%. 
Regarding other SpA manifestations, proven Crohn’s disease and acute anterior uveitis were 
present in only one patient each with a disease duration of 6.4 years and 0.6 years respectively. 
Only 7 out of 60 patients reported having experienced inflammatory back pain (IBP) in their past 
medical history with a median VAS back pain of 2 [0.0-9.0]; nevertheless 35% of patients (21/60) 
exhibited BME of the SI joints on MRI fulfilling the ASAS definition of a positive MRI. In patients with 
a positive MRI of the SIJ, the median VAS back pain was 2.0 versus 1.0 in patients without sacroiliitis 
on MRI (p= 0.597).  
 
Table 1. Demographic features and baseline disease characteristics of the study patients by 
treatment group. 
 Total group (n=60) Golimumab (n=40) Placebo  (n=20) 
Demographics    
Male, n (%) 39 (65) 26 (65) 13 (65) 
Age, mean ± SD years 39.7 ± 13.4 38.3 ± 13.2 42.3 ± 13.7 
HLA-B27 positive, n (%) 33 (55) 20 (50) 13 (65) 
Disease characteristics    
Symptom duration, mean ± SD weeks 5.0 ± 2.4 5.2 ± 2.8 4.4 ± 2 
TJC, median (p25,p75) 4 (3 , 8) 5 (3 , 8) 4 (2 , 9) 
SJC, median (p25,p75) 4 (2, 5) 4 (2 , 5) 3 (2 , 5) 
Number of patients with SJC >5, n (%) 14 (23.3) 9 (22.5) 5  (25) 
Percentage of patients with enthesitis n (%) 25 (41.7) 16 (40) 9 (45) 
Percentage of patients with dactylitis, n (%) 24 (40) 15 (37.5) 9 (45) 
Concomitant NSAIDs use at baseline, n (%) 50 (83.3) 32 (80) 18 (90) 
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HLA-B27, human leucocyte antigen B27; TJC, tender joint count; SJC, swollen joint count; NSAID nonsteroidal 
antiinflammatory drug; IBD Inflammatory Bowel Disease; CRP C-reactive protein; SpA spondyloarthritis; MRI, magnetic 
resonance imaging; NRS, numeric rating scale; ESR, erythrocyte sedimentation rate. † Acute diarrhea or nongonococcal 
urethritis or cervicitis 1 month before arthritis. Sacroiliitis on imaging is defined as active sacroiliitis on MRI according to 
the ASAS consensus definition. 
Proportion of patients achieving a status of clinical remission, major response and non-response 
At week 12, 70% (28/40) of golimumab-treated patients reached a status of complete absence of 
arthritis, enthesitis and dactylitis compared with only 15% (3/20) in the placebo group (p<0.001). 
At week 24 even 75% (30/40) of golimumab-treated patients reached a status of complete absence 
of arthritis, enthesitis and dactylitis compared with only 20% (4/20) in the placebo group (p<0.001).  
In total, 82 % (49 out of the 60 patients) achieved the status of ‘sustained clinical remission’ (fig 1A) 
of which 61% (n=30) achieved this at week 24 and 22.5% (n=11) and 16.3% (n=8) at week 36 and 48 
respectively (fig 1B). Of those 49 patients achieving sustained clinical remission, only 4 were coming 
out of the placebo arm, whereas all other patients were treated with golimumab from baseline or 
used the rescue arm with golimumab treatment. 10 patients did not reach ‘sustained clinical 
remission’ at week 48, but were major responders defined as meeting the Peripheral 
Spondyloarthritis 40% Response Criteria (PSpARC 40) and went directly to the ‘CRESPA extension’ 
part of the study in order to receive uninterrupted treatment with golimumab 50 mg SC every 4 
weeks for a total of 104 weeks. One patient was a non-responder at week 24 and treatment with 
golimumab was discontinued. 
 
 
NSAID index, median (p25, p75) 92.9 (50,100) 89.3 (35 ,100) 100 (65 , 100) 
SpA features    
Anterior uveitis, past or present, n (%) 1 (1.7) 1 (2.5) 0 (0) 
IBD, past or present, n (%) 1 (1.7) 0 (0) 1 (5) 
Preceding infection†, n (%) 5 (8.3) 3 (7.5) 2 (10) 
Skin and/or nail psoriasis, n (%) 23 (38.3) 15 (37.5) 8 (40.0) 
Duration of skin and/or nail psoriasis (years), median 
(p25,p75) 
4.0 (0.2, 16.6) 4.0 (0.2, 19.8) 8.5 (1.9, 15.1) 
Number of patients with elevated CRP (≥5mg/L), n (%) 39 (65) 24 (60) 15 (75) 
Family history of SpA, n (%) 21 (35) 13 (32.5) 8 (40) 
Inflammatory back pain (history/presence), n (%) 7 (11.7) 5 (12.5) 2 (10) 
Sacroiliitis on MRI, n (%) 21 (35) 12 (30) 9 (45) 
Patient Reported Outcomes    
Patient Global Pain (0-10 NRS scale),  median (p25,p75) 6 (4 ,7 ) 5 (4 , 7) 6 (4 , 8) 
Patient Global Disease Activity (0-10 NRS scale ),  median 
(p25,p75) 
7 (5 , 9 ) 7 (5 , 8) 8 (4 , 9) 
Laboratory findings    
ESR, mm/h,  median (p25,p75) 23 (10 , 44) 21 (8 , 41) 28 (11 , 60) 




Fig 2: A. Patient disposition at week 48: proportions of patients in sustained clinical remission, 
having a major response or who were non-responder. B. Proportion of patients achieving sustained 
clinical remission at different timepoints. 
pSpARC 40%, Peripheral Spondyloarthritis 40% Response Criteria. 
 
In all patients achieving a status of sustained clinical remission, treatment was stopped to evaluate 
drug-free remission. All patients had a follow-up after treatment discontinuation of at least 18 
months with a maximum of 4,5 years to date. Currently, 53% (26/49) of these patients are still in 
clinical drug-free remission whereas 47% (23/49) relapsed after golimumab discontinuation. The 
median time to relapse was 31,5 weeks. Re-initiation of golimumab promptly restored clinical 
remission in all patients with recurrence of disease.  
Analyses were performed in different subtypes of peripheral SpA (Table 2). A rather low percentage 
of patients in drug-free remission (29,4%) was observed in PsA patients compared with other 
subtypes of peripheral SpA without psoriasis (Table 2). In all Reactive arthritis (n=5), 4 of them were 
HLA B27 positive of which 2 patients experienced a clinical relapse upon treatment withdrawal, 
whereas the one HLA B27 negative patient is still in drug-free remission. Of interest, in the HLA-B27 
positive group (n=32), a better response to treatment, a higher percentage of patients in sustained 
clincical remission, and a lower percentage of clinical relapse after treatment withdrawal,  was 









Table 2: The percentages of patients achieved sustained clinical remission, are still in drug-free 
remission or experienced clinical relapse after treatment withdrawal and time to relapse for the 
total group and by different subtypes SpA. 
PsA, psoriasis arthritis; pSpA, peripheral spondyloarthritis; IBD, inflammatory bowel disease; HLA-B27, human leucocyte 
antigen B27. 
 
Description of patient’s characteristics at the moment of clinical relapse after drug withdrawal 
The majority of the relapsing patients were male. Recurrence of disease was characterized by 
development of arthritis in all 23 patients (table 3 online supplementary material) with a median of 
3 painful and 2 swollen joints.  Similar proportion of entheseal symptoms (35%) and dactylitis (48%) 
compared with baseline during recurrence of disease was observed. 48% were HLA-B27 positive 
and were having psoriasis. The severity of skin disease during recurrence of disease in these 
patients was mild and comparable with baseline. Severity of joint complaints was also reflected by 
substantial increases of the NRS scale Patient global Disease Activity and Patient global pain. All 
patients restarted treatment with golimumab 50mg q4wk and clinical remission was regained in all 
of them within 12 weeks. 
 
Table 3: Patient characteristics at time of clinical relapse (online supplementary material). 
Total number of patients, n 23 
Males, n (%) 17 (74%) 
Duration of drug-free remission (weeks), median (p25,p75) 31,5 (19,49) 
Arthritis *, n (%) 23 (100) 
Enthesitis, n (%) 8 (35%) 
Dactylitis, n (%) 11 (48%) 
TJC, median (p25,p75) 3 (2,8) 
SJC, median (p25,p75) 2 (1,4) 
HLA-B27 positivity, n (%) 11 (48%) 
Psoriasis of skin/nail, n (%) 12 (52%) 
Patient Global Disease Activity (0-10 NRS scale ), median (p25,p75) 6 (4,7) 
Patient Global Pain (0-10 NRS scale), median (p25,p75) 6 (4,7) 
Physician global (0-10 NRS scale), median (p25,p75) 5 (3,6) 
*As defined by at least one swollen joint. TJC, Tender Joint Count; SJC, Swollen Joint Count; HLA-B27, human 
leucocyte antigen; NRS, numerical rating scale.  
 
      











Withdrawal n, (%) 
Time to relapse upon 
Treatment Withdrawal 
median (p25 – P75) 
(weeks) 
Total population 60/60 (100%) 49/60 (81,7%) 26/49 (53%) 23/49 (47%) 32 (19 – 49)  
SpA subtype     
 
   
PsA (fulfilling CASPAR 
criteria) 
23/60 (38,3%) 17/23 (73,9%) 5/17 (29,4%) 12/17 (70,6%) 29 (15 – 57) (n=11) 
Reactive Arthritis HLA B27 
- 
1/60 (1,7%) 1/1 (100% 1/1 (100%) 0/1 (0%) NA 
Reactive Arthritis HLA B27 
+ 
4/60 (5%) 4/4 (100%) 2/4 (50%) 2/4 (50%) 46 (36 – 56) (n=2) 
IBD related arthritis 1/60 (1,7%) 0/1 (0%) NA NA NA 
pSpA HLA-B27+ 32/60 (53,3%) 29/32 (90,6%) 18/29 (62,1%) 11/29 (37,9%) 36 (8 – 56) 
pSpA HLA-B27- 28/60 (46,7%) 20/28 (71,4%) 8/20 (40%) 12/20 (60%) 29 (19 – 49) 
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Parameters predictive for occurrence of drug-free sustained clinical remission and clinical relapse  
The estimated odds for sustained drug-free remission is 80% lower for patients with psoriasis (OR 
= 0.2, 95% CI 0.06 to 0.65, p=0.008) (Fig 2). Additionally, in patients with polyarticular disease 
(SJC≥5) the odds are 83% lower for sustained drug-free remission (OR =0.17, 95% CI 0.03 to 0.84, 
p=0.03) compared to patients with oligo-articular disease. Contrary, HLA B27-positivity was a 
positive predictor for sustained remission with an estimated OR of 3.68 (95% CI 1.22 to 11.16, 
p=0.021).  Regarding the predictive value of the same parameters for the outcome clinical relapse, 
similar findings were observed: the OR of psoriasis was 4.58 (95%CI 1.28 to 16.36, p= 0.019) and for 
polyarticular disease (SJC≥5) 5.25 (95%CI 0.97 to 28.57, p=0.055). Other parameters, including 
treatment duration, age, CRP, ASDAS, BASDAI and BASFI and rapid response to treatment were not 
significantly associated with sustained clinical remission or occurrence of relapse. Time to relapse 
was not correlated with the duration of golimumab treatment (R=0.24, p=0.29) assessed by 
Spearman correlation test. In Fig 4 the survival distribution for drug-free clinical remission over time 
is depicted for the overall population and for the subgroups with presence or absence of psoriasis, 
SJC>5 and HLA B-27 positivity. The survival distribution were statistically significantly different for 
the presence of psoriasis (p=0.02) and SJC>5 (p=0.01) whereas no significance was found for HLA 
B-27 positivity (p=0.10). 
Fig 3: Logistic regression analyses for each predictor at baseline for the outcome sustained clinical 






Fig 4: Survival distribution for drug-free clinical remission over time for the overall population and 
for the subgroups with presence or absence of psoriasis, SJC>5 and HLA B-27 positivity. 
 
Safety analysis  
All patients completed the first 48 weeks and have a follow-up of at least 18 months upon drug-
withdrawal or are treated in the CRESPA extension part. Overall, there were no unexpected safety 
signals or serious adverse events. The most common events (MedDRA preferred terms) were 
nasopharyngitis and upper respiratory tract infection in both groups. No local injection reactions 
were observed. No deaths or malignancies were noted during the study period. No tuberculosis 




This is the first study indicating that drug free remission is an achievable target in early 
spondyloarthritis in at least 50% of patients. This corroborates and extends our earlier results that 
initiation of TNF blockade in very early pSpA yields remarkably high rates of clinical remission. In 
contrast,  substantially lower responses in patients with more established disease are observed 
[27]. Importantly, the lack of significant response in placebo treated patients ruled out the 
possibility of spontaneous remission. Poly-articular disease or preexisting psoriasis were strong 
predictors for relapse after drug withdrawal. Collectively, these data establish a novel therapeutic 
framework for longterm therapy in defined subsets of pSpA.  
It remains unclear if achieving biologic-free and drug-free remissions are primarily due to the 
natural course of  peripheral spondyloarthritis or to the early therapeutic intervention according to 
the ‘window of opportunity’ hypothesis. The rationale for including a placebo-group in the first 24 
week study design, was indeed to estimate the spontaneous remission rate. We observed that only 
20% of the patients in the placebo group reached our definition of clinical remission. This number 
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should however be interpreted with caution, because these patients had a higher intake of NSAIDs 
which makes it impossible to exclude remission induced by continuous NSAID use. 
Contrary to most phase III clinical trials in PsA, our patient population consisted of very early mainly 
oligo-articular and DMARD-naïve disease with pre-existing psoriasis as the most prevalent extra-
articular manifestation. Our hypothesis is that, in accordance with the window of opportunity 
theory, the potential reversibility of autoimmunity decreases over time in pSpA and alters the 
potential efficacy of therapies. In the early phase of the disease, aggressive therapy leads to 
disproportionate benefits and patients have a high chance for remission, even drug-free remission 
might be feasible. Importantly, immune dysregulation appears to be reversible in this phase in some 
patients. Since autoimmunity is characterized by the loss of tolerance toward self-structures, drug-
free remission at the molecular level probably means not only complete suppression of disease 
activity, but also the re-establishment of tolerance. Improved function of regulatory T helper cells 
is likely necessary for the recovery of normal immunological tolerance. Later, in the progressive 
phase of the disease, autoimmunity is no longer reversible.  In this late phase adequate therapy 
leads to moderate benefit, patients have a low chance of remission and there is no chance for drug-
free remission. This hypothetical model suggests that, among other known and unknown factors, 
disease duration is a crucial risk factor for progressive disease, which is generally characterized by 
irreversible immune dysregulation that could be due to autoimmune processes. This hypothesis 
could be an explanation for the high rates of clinical remission and high percentage of patients 
staying in sustained drug-free remission that were observed since the mean disease duration in our 
cohort was only 5 weeks.  
The higher chance that patients with already longstanding pre-existing psoriasis relapsed after 
achievement of clinical remission may be explained by the stage of development of the underlying 
pathophysiological mechanisms. Arbitrarily, three consecutive but partially overlapping phases in 
the immunopathogenesis of psoriasis can be distinguished: an initiation, an amplification, and an 
effecter phase [31]. The latter two could also be considered the disease progression phase. Parallels 
are observed in psoriatic arthritis [32]. Innate immune mechanisms appear essential in the initiation 
of the cascades, but in the further development of the chronic inflammatory reaction, adaptive 
immune mechanisms also contribute. In the effecter phase, tissue specificity of the reaction may 
be a critical factor in determining the outcome of disease. The patients with pre-existing psoriasis 
in our trial may have developed a chronic immune reaction since the mean time of presence of 
psoriasis was 4 years and as a consequence are less susceptible for sustained drug-free remission. 
It has already been described, in other early oligoarthritis cohorts followed up longitudinally, that 
the presence of psoriasis predicted significantly worse outcome[33]. Thus, the existence of psoriasis 
could be viewed as indicator of chronicity of disease. 
Our study was the first to explore the therapeutic potential of anti-TNF treatment to achieve drug-
free remission in very early peripheral SpA patients. Paramarta et al explored drug-free remission 
in longstanding peripheral non-psoriatic SpA. The mean symptom duration was around 7 years [26]. 
Patients received either 12 (n=12) or 24 weeks (n=14) adalimumab before discontinuation of the 
anti-TNF therapy and must have reached the primary end point which was an improvement in the 
patient’s global assessment of disease activity [34]. Relapse was defined as increase of ≥1 swollen 
joint, or ≥2 points in patient’s or physician’s global assessment of disease activity or Bath Ankylosing 
Spondylitis Disease Activity Index. At the time point of adalimumab discontinuation, 11 patients 
(42.3%) had reached a 66 swollen joint count of zero and 14 patients (53.8%) a ASDAS inactive 
disease status. After adalimumab discontinuation, 73.1% relapsed after a mean of 10.0±3.2 weeks 
[26]. Comparing these findings with ours, major differences can possibly explain the higher relapse 
rate in other studies. First, there was a clear distinction in the mean symptom duration in both 
studies:  approximately 7 years compared with only 5 weeks in our trial. Also the included study 
population was not exactly identical: patients had to fulfill the European Spondyloarthropathy 
Study Group (ESSG) criteria and/or the Amor criteria for SpA without fulfilling the criteria for AS or 
PsA whereas in our study all included patients fulfilled the ASAS criteria. However, post hoc 
application of the ASAS criteria to their study population revealed that 38 out of the 40 patients 
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also fulfilled the ASAS criteria for peripheral SpA. Another important difference which could 
possibly explain the lower rate of relapse in our study, is the use of more strict remission criteria to 
discontinue anti-TNF treatment: : patients had to be without joint swelling, as well as signs of 
enthesitis or dactylitis during 3 which excludes patients with unstable remission. In the Paramarta 
trial anti-TNF therapy was stopped if patients had an improvement in the patient’s global 
assessment of disease activity. Consequently, only 42.3% patients in that trial had reached a 66 
swollen joint count of zero at the time point of discontinuation whereas it was obligatory in our 
trial. Other studies also have confirmed that early treatment in oligoarthritis leads to good 
remission rates [35, 36].  
Recently, the possibility of drug-free remission was  investigated in disease modifying anti-
rheumatic drug (DMARD)-treated PsA patients in continuous disease remission (no musculoskeletal 
symptoms, no or minimal skin/nail disease) for at least 6 months. The mean disease duration was 
6.54 years. They found a high incidence of recurrence of disease (76.9%) which occurred rapidly 
(74.50±51.72 days) after treatment discontinuation [37]. The median time to relapse after 
discontinuation of treatment in our trial was 31.5 weeks  which was longer than what was observed 
in more longstanding pSpA and PsA [26, 37].  
Also in rheumatoid arthritis (RA), there is accumulating evidence that appropriate therapy, initiated 
during the window of opportunity, may lead to rapid and sustained improvement in RA, frequently 
enabling the cessation of biologicals and in some cases all medications might be tapered [38]. 
Although only a few trials aimed to study drug-free remission, there is some evidence that 
biologicals increase its likelihood; there might be differences between medications in this respect. 
The prevalence of drug-free remission is now around 3.6 to 22 % but further studies are needed to 
select the most favorable treatment strategies [39-46]. 
The data of our proof of concept study will need to be confirmed in larger multicenter studies. In 
any case, the data reiterate the importance of early recognition and referral  strategies from 
primary care to rheumatologists, in order to install adequate treatment and consequently achieve 
better outcomes and even drug-free remission.  
CONCLUSION 
The advent of new medications and new treatment strategies in early stages of pSpA make it 
possible to achieve remission in more patients than before. In addition to a decrease in signs and 
symptoms, early and aggressive therapy with TNF blocking agents in pSpA may improve the 
underlying immune disturbance, leading to even drug-free remission in more than half of patients 
resembling recovery. Poly-articular disease and pre-existing  psoriasis in early pSpA patients may 
provide important information as predictive factors for clinical relapse and in the underlying 
mechanisms. Characterizing the subset of patients staying in drug-free remission, may decrease the 
risk for long-term side effects and attenuate the economic burden of the disease.   
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This thesis describes our clinical research in the field of inflammatory arthritis with specific focus 
on imaging, early diagnosis and treatment strategies, including fast remission-induction and drug-
free remission.  In part I, we describe the results of 3 studies with a novel immunological imaging 
technique.  In part II, we focus on the importance of peripheral joint manifestations in patients with 
spondyloarthritis, and describe the results of the CRESPA-trial, an investigator-initiated study that 
explored early remission-induction in patients with very early SpA. 
Part I 
In a first step, as described in chapter 3, we developed a radiolabelling method for certolizumab 
(CZP), a commercially available humanized Fab′-fragment directed against TNF and tested the TNF-
neutralizing effect of this tracer in vitro. Before using 99mTc-S-HYNIC CZP in vivo for the first time, 
we explored and confirmed that the in vitro TNF neutralizing effect of various concentrations 
99mTc-S-HYNIC CZP formulation was comparable to the blocking effect observed for the unlabelled 
S-HYNIC CZP and the non-conjugated CZP. In a second step, also described in chapter 3, the 
biodistribution, dosimetric profile and the effective dose were calculated in patients with active RA 
and SpA. Following injection of 690 MBq 99mTc-S-HYNIC CZP in eight patients, an effective dose of 
6.1 mSv was estimated. The distribution and elimination half-life in blood was estimated to be 
respectively 1.2h and 26.9h. The obtained estimate for ED60 (8.9 μSv/ MBq) should be viewed in 
the light of other tracers, such as 99mTc-labelled bisphosphonates (5.7 μSv/MBq) and HIG (Human 
ImmunoglobulinesG) (7.0 μSv/MBq), which are often used in this patient population, despite their 
limited clinical value in this specific context. We could conclude that the proposed 
immunoscintigraphy was a safe technique which did not reveal any unexpected adverse events. To 
assess the tracer accumulation in joints, each joint was scored quantitatively and semi-
quantitatively by using the following scoring system: score 0=no tracer uptake, score 1=faint uptake 
of the tracer and score 2=clear uptake of the tracer. The semi-quantitative scoring system showed 
a good correlation with the quantitative scoring system and was feasible to use in daily practice. 
This semi-quantitative score was also applied to every quadrant of the SIJs in patients with axSpA. 
The scintigraphic result was defined as positive if there was faint or clear tracer uptake 4–6 hours 
postinjection.  
In chapter 4 we investigated this immunoscintigraphic procedure in a proof-of-concept study in 20 
patients with RA and SpA to detect in vivo TNF-α-driven inflammation. We were able to visualize in 
most of the clinically involved joints a marked tracer uptake within minutes following injection, 
suggesting fast uptake into the inflamed tissue. The best results were seen at 4–6 hours 
postinjection, but tracer uptake was still observed on the 24 hours postinjection scan, suggesting 
that uptake is not solely caused by a vascularisation effect. Specific tracer uptake patterns – 
pathognomonic for the studied diseases – were observed: poly-articular pattern in RA, distal 
interphangeal involvement and dactylitis in psoriatic arthritis, and enthesitis and sacroiliitis in SpA. 
Although similar results have been reported with radiolabelled adalimumab in patients with RA, 
this was — to our knowledge — the first study evaluating immunoscintigraphic patterns in patients 
with different subtypes of SpA by visualising enthesitis, dactylitis and sacroiliitis. In patients with 
peripheral joint involvement, we could establish a good correlation between the clinical evaluation, 
ultrasound evaluation of the individual joints, and the tracer uptake on scintigraphy. Interestingly, 
this correlation was strongest for more objective signs of inflammation: higher ORs were observed 
for the swollen joint count and PD-positive joints as compared with the tender joint count and GS-
positive joints. At the patient level however, no significant correlation was found between the 
scintigraphic sum score and global disease activity scores or relevant patient reported outcomes, 
possibly because of the small sample size in this proof-of-concept study. In patients with axSpA, the 
scintigraphic findings correlated well with BME on MRI of the SIJs, which is the item that is required 
in the ASAS definition of a positive MRI, and is one of the anchors of the ASAS classification criteria 
for axSpA. There was an even better correlation between the scintigraphic findings and MRI, when 
taking only “deep” extended lesions into account; these lesions are considered more typical for 
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SpA. Finally, at the patient level, there was a significant relation between the scintigraphic sum 
score of the SIJs and the SPARCC scoring system. After the baseline scintigraphy with radiolabelled 
CZP, we treated all patients with “cold” CZP and noted an overall good clinical response: we looked 
whether the baseline scintigraphic detection of TNF could predict a therapeutic response to CZP 
therapy after 12–24 weeks. We need to emphasise that this study was not designed or powered to 
predict therapy response by baseline scintigraphic results. Nevertheless, we could demonstrate a 
significant predictive value of the immunoscintigraphy at the joint level with regard to the tender 
joint count: tender joints with uptake at baseline had a significantly higher probability of not being 
painful anymore after 24 weeks of treatment. The lack of predictive value for the other joint 
assessments, as well as for the global disease activity scores at the patient level, could probably be 
explained once again by the fact that the study included only small numbers of patients with 
heterogeneous inflammatory diseases. However, these preliminary findings are interesting because 
a positive scintigraphic result might indicate that joint tenderness in an individual patient at 
baseline is TNF-driven, and this result could serve as a more objective measurement tool for tender 
joints, especially when – in this specific patient – pain would be an important driver in composite 
disease activity scores, currently used for reimbursement of biological agents.  
In chapter 5 we evaluated the immunoscintigraphic technique in five patients with erosive hand 
osteoarthritis (EOA). Important differences regarding tracer uptake in patients with EOA were 
observed. First, uptake of Tc99m-radiolabelled CZP in EOA was observed almost exclusively at the 
4-6 hour timepoint, and not immediately post injection. In contrast to RA and PsA patients, a 
marked uptake was already visualised in most of the clinically involved joints within minutes 
following injection of the tracer. Second, almost all scintigraphic positive IP joints in patients with 
EOA had only a faint uptake of the tracer. This study was the first to show the presence of (probably 
small amounts of) TNF in erosive hand OA by immunoscintigraphy with radiolabelled TNF-blocking 
agents. These findings underline the good efficacy of TNFi on signs and symptoms in PsA patients 
and not in EOA.  A few additional SpA patients with TNFi-refractory disease (another than CZP) were 
also scanned with radiolabelled CZP; although we currently only have anecdotal evidence, it looks 
that switching from one TNFi to another could make sense when there would still be in vivo 
demonstration of the cytokine.  
In clinical trials, both for RA and SpA, approximately 50% of patients achieve a clinically important 
response such as an ACR 50% response rate or an ASAS 40% response rate [1-10]. Despite an overall 
impressive improvement in clinical signs and symptoms when a TNF-blocking agent is administered, 
there is still a significant proportion of patients who do not reach a relevant response (primary non-
responder), have insufficient improvement, or who lose an initial good response over time 
(secondary non-responder). In an era of evidence-based medicine, it is disappointing to realize that 
treatment decisions or strategies, even for expensive biological agents, are driven by patient 
reported outcomes, the difficult to standardize clinical examinations (joint counts), rather aspecific 
laboratory parameters (elevated CRP) or questionable imaging cut-offs (erosions, sacroiliitis grade 
2 by modified New York criteria for AS). An accurate way of predicting a relevant clinical response 
to a certain targeted treatment would allow for a better patient selection.  
There is a need for new imaging techniques visualizing, characterizing and quantifying molecular 
and cellular processes non-invasively providing information on the processes preceding changes in 
synovial tissue, cartilage, and bone. These imaging techniques can help evaluate physiological and 
pathophysiological processes, facilitate diagnosis and monitor effects of therapy. At the preclinical 
stage, novel molecular imaging techniques can also facilitate the development of new therapies 
and understanding of novel mechanisms of action of targeted biological agents. Molecular imaging 
studies aiming at selectively visualizing TNF-α (or another suspected culprit cytokine) in vivo at the 
site of clinical inflammation could be an attractive alternative to other less specific and/or invasive 
techniques such as bone scintigrapy with 99mTc-labelled diphosphonates or synovial biopsies taken 
by arthroscopic procedures. If confirmed, this technique could be a step towards personalised 
medicine, where each patient receives the right drug and the right intensity of treatment for as long 
as needed; it could allow the selection of patients for a specific therapy in a much more rational 
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way than the current ‘trial and error’ approach. In particular, future studies should address if a pre-
therapy scintigraphic approach with a radiopharmaceutical targeting TNF identifies the presence of 
the target cytokine in the inflammatory lesion and if positive, whether these patients with clear 
uptake of the anti-TNF tracer would respond better to anti-TNF therapy as compared with 
strategies targeting other inflammatory pathways. This might be a crucial step in enhancing the 
safe and cost-effective use of expensive biological treatment by avoiding exposure of non-
responders to treatments such as anti-TNF therapy.  Potentially, the technique might also help to 
diminish the number of patients needed in early phases of clinical research. 
Future perspectives 
Future research should confirm these preliminary results, specifically with regard to the potential 
to predict clinical response to a biological treatment targeting TNF in RA and SpA. Currently, we are 
planning to evaluate a treatment decision algorithm based upon the ‘in vivo’ demonstration of 
TNFα by using this immunoscintigraphy in a larger cohort of 100 RA patients. A relevant proportion 
of RA patients does not experience a sufficient response to TNFα-blockers (primary failure), may 
lose an initial good response (secondary failure), or may develop side effects. In this clinical 
situation rheumatologists have the choice between switching to another TNFα-blocker (TNFα Class 
Switch) or starting a biological with another immunological target (Mode of Action Switch). 
Currently there are no good candidate biomarkers that could be used to identify subsets of RA 
patients likely to respond to a particular therapeutic strategy. Thus, the decision for treatment 
switch does not appear to be very evidence-based: it seems rather based upon the rheumatologist’s 
own preference and/or experience and is to a large extent the result of “trial and error”. We plan 
to stratify active RA patients, that failed a prior anti-TNFα treatment, according to the 
immunoscintigraphic result (positive/negative); in both groups we will randomize patients to 2 
different treatment strategies: “anti-TNF class switch” versus “switch to a biological with another 
mode of action”. In this study, we would like to explore the hypothesis that demonstration of 
significant ‘in vivo’ TNFα expression would predict a good response to the ‘TNFα Class Switch’-
option, whereas absence of demonstrable TNFα would result in a better response to a biological 
with another mode of action. 
Part II 
In the second part of this thesis, we evaluated treatment strategies in SpA. The individual treatment 
of patients with SpA is extremely challenging because of the heterogeneous character of the 
diseases that are part of this family of interrelated conditions. In chapter 6, the relevance of 
peripheral manifestations for diagnosis, classification and follow-up was reviewed.  Over recent 
years a reappraisal has been done with regard to considering again the full spectrum of diseases 
belonging to the SpA concept, especially in early disease stages. Peripheral joint manifestations, 
such as arthritis, enthesitis and dactylitis, are inherently part of the different diseases belonging to 
the SpA concept. They should be recognized as such and could act as a red flag in young patients 
with a suspicion of SpA, with the presence of arthritis potentially a more stringent reason for 
referral compared with chronic back pain as the main presenting rheumatological manifestation. 
The ASAS classification criteria for peripheral SpA provide a framework for clinicians to recognize 
peripheral manifestations. Especially with regard to therapeutic studies, they allow definition of 
groups of patients with similar signs and symptoms within the full SpA concept. Although 
subclassification in specific diseases such as AS and PsA might still be useful when studying specific 
pathogenetic disease mechanisms, the classification according to the predominant symptom seems 
to be closer to the daily practice of clinicians, evaluating patients, especially in an early stage of the 
disease. The overall prevalence of peripheral manifestations seems to be very similar across 
different studies and registries, and these manifestations are present both in early and longstanding 
disease. There is a growing interest in the field of SpA to move from rather restricted and 
longstanding diseases such as AS to a more comprehensive view, encompassing not only 
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inflammatory back pain, but also peripheral arthritis and enthesitis, as well as extra-articular 
manifestations. Recognition and monitoring of these manifestations should be part of a concise 
standard evaluation of SpA patients, especially because they seem to be playing a role in the 
decision on initiation or continuation of (anti-TNF) treatment. 
In chapter 7 we evaluated the efficacy and safety of golimumab in the first 24 weeks, to induce 
clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA). All patients 
fulfilled the ASAS classification criteria for pSpA, with a symptom duration ≤12 weeks. Patients were 
randomised 2:1 to receive golimumab 50 mg every 4 weeks or matching placebo for 24 weeks. 
Contrary to most phase III clinical trials in PsA, our patient population consisted of mainly oligo-
articular and very early, DMARD-naïve peripheral SpA with pre-existing psoriasis as the most 
prevalent extra-articular manifestation. The results from our study provide several novel and 
clinically relevant findings with important implications for management of patients with pSpA. First, 
very early recognition of disease and initiation of biological treatment leads to a substantially higher 
response compared with published reports in patients with more established disease. Second and 
of equal importance, the results from the placebo arm do not support the hypothesis that a 
substantial proportion of patients with early pSpA goes into spontaneous clinical remission. We 
observed that only 20% of the patients in the placebo group reached our definition of clinical 
remission. This number should however be interpreted with caution, because these patients had a 
higher intake of NSAIDs, which makes it impossible to exclude remission induced by continuous 
NSAID use. Starting at week 12, there was an option to start rescue medication with open-label 
golimumab. In the placebo group, 10 out of 20 patients (50%) entered the rescue arm compared 
with only 4 out of 40 (10%) patients in the golimumab arm. This finding, together with the difference 
in NSAID intake over time in both groups and the clinical evolution (persistence of increased TJC 
and SJC, enthesitis and dactylitis in up to 80% of the placebo patients at weeks 12 and 24), indicates 
that our patient population with pSpA does not have self-limiting disease. Overall, there were no 
unexpected safety signals and rates of adverse events were low and similar in both groups. Patients 
were prospectively followed to assess the percentage of patients in sustained drug-free clinical 
remission and those who experienced a relapse of arthritis, dactylitis or enthesitis, as described in 
chapter 8. Sustained clinical remission was defined as the absence of clinical arthritis, enthesitis 
and dactylitis at two major consecutive visits planned with intervals of 12 weeks; when this state 
was reached, all treatment was withdrawn. 82% (49 out of 60 patients) achieved this status of which 
53% (26 out of 49 patients) of these patients are still in clinical sustained drug-free remission. In 
those patients that experienced a relapse of peripheral joint manifestations, the mean time to 
relapse after achieving a status of sustained clinical remission was 31 weeks. Patients who relapsed 
(47%) were retreated with golimumab; all experienced again a good clinical response. HLA B27-
positivity was predictive for reaching sustained clinical remission, whereas the presence of psoriasis 
and poly-articular disease (SJC≥5) at baseline were negative predictors for this outcome. This 
remarkably high percentage of patients in sustained drug-free clinical remission indicates a 
potential window of opportunity for drug-free remission in early peripheral spondyloarthritis. Our 
hypothesis is that, in accordance with the window of opportunity theory, the potential reversibility 
of autoimmunity decreases over time in pSpA, and this alters the potential efficacy of therapies, 
just like it has been speculated in RA. In the early phase of the disease, aggressive therapy could 
lead to disproportionate benefits and patients may have a high chance for remission, and even 
drug-free remission might be feasible. Importantly, autoimmunity appears to be reversible in this 
phase in some patients. Since autoimmunity is characterized by the loss of tolerance toward self-
structures, drug-free remission at the molecular level probably means not only complete 
suppression of disease activity, but also the re-establishment of tolerance. Improved function of 
regulatory T helper cells is likely necessary for the recovery of normal immunological tolerance. 
Later, in the progressive phase of the disease, autoimmunity is no longer reversible.  In this late 
phase, adequate therapy leads to moderate benefit, patients have a lower chance of remission and 
there is virtually no chance for drug-free remission. This hypothetical model suggests that, among 
other known and unknown factors, disease duration is a crucial risk factor for progressive disease, 
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which is generally characterized by irreversible autoimmunity. This could be an explanation for the 
observation of high rates of clinical remission and high percentage of patients staying in sustained 
drug-free remission since the mean disease duration in our cohort was only 4 weeks. Also in RA, 
there is accumulating evidence for a ‘window of opportunity’ referring to the existence of a 
transient time frame in which the disease is more susceptible to treatment. Although only a few 
trials aimed to study drug-free remission, there is some evidence that biologicals increase its 
likelihood; there might be differences between medications in this respect. The prevalence of drug-
free remission after an induction treatment with a biological agent is now around 3.6 to 22 % in RA, 
but further studies are needed to select the most favorable treatment strategies.  
The data of our proof of concept study will need to be confirmed in larger multicentre studies. In 
any case, the data reiterate the importance of early recognition and referral strategies from primary 
care to rheumatologists, in order to install adequate treatment and consequently achieve better 
outcomes and even drug-free remission. Nevertheless, more than 3 years were needed to include 
all patients.  Most of the referrals came from other rheumatologists and not from general 
practitioners. It will be very challenging to find and apply a good referral strategy in primary care. 
Still a lot of work regarding education in early recognition has to be done.  
Poly-articular disease and pre-existing psoriasis in early pSpA patients may provide important 
information as negative predictors for sustained drug-free remission. This findings could suggest 
that patients with pSpA presenting with psoriasis and/or poly-articular disease do not benefit from 
this withdrawal strategy and that from an economical point of view, biological therapy could be 
started after an adequate trial and subsequent failure of conventional DMARD therapy. Further 
characterisation of patients that achieve and maintain clinical remission, even after drug 
withdrawal, might lead to the identification of specific “high risk” pSpA populations that would 
benefit from the remission-induction approach that we explored in our studies and may decrease 
the risk for long-term side effects and attenuate the economic burden of the disease.   
Future Research 
As part of this study project, we also performed both ultrasound and MRI at baseline and at other 
time points in this study population. All patients underwent bilateral multiplanar grey scale (GS) 
and Power Doppler (PD) ultrasonography examinations of knee, ankle, subtalar and 
metatarsophalangeal joints (MTP) at baseline, week 12, 24, 36 and 48 carried out on a high-level 
machine (ESAOTE MyLab60) using multifrequency linear transducers (6–18 MHz). Entheseal sites 
were also bilaterally evaluated. A whole body MRI was performed in all patients between the 
screening and baseline visit and a second time in patients fulfilling sustained clinical remission 
criteria when drug was withdrawn. Images were obtained on a 1.5 T MRI unit (Avanto/Symphony, 
Siemens Medical, Erlangen, Germany). The whole body MRI was not performed by a “one run” 
approach but multiple locations (with different coils) were scanned individually in order to 
investigate SpA-specific locations in detail. The sequence protocol included full spine, pelvis, knees 
and ankles.  
We will analyze the correlation of enthesitis detected by clinical examination (MASES scoring) and 
detected by US and MRI. Another remaining research question is whether the whole body MRI and 
US findings at baseline and at drug withdrawal, as more objective signs of inflammation, could have 





Roughly, rheumatic diseases can be divided into two groups: inflammatory and degenerative 
diseases. The most prevalent inflammatory rheumatic diseases are Rheumatoid Arthritis (RA) and 
Spondyloarthritis (SpA) with a combined prevalence close to 2%. Both are chronic systemic 
inflammatory joint diseases, that may affect many tissues and organs, but pain and inflammation 
of joints is still the hallmark. Over time, persistent joint inflammation frequently leads to 
destruction of joints and periarticular structures.   
It is clear that there are a number of unmet needs in diagnosing and treating patients with 
inflammatory arthritis. In the first part of this thesis, our aim was to evaluate an 
immunoscintigraphic procedure with radiolabeled CZP as a new imaging modality in patients with 
SpA, RA and erosive osteoarthritis.  In Part II of this thesis we explored the ‘window of opportunity’ 
hypothesis in very early peripheral SpA and evaluated if early treatment with a TNF-blocker can 
induce sustained clinical remission; in a second phase of this research project drug withdrawal and 
drug-free remission were explored.  
Given the lack of specificity of current imaging modalities and the late appearance of definitive 
abnormalities, we hypothesized that in vivo demonstration of TNF could be an attractive alternative 
to other less specific and/or invasive techniques such as bone scintigrapy or synovial biopsies taken 
by arthroscopic procedures. This could provide a clue to more rational treatment decisions. Despite 
an overall impressive improvement in clinical signs and symptoms when treated with TNFi, there is 
still a significant proportion of patients who do not reach a relevant response or who lose an initial 
good response over time. In an era of evidence-based medicine, it is disappointing to realize that 
treatment decisions or strategies, even for expensive biological agents, are driven by patient 
reported outcomes, the difficult to standardize clinical examinations, rather aspecific laboratory 
parameters or questionable imaging cut-offs. Therefore, we performed a proof-of-concept study of 
in vivo detection of TNF by using an immunoscintigraphic procedure with Tc99m-labelled CZP as 
tracer. After the development of a radiolabelling method for CZP, we confirmed that the in vitro 
TNF neutralizing effect of various concentrations 99mTc-S-HYNIC CZP formulation was comparable 
to the blocking effect observed for the unlabelled S-HYNIC CZP and the non-conjugated CZP. An 
effective dose of 6.1 mSv was estimated. The distribution and elimination half-life in blood was 
estimated to be respectively 1.2h and 26.9h. To assess the tracer accumulation in joints, a semi-
quantitative scoring system was developed, which was feasible to use in daily practice. We were 
able to visualize in most of the clinically involved joints a marked tracer uptake within minutes 
following injection, suggesting fast uptake into the inflamed tissue. Specific tracer uptake patterns 
– pathognomonic for the studied diseases – were observed: poly-articular pattern in RA, distal 
interphangeal involvement and dactylitis in psoriatic arthritis, and enthesitis and sacroiliitis in SpA. 
In patients with axSpA, the scintigraphic findings correlated well with BME on MRI of the SIJs. 
Finally, we could demonstrate a significant predictive value of the immunoscintigraphy at the joint 
level with regard to tender joints: tender joints with uptake at baseline had a significantly higher 
probability of not being painful after 24 weeks of treatment. In patients with erosive hand 
osteoarthritis, we found important differences regarding tracer uptake compared with RA and SpA 
patients: no early and only faint uptake in IP joints. These findings underline the discriminatory 
capacity of this technique.  This immunoscintigraphy could allow the selection of patients for a 
specific therapy in a much more rational way than the current ‘trial and error’ approach and could 
be a step towards personalised medicine, where each patient receives the right drug and the right 
intensity of treatment for as long as needed. 
 
In the second part of this thesis our aim was to explore the ‘window of opportunity’ hypothesis in 
very early pSpA. There is a growing interest in the field of SpA to move from rather restricted and 
longstanding diseases such as AS to a more comprehensive view, encompassing not only 
inflammatory low back pain, but also peripheral arthritis, enthesitis and dactylitis, as well as extra-
articular manifestations. Mounting evidence from RA studies has shown that early, aggressive 
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treatment using synthetic and biologic DMARDs improves the outcome of the disease. Such a novel 
therapeutic approach allowed clinical remission to become an achievable goal in many patients 
treated with bDMARDs, mainly TNFi. In axial SpA, TNFi were also shown to be effective in treating 
the early stages of SpA. Studies in patients with non-radiographic axial SpA have demonstrated at 
least similar, if not better, efficacy responses compared to treatment in a more advanced stage of 
the disease. By contrast, data in treating pSpA in an early stage are still sparse and lacking. 
Currently, the sustainability of drug-free remission is not yet evaluated in early pSpA, although a 
fast relapse was observed in patients with longstanding pSpA after anti-TNF discontinuation. As a 
result, we hypothesized that there is at least also a window of opportunity in peripheral SpA; a time 
frame in which the disease is more susceptible to treatment leading to better outcomes and 
investigated the possibility of drug-free remission after drug withdrawal. 
We evaluated the efficacy and safety of golimumab to induce clinical remission in patients with very 
early, active pSpA (symptom duration ≤12 weeks) in a placebo-controlled trial. At week 24, a 
significantly higher percentage of patients receiving golimumab achieved clinical remission 
compared with placebo (75% vs 20%). If patients were in sustained clinical remission, defined by 
the absence of clinical arthritis, enthesitis and dactylitis at two major consecutive visits, then all 
treatment was withdrawn. Out of the 60 patients, 49 (82%) achieved a status of sustained clinical 
remission and a treatment withdrawal was installed. 53% (n=26) of these patients are still in 
sustained drug-free remission. Pre-existing psoriasis and polyarticular disease (SJC>5) at baseline 





Reumatische aandoeningen kunnen grosso modo ingedeeld worden in twee groepen: 
inflammatoire en degeneratieve aandoeningen. De meest voorkomende inflammatoire 
reumatische aandoeningen zijn reumatoïde arthritis (RA) en spondyloarthritis (SpA) met een 
gecombineerde prevalentie dicht bij 2%. Beiden zijn chronische systemische inflammatoire 
gewrichtsziekten die vele weefsels en organen kunnen aantasten, maar pijn en ontsteking van 
gewrichten blijven de typische kenmerken. Na verloop van tijd, leidt blijvende gewrichtsontsteking 
tot destructie van gewrichten en peri-articulaire structuren. Het is duidelijk dat er een aantal 
lacunes zitten in het diagnosticeren en behandelen van patiënten met onstekingsreuma. In het 
eerste gedeelte van deze thesis was het ons doel om een immunoscintigrafische procedure met 
radiogelabeld CZP te evalueren als een nieuwe beeldvormingstechniek bij patiënten met SpA, RA 
en erosieve handartrose. In het tweede gedeelte onderzochten we de ‘window of opportunity’ 
hypothese bij zeer vroege perifere SpA en evalueerden we of een behandeling met een TNF-blokker 
blijvende klinische remissie kan induceren; in een tweede fase van dit onderzoeksproject werd het 
stopzetten van behandeling en de remissie zonder medicatie geëvalueerd. 
Gezien het gebrek aan specificiteit bij de huidige beeldvormingstechnieken en het laattijdig 
verschijnen van definitieve afwijkingen, hadden we de hypothese dat het ‘in vivo’ aantonen van 
TNF een mooi alternatief bood ten opzichte van minder specifieke en/of invasieve technieken zoals 
botscintigrafie of artroscopie met afname van synoviale biopten.  Dit kan een aanleiding zijn tot 
meer rationele beslissingen betreft behandelingen. Desondanks een algemene indrukwekkende 
verbetering van klinische tekenen en symptomen bij het behandelen met TNF-blokkers, zijn er nog 
steeds een significant aantal patiënten die nooit een relevant klinisch antwoord op de behandeling 
hebben, of bij wie de initeel goede response verloren gaat na verloop van tijd. Het is teleurstellend 
in een tijdperk van evidence-based geneeskunde dat beslissingen en behandelingsstrategieën, zelfs 
voor dure biologische therapieën, gedreven worden door patiënten-vragenlijsten, moeilijk te 
standaardiseren klinische onderzoeken (gewrichtsscores), aspecifieke labo resultaten en 
twijfelachtige grenzen van beeldvormingsafwijkingen. Om die reden, voerden we een proof-of-
concept studie uit waarbij we in vivo TNF detecteerden door gebruik te maken van een 
immunoscintigrafische procedure met Tc99m gelabeled CZP als tracer. Na de ontwikkeling van een 
radiolabelling methode voor CZP, konden we bevestigen dat de in vitro TNF-neutraliserende 
werking van verschillende concentraties 99mTc-S-HYNIC CZP formulering vergelijkbaar was met het 
blokkerende effect waargenomen voor de S-HYNIC-CZP en het niet-geconjugeerd CZP. Een 
effectieve dosis van 6.1 mSv werd berekend. De distributie en de eliminatie halfwaardetijd in bloed 
werd geschat op respectievelijk 1.2h en 26.9h. Om de tracer-accumulatie in de gewrichten te 
beoordelen, werd een semi-kwantitatief scoresysteem ontwikkeld dat goed bruikbaar was in de 
dagelijkse praktijk. We konden een duidelijke tracer-opname visualiseren in de meeste van de 
klinisch betrokken gewrichten en dat reeds binnen enkele minuten na injectie, hetgeen een snelle 
opname suggereert in ontstoken weefsel. Specifieke tracer-opname patronen werden 
waargenomen pathognomonisch voor de te bestuderen ziekten: een poly-articulair patroon bij RA, 
distale interfalangeale aantasting en dactylitis bij PsA patiënten, en enthesitis en sacroiliitis bij SpA. 
Bij patiënten met axSpA, vonden we een goede correlatie tussen de scintigrafisch bevindingen en 
botoedeem op MRI van de sacroiliacale gewrichten. Tenslotte, konden we aantonen dat de 
immunoscintigrafie een significant voorspellende waarde heeft op de pijnlijke gewrichten score op 
gewrichtsniveau:  pijnlijke gewrichten met tracer-opname op baseline hadden een hogere kans om 
niet meer pijnlijk te zijn na 24 weken behandeling. Bij patiënten met erosieve handartrose vonden 
we belangrijke verschillen betreft tracer-opname in vergelijking met RA en SpA patiënten: er was 
geen vroege opname en enkel zwakke tracer-opname ter hoogte van de interfalangeale 
gewrichten. Deze bevindingen onderstrepen de onderscheidende capaciteit van deze nieuwe 
beeldvormingstechniek. Deze immunoscintigrafie zou de selectie van patiënten voor specifieke 
therapie op een meer rationelere manier kunnen maken dan de huidige 'trial and error' aanpak en 
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zou een stap in de richting van gepersonaliseerde geneeskunde kunnen zijn, waar elke patiënt het 
juiste middel en de juiste intensiteit van de behandeling zo lang als nodig krijgt.  
In een tweede deel van deze thesis was het ons doel om de ‘window of opportunity’ hypothese in 
zeer vroegtijdige perifere SpA te onderzoeken. Er is groeiende interesse in het SpA veld om over te 
stappen van langbestaande, historisch beschreven ziektebeelden met als gevolg daarvan reeds 
irreversibele beperkingen voor de patiënt, naar een meer allesomvattend klinisch concept met 
focus op vroegtijdige manifestaties, niet alleen inflammatoire lage rugpijn, maar ook perifere 
artritis, enthesitis en dacylitis, alsook extra-artculaire manifestaties. Uit RA studies is reeds 
gebleken dat vroege en aggressieve behandeling met synthetische of biologische DMARDs het 
resultaat op langer termijn van de ziekte verbetert. Dergelijke nieuwe therapeutische benadering 
laat toe klinische remissie als haalbare doelstelling voorop te stellen bij veel patiënten behandeld 
met bDMARDs, voornamelijk TNF-blokkers. In axiale SpA, zijn TNF-blokkers ook efficiënt in de 
behandeling van vroegtijdige stadia van SpA; in deze studies met TNF-blokkers bij patiënten met 
niet-radiografische axiale SpA werd aangetoond dat gelijkaardige, zo niet betere resultaten werden 
bekomen in vergelijking met reeds verder gevorderde stadia. Gegevens in het behandelen van 
perifere SpA in een vroeg stadium zijn daarentegen nog steeds schaars en beperkt. De 
duurzaamheid van medicatie-vrije remissie is nog niet onderzocht geweest bij vroegtijdige perifere 
SpA, hoewel een snelle relapse werd waargenomen bij patiënten met langdurige perifere SpA na 
stopzetten van TNF-blokkers. We hadden de hypothese dat er op z’n minst ook een ‘window of 
opportunity’ moest bestaan in perifere SpA; een periode waarin de ziekte meer gevoelig is voor 
behandeling en leidt tot betere resultaten en de mogelijkheid van medicatievrije remissie na het 
stoppen van medicatie. We evalueerden de efficiëntie en veiligheid van golimumab bij patienten 
met zeer vroegtijdige perifere SpA (symptoomduur ≤12 weken) met een placebo-gecontroleerde 
studie. Op week 24 bereikt een significant hoger aantal patiënten klinische remissie in vergelijking 
met de placebo groep (75% vs 20%). Als patiënten in blijvende klinische remissie waren, 
gedefinieerd als de afwezigheid van artritis, enthesitis en dactylitis, dan werd alle medicatie stop 
gezet. Van de 60 patiënten bereikten er 49 (82%) een status van blijvende klinische remissie en 
werd medicatie stopgezet. 53% (n=26) van deze patiënten zijn nog steeds in medicatie-vrije 
remissie. Voorafbestaande psoriasis en patiënten met poly-articulaire ziekte (SJC>5) bij de start 
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Eindelijk! Het is af! Zonder het volgen van een specifiek officieel doctoraatstraject, is deze thesis er 
dan toch gekomen! Een doctoraat tot een goed einde brengen is op zich al een huzarenstukje; en 
zeker in combinatie met voltijds ‘reumatoloog zijn’ en heel veel andere professionele activiteiten. 
Dankzij de hulp en steun van heel wat mensen is het uiteindelijk toch gelukt! Na mijn opleiding 
reumatologie had ik nochtans niet de ambitie een universitaire carrière uit te bouwen, maar door 
allerlei omstandigheden ben ik langzaam en spontaan in het wetenschappelijk onderzoeksveld 
gerold. Ik had het mezelf een heel stuk gemakkelijker kunnen maken om verder te werken op een 
reeds bestaand project en zo tot een doctoraat te komen. Maar neen, ik moest het weer anders 
doen, eigenwijs zoals we zijn… En de nieuwe onderzoekslijn diende sowieso een link te hebben met 
een frequent voorkomende klinische probleemstelling; anders zag ik het nut er niet van in en zag ik 
mezelf er nooit aan beginnen…. En niet 1 maar 2 ambitieuze ideeën werden van scratch helemaal 
uitgewerkt en opgestart. Het was een boeiende tocht van schrijven van protocollen en ethische 
comités, negotiëren met farmaceutische bedrijven over de financiële ondersteuning, 
contractbesprekingen met juristen over de invulling van ‘Intellectual Property’, strategieën zoeken 
om een ‘early arthritis clinic’ op poten te zetten, patiënten overtuigen tot deelname en verdere 
opvolging, toedienen van studiemedicatie, verzamelen en analyseren van de data, tot het 
neerschrijven van de bevindingen in manuscripten. Een hele dikke merci aan iedereen die mij hierbij 
heeft geholpen. Ik wil van deze gelegenheid dan ook gebruik maken om een aantal mensen in het 
bijzonder te bedanken. 
Eerst en vooral wil ik mij richten tot alle studiepatiënten en hen bedanken voor deelname. Zonder 
jullie medewerking zou er voor mij niet veel te onderzoeken zijn geweest. De grootste motivator 
voor het uitvoeren van dit onderzoek was ongetwijfeld de ongelofelijke dankbaarheid en respect 
die ik van jullie heb teruggekregen. Maar het was niet altijd eenvoudig voor jullie: je kreeg nog maar 
juist een diagnose van een reumatische aandoening en moest al direct nadenken om in een studie 
te stappen met frequente visites en opstarten van biologische geneesmiddelen. Het waren soms 
heel wat stappen die in 1 keer dienden verwerkt te worden. Het kwam erop neer om snel een 
vertrouwensband op te bouwen.,Het grote belang van het snel ontwikkelen van een 
vertrouwensrelatie had ik reeds ervaren in de dagelijkse praktijk en maakt ons beroep zo fantastisch 
en uitdagend! In wetenschappelijke studies dient de behandelende arts misschien zelfs nog een 
betere ‘psycholoog’ dient te zijn die op korte tijd, naast het winnen van vertrouwen, patiënten 
tracht te overtuigen mee te stappen in het verhaal dat vroegtijdige behandeling leidt tot hogere 
kans op genezing. De juiste patiënt met de juiste indicatie, ingesteldheid en verwachtingspatroon 
kunnen behandelen met snelwerkende en krachtige geneesmiddelen kon alleen maar leiden tot 
spectaculaire resultaten en dat hebben we samen gedaan!  
Vervolgens wil ik graag mijn promotor, Filip Van den Bosch, bedanken. Beste Filip, ondanks de zeer 
grote vrijheid die ik kreeg in de manier waarop ik dit wetenschappelijk onderzoek aanpakte, stond 
je altijd klaar om mij op een adequate manier bij te staan en te ondersteunen. Ik had en heb nog 
steeds het gevoel dat we heel vaak op dezelfde golflengte zitten betreft onze visie op reumatologie 
en geneeskunde in het algemeen; ik vind het fantastisch dat je in gelijk welke professionele activiteit 
altijd op zoek gaat naar de klinische relevantie en hierbij het gezonde boerenverstand laat 
zegevieren! Zelfs op gerenommeerde congressen probeer je, als veel gevraagde en geliefkoosde 
spreker, telkens de link met dagelijkse praktijk te leggen! Misschien is mijn therapeutische aanpak 
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ietwat impulsiever, maar je hebt me geleerd dat het soms beter is om iets meer afwachtend te zijn! 
Het was een hele eer om jou als promotor te hebben! De grote ‘workload’ zorgde er weliswaar vaak 
voor dat ik lang moest wachten op je gewaardeerde feedback, maar het zorgde ervoor dat ik alle 
vrijheid en tijd kreeg om mijn eigen ding te doen en dat op mijn eigen tempo. 
Daarnaast wil ik mijn co-promotor, Dirk Elewaut bedanken. Beste Dirk, het is niets nieuws om je te 
omschrijven als een top-wetenschapper! Maar je ‘niet-klassiek professor gehalte’ in combinatie 
met een grote wetenschappelijke kennis werken inspirerend. Naast je terechte hekel aan ‘salami-
slice publiceren’, kan je super enthousiast worden van fancy beeldvormingstechnieken met dito 
beeldjes en figuren. Het is fascinerend om te zien hoe je wetenschappelijke ‘thinking-out-of-the-
box’ ideeën soms zegevieren op de praktische invulling. Hiernaast heb je me altijd het gevoel 
gegeven dat je mijn werk als clinicus enorm waardeert, wat mij een groot vertrouwen geeft. Het 
was uitermate leerrijk om samen met Filip manuscripten door te nemen en te observeren hoe je 
als geen ander de ‘novelty’ van een manuscript in een ‘crisp’ jasje kan steken en hoe je de 
begeleidende ‘cover letters’ op een zodanige manier weet te ‘boosten’ zodat gelijk welke editor 
direct wil starten met het lezen van het ingediende manuscript.  
Hiernaast wil ik ook Herman Mielants bedanken! Beste Herman, het is dankzij jou en je ‘mecenas-
vriend’ Fred Wilms dat ik de studies van reumatologie heb kunnen aanvatten! Deze inspanningen 
zal ik nooit vergeten! Ook je klinisch zeer scherpe blik op locomotorische problemen en teaching 
hebben me gevormd tot wie ik nu ben! 
Bijzonder dank aan ons studieteam. Kristel, Anuschka, Ilse, Karlien en Vicky zonder jullie hulp zou ik 
hier zeker niet kunnen staan! Hilde, Melissa en Joke, ook jullie bedankt voor de administratieve 
ondersteuning. Kim, bedankt om alle facturen in orde te brengen ;-) 
Hartelijk dank aan alle verwijzende reumatologen binnen het CRESPA project. Natuurlijk dien ik ook 
de BE-GIANT meisjes en Thomas te bedanken; Liesbet, Heleen, Gaëlle, Ann-Sophie en Thomas, 
bedankt om voor mij in te springen wanneer nodig voor evaluaties van CRESPA patiënten. Bijzonder 
dank aan Gaëlle om mij telkens te willen helpen om data uit Filemaker te halen en met alle 
administratieve vragen rond het afleggen van een doctoraat! Het was ook een leuke periode om 
met jou en Heleen tijdelijk een bureau te delen en wens je veel succes toe met je waarschijnlijk 
reeds afgelegd doctoraat.  
Betreft het SCINTRA project dien ik zeker een aantal mensen in het bijzonder te bedanken. De 
sleutelfiguren zijn zonder twijfel Bieke, Filip De Vos en Ingrid! Allen bedankt om het SCINTRA project 
tot een goed eind te brengen. Het heeft heel lang geduurd vooraleer we dit project op de rails 
kregen, maar dankzij jullie stuwende kracht op verschillende vlakken is het uiteindelijk toch gelukt 
en mag het resultaat echt wel gezien worden! Er is een leuke samenwerking ontstaan tussen 
verschillende diensten!  
Dank aan Lennart voor het regelen van de logistieke ondersteuning voor het uitvoeren van de whole 
body MRI’s en het scoren van de beelden in beide projecten! Cheers to the best radiologist of 
Belgium; you are the best! 
Ik wel ook mijn toffe bureau-vriendjes bedanken: Sophie en Peggy! Bedankt voor alle informatie en 
nuttige tips in de cursus ‘een doctoraat afleggen voor dummies’! Van het oplossen van IT-
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gerelateerde problemen, tips om academic english writing skills te volgen, tot het voorzien van 
grote snoeppotten op onze bureautafel in combinatie met gezellige babbels over van alles en nog 
wat,…Merci! Er wachten ons nog vele leuke jaren! 
Graag wil ik ook alle mensen betrokken bij het Fonds voor Wetenschappelijk Onderzoek (FWRO) en 
het ‘hand in hand, samen tegen Reuma’-team van harte bedanken. Alle contacten tijdens de vele 
projecten waren telkens heel verrijkend en leerzaam. Nooit gedacht dat ik ooit een rol ging spelen 
binnen het FWRO maar in de zoektocht naar financiële ondersteuning voor mijn project ‘AS in 
beweging’ heeft het opzwepend enthousiasme van Xavier Janssens, een zeer uitzonderlijk man in 
de reumatologie, mij geraakt…met alle gevolgen van dien! 
Naast al andere collega’s en paramedisch personeel (mijn oprechte excuses mocht ik iemand 
vergeten zijn) nog een speciaal dankwoord aan enkele belangrijke mensen in mijn leven.  
De Boys: Lexie, Nicootje, Duut, Grimpie en de Lennie; onze leuke ‘boys-weekend’ tripjes zijn nu al 
legendarisch en de perfecte manier om alles eens aan de kant te zetten! Ze zorgen voor een 
blijvende unieke vriendschap! Thanks and be prepared for the next edition: ‘Back to the basics’! 
Liefste mama, bedankt om er gewoonweg…te zijn! Door jou ben ik nu wat ik ben! Je hebt mij als 
kind geleerd wat het verschil is tussen ‘hebben’ en ‘zijn’, wat onvoorwaardelijke liefde is, hoeveel 
onnodige balast we meedragen in dit leventje en wat het diepe weten in ons zelf kan losmaken. Ik 
weet dat jij het weet, maar ik weet het ook! Broere, onze band is er ook niet zomaar en op de één 
of andere manier slaag je er telkens in om mij op de juiste manier te prikkelen! Bedankt hiervoor! 
Papa, bedankt voor altijd mij te steunen en in mij te blijven geloven. 
Mijn lieve schoonfamilie: Diane, Erik, Marianne en Wim en Liesbet: bedankt voor al jullie hulp reeds 
vele jaren en om er altijd voor ons te zijn in gelijk welke situatie! Het lijkt evident, maar dit is het 
echt niet! 
En tot slot, mijn allerliefste vrouw, mijn enige echte schattie! Elke dag opnieuw schenk je me zoveel 
onvoorwaardelijke liefde en steun; het lijkt onbegrensd. Jouw graag zien is als ademen; het kost mij 
totaal geen moeite. Je hebt mij de nodige tijd en ruimte gegeven om dit te kunnen doen, ook al 
heeft het heel wat langer geduurd dan voorspeld! Ik weet dat je uitermate trots op mij bent, maar 
dat ben ik ook op jou… En dan mijn twee andere schatties: Bassie, the Special One en Tannie, de 
grote kampioen! Elke dag opnieuw besef ik hoe graag ik jullie zie! De momenten die we samen 
doorbrengen zijn de mooiste in mijn leven! Jullie zorgen voor een extra dimensie in mijn leven! 
 
